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INTRODUCTION 
There is growing evidence from recent publications that many drugs, besides 
their well-known pharmacodynamic actions, display other effects especially as 
far as their influence on drug-metabolizing enzymes in the liver is concerned. 
Moreover, their stimulating effect on carbohydrate metabolism via the glucur-
onic acid system should be mentioned in this respect. Drugs belonging to 
essentially different pharmacological groups appear to have in common the initi-
ation of these phenomena. 
Because of the possible significance of the phenomena mentioned for thera-
peutic and toxic effects of drugs, the biochemical backgrounds of these pheno-
mena are being intensively studied (Conney, 1967). 
In the study described in this thesis the stimulating effect of drugs on carbo-
hydrate metabolism via the glucuronic acid pathway takes a central position. 
The term 'glucuronic acid pathway' has been introduced by Bums (1959). By 
this he means the formation of D-glucuronic acid from D-glucose. The dis-
covery that D-glucuronic acid can be processed further via D-xylulose and 
pentose phosphate resulted in an extension of the concept of the glucuronic acid 
pathway. We will use the wider term 'glucuronic acid system' for the sequences 
of biochemical processes leading from D-glucose or D-galactose to D-glucur-
onic acid and those leading from D-glucuronic acid to the various products 
such as D-glucaric acid, L-ascorbic acid and D-xylulose (Fig. 1). 
In the glucuronic acid system D-glucuronic acid has a key-position as a 
metabolic intermediate in the biosynthesis of L-ascorbic acid, D-glucaric acid 
and D-xylulose. The intermediate D-glucuronic acid as well as the products 
mentioned, are excreted in the urine of mammals. The stimulating effect of 
drugs on the glucuronic acid system becomes manifest by the enhanced ex-
cretion in the urine of one or more of the compounds mentioned. Neither the 
pharmacodynamic properties of the drugs, nor their chemical structures appear 
to be of special significance for their stimulating capacity. 
Greenwald (1930) observed an increased excretion of pentose in patients 
with congenital pentosuria during treatment with borneol, aminophenazone or 
Phenazone. Enklewitz and Lasker (1935) identified this pentose as L-xylulose 
and also observed that after giving D-glucuronic acid as a lactone to patients 
with pentosuria an increased excretion of L-xylulose in the urine takes place. 
Longenecker et al. (1940) reported that in the urine of rats treated with 
barbiturates or pyrazolone derivatives the quantity of L-ascorbic acid in 24-hr 
periods, largely surpasses the total normal content of L-ascorbic acid in the 
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FIG. I The glucuronic acid system and related pathways. 
I and la The glucuronic acid pathway. The formation of D-glucuronic acid from 
D-hexoses takes place along this pathway. 
II The ascorbic acid pathway which results in the formation of L-ascorbic acid 
from D-glucuronic acid. 
III The glucanc acid pathway which results in the formation of D-glucaric acid 
from D-glucuronic acid. 
IV The xylulose pathway. The formation of D-xylulose takes place along this 
pathway. The pentose on its turn is metabolized further along the pentose 
phosphate pathway (VI). 
V The glucuronide formation which may be linked to the glucuronic acid 
pathway. 
VI The pentose phosphate pathway, which together with the glucuronic acid 
pathway (I) and the xylulose pathway (IV) forms the glucuronic acid cycle. 
body. These investigators postulated that either an increased biosynthesis or 
an inhibition of the degradation of L-ascorbic acid in the organism is involved. 
Examples of other drugs which bring about an increased excretion of L-
ascorbic acid are the muscle relaxants orphenadrine and meprobamate, the 
antihistaminics diphenhydramine and chlorcyclizine, the antirheumatic drug 
phenylbutazone (Conney and Burns, 1961), the neuroleptic drug chlordiazep-
oxide (Hoogland et al., 1966) and the insecticide DDT (Aarts, 1968). By means 
of tracer studies, using radio-active D-hexose, Burns et al. (1957) and Evans et al. 
(i960) were able to prove that the increased excretion of L-ascorbic acid takes 
place through an increased biosynthesis via D-glucuronic acid. The increased 
excretion in the urine of L-ascorbic acid as well as of L-xylulose could be 
ascribed to an increased formation of D-glucuronic acid in the liver cells 
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(Conney et al., 1961). An increased formation of D-glucuronic acid is also 
manifested in an increased excretion of D-glucuronic acid in the urine during 
treatment of animals (rat and guinea pig) with barbital (Burns et al., 1957). 
In the past 10 years much attention has been paid to the phenomenon of 
enhanced enzyme activities in liver tissue, caused by drugs. One of the aspects 
most intensively studied is the drug-induced enhanced capacity of drug-
metabolizing enzyme systems in the liver. Brown et 31.(1954) reported in rats an 
enhanced metabolism of drugs by liver tissue after treatment with some car-
cinogenic polycyclic hydrocarbons. From other experiments (Conney et al., 
1956,1957a, b) it appeared that probably an increased synthesis of drug-
metabolizing enzyme systems is involved. Conney and Burns (1959) and 
Remmer (1959) reported that also drugs such as the sedative phénobarbital, the 
antipyretic aminophenazone and the antirheumatic drug phenylbutazone can 
act as inducers of enhanced drug metabolism in the rat. 
Clinically, similar observations were made. It appeared that in patients 
treated for some time with phénobarbital or phenylbutazone the elimination of 
other drugs such as the anticoagulant dicoumarol (Dayton et al., 1961), the 
antipyretics novaminsulfone (Remmer et al., 1961) and aminophenazone (Chen 
et al., 1962) was speeded up. These data support the idea that not only in 
animals, but also in man during and after application of drugs an induction of 
an increased synthesis of drug-metabolizing enzyme systems takes place. After 
these initial observations many other experimental examples supporting this 
idea were reported in the literature (Burns and Conney, 1965; Cucinell et al., 
1965,1966; van Dam, 1968). The microsomal drug-metabolizing enzyme systems 
in the liver, which appear to be involved in the induction phenomenon as a rule 
show little specificity, which means that a variety of drugs can be converted by 
the same enzyme system (Gillette, 1966). Moreover, the induction phenomenon 
also shows little specificity. One drug brings about an increased activity in 
various enzyme systems, and various unrelated drugs can induce an increased 
activity of the same enzyme system. These relationships imply that it is hardly 
possible to combine drugs which are really independent in this respect. This is 
of great consequence for pharmacotherapy. As a rule the dosis of a drug A is 
chosen in such a way that via an optimal concentration of it in plasma or at the 
site of action the wanted therapeutic effect is obtained. Application of a drug B, 
given before or simultaneously, will often result in an enhanced metabolism and 
in an attendant increase of the inactivation of drug A, resulting in an inter-
ference with its therapeutic effect. Besides this, drug A as well as drug В may act 
as inducers of the enzyme systems involved in their own biochemical degrad­
ation. May be that part of the unexpected and partly undetected complications 
after application of combinations of drugs find their origin in the phenomena 
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TABLE I Drugs with a stimulating influence on drug metabolism in rat liver and on the 
urinary excretion of L-ascorbic acid in rats. 
Function 
Analeptic 
Analgesic 
Antidiabetic 
Ataractic 
Antihistaminic 
Antirheumatic 
Antiseptic 
Hypnotic 
Muscle relaxant 
Uricosuric 
Antoxidant 
Carcinogenic 
Insecticide 
Inhibitor of 
drug metabolism 
Inducer of 
porphyria 
Drug 
on 
Nikethamide 
Aminophenazone 
Phenazone 
Chlorpropamide 
Tolbutamide 
Chlordiazepoxide 
Diphenhydramine 
Chlorcyclizine 
Phenylbutazone 
Salicylic acid 
Borneol 
Barbiturates 
Chloretone 
Bromisoval 
Paraldehyde 
Orphenadrine 
Meprobamate 
Sulfinpyrazone 
Butylated 
hydroxytoluene 
Butylated 
hydroxyanisole 
3-Methylcholan-
threne 
3,4-Benzpyrene 
DDT 
SKF525A* 
Sulphonal 
2-Allyl-2-iso-
propylacetamide 
Stimulating 
influence 
ι drug metabolism 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- Γ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Ref. 
1 
b 
b 
η 
d 
с 
с 
b 
b 
b 
b 
b 
e 
e 
b 
к 
m 
m 
Ratio of L-ascorbic acid 
production in urine: 
during drug treatment/ 
before drug treatment 
4 
35 
30 
2 
I.I 
6 
5 
18 
12 
2 
2 
6-50 
4 0 
10 
50 
2 0 
7 
7 
> I 
> I 
30 
20 
5 
5 
27 
24 
Ref. 
0 
a 
a 
0 
0 
d 
с 
с 
b , c 
a 
0 
a, b, с 
a 
a 
a 
a , b 
a , b 
с 
e 
e 
b 
b 
0 
f, g 
h 
h 
* This drug displays a diphasic effect: first phase a diminished capacity for drug 
metabolism, dependent on the presence of the drug in the liver, and second phase, 
an enhanced capacity for drug metabolism which may go on for a certain time after 
elimination of the drug. 
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Ref.: 
a 
b 
с 
d 
e 
f 
g 
h 
Longenecker et al., 1940 
Conney and Burns, 1959 
Burns et al., i960 
Hoogland et al., 1966 
Gilbert and Goldberg, 1965 
Kato et al., 1962 
Neumann et al., 1963 
de Matteis, 1964 
i 
j 
к 
1 
m 
η 
о 
Baumann et al., 1942 
Conney et al., i960 
Bums et al., 1963 
Brazda and Baucum, 1961 
Gerboth and Schwabe, 1964 
Remmer, 1962 
This thesis 
under discussion. In that case a better understanding of these phenomena may 
in the future convert these unexpected reactions into expected, so that un­
desirable complications can be avoided. 
For many of the drugs which act as inducers of drug-metabolizing enzyme 
systems the effect on the L-ascorbic acid excretion, especially in the rat, has 
also been studied (Table 1). In all cases the drugs studied were found to be 
capable of evoking an increased excretion of L-ascorbic acid. As mentioned 
before, the increase in the excretion of L-ascorbic acid is found to be based for 
a number of drugs on the stimulation of carbohydrate metabolism via D-
glucuronic acid. Because of the co-incidence of the latter phenomenon with the 
induced increase in drug metabolism, a direct relationship or biochemical link 
between them is assumed to exist. A strong argument in this respect is found in 
the observation that after treatment of animals with strong inducers of drug-
metabolizing enzyme systems in the liver such as chloretone, barbital, amino­
phenazone or the carcinogenic hydrocarbons, the activities of some of the 
enzymes involved in the glucuronic acid system such as uridine diphosphate 
glucose dehydrogenase and uridine diphosphate glucuronyltransferase in the 
liver are also increased (Conney et al., i960; Hollmann et al., 1962). Treatment 
of the animals with ethionine, an inhibitor of protein synthesis, suppressed the 
induction of the enhanced drug metabolism as well as the enhanced L-ascorbic 
acid excretion (Touster et al., i960; Hollmann et al., 1962). 
The stimulation of the glucuronic acid system by drugs has been studied less 
extensively than that of the drug-induced enhanced drug metabolism. In 
humans, besides the observations of the increased L-xylulose excretion by 
patients with pentosuria after treatment with phenazone, aminophenazone or 
borneol, no definite information on the stimulation of the glucuronic acid 
system is available. 
THE AIMS OF THIS INVESTIGATION 
As indicated already the effects of drugs on drug metabolism may be of great 
significance to therapy with regard to the therapeutic effects, as well as to the 
side-effects. The same holds true, although to a lesser degree, for the influence 
of drugs on carbohydrate metabolism via the glucuronic acid system. The fact 
that both phenomena occur simultaneously resulted in the assumption (Burns 
et al., 1963) that the increase in the excretion of L-ascorbic acid in the urine can 
be considered as an indication for an enhanced capacity for drug metabolism. 
For the biochemical background of the enhanced drug metabolism during and 
after drug treatment, reasonable progress has been made in the past years. This 
is not the case as far as the stimulation of carbohydrate metabolism via the 
glucuronic acid system is concerned. 
In this thesis the main emphasis will be laid on the stimulation of the glucur-
onic acid system under the influence of drugs. The questions that arise in this 
respect and that require to be studied more closely, are : 
1. Does the enhanced metabolism via the various pathways of the glucuronic 
acid system during drug treatment, as observed in animals, also occur in 
patients? In man (like in monkey and guinea pig) L-ascorbic acid cannot be 
used as an indicator for such an enhanced metabolism since in these species no 
biosynthesis of L-ascorbic acid takes place. In patients with pentosuria L-xylul-
ose might be used as a criterion. This possibility, however, is as a matter of fact 
very restricted. For this reason it is worthwhile to investigate whether in man 
other products, especially endproducts, of the glucuronic acid system or of 
pathways linked to it can serve as an indicator for the stimulating effect of 
drugs on the glucuronic acid system. 
2. What is the time pattern of the drug-induced response of the glucuronic 
acid system? The assumption that the increase in the excretion of L-ascorbic 
acid might serve as an indicator for an increased capacity for drug metabolism, 
is based on a few, mainly qualitative experiments. The study of the drug-
induced enhanced drug metabolism as well as the drug-induced enhanced 
activity in the glucuronic acid system as a function of time is required in order 
to get a better insight in the possible interrelationships between these pheno-
mena. Especially as far as the enhanced activity in the glucuronic acid system 
is concerned, additional data will have to be obtained. 
3. What are the basic processes in the induction of the enhanced enzymatic 
activity by drugs? In order to get a better insight in the basic processes involved 
in the stimulation of the glucuronic acid system a more detailed analysis of the 
significance of certain hormones and of certain enzymatic steps respectively, 
in the glucuronic acid system for the phenomena under consideration was set as 
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a further goal. Moreover, a comparison should be made between the drug 
stimulation of the pentose phosphate pathway and that of the glucuronic acid 
system. 
4. Is there a functional link between the glucuronidation of drugs or drug 
metabolites and the stimulation of the glucuronic acid system ? Often metab-
olism of drugs implies the formation of glucuronides as a result of the trans-
ference of the glucuronyl moiety from uridine diphosphate glucuronic acid to 
the drugs or their metabolites. Uridine diphosphate glucuronic acid is an inter-
mediate of the glucuronic acid system. In this light the stimulation of the 
glucuronic acid system by drugs may be of special significance. In the literature 
there are indications for an increased glucuronidation of drugs or their metab-
olites under the influence of barbiturates, which are stimulators of the glucur-
onic acid system (Buch et al., 1967). 
In the following chapters a review will be presented of the literature with 
respect to the glucuronic acid system and with respect to the effect of drugs on 
it, followed by the experiments performed to get answers to the questions posed. 
After that the results obtained will be discussed. 
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CHAPTER I 
THE FORMATION AND CONVERSION OF 
D-GLUCURONIC ACID 
/ . / Introduction 
The stimulation of carbohydrate metabolism via the glucuronic acid system 
by drugs is manifested by an increased excretion of D-glucuronic acid and also 
of products formed from it such as L-ascorbic acid and L-xylulose. For the 
study and the analysis of the various phenomena related to the glucuronic acid 
system, insight in the various metabolic pathways and enzymatic steps related 
to and involved in them is required. Of special importance are those steps and 
products which, although not studied in relation to the stimulation phenomenon 
up to now, may possibly be suitable indicators for the detection of an increased 
activity and suitable points of attack for the analysis of the glucuronic acid 
system. The formation of D-glucaric acid from D-glucuronic acid and also the 
formation of glucuronides can be mentioned in this respect. Thorough reviews 
on the metabolic systems involved in D-glucuronic acid and glucuronide for-
mation are written by Touster and Shaw (1962) and Dutton (1966). In the past 
2 years new information and new points of view have arisen, especially as far as 
the formation of D-glucuronic acid and its conversion to other products are 
concerned. This implies that a discussion of the glucuronic acid system, taking 
into account these new aspects, is suitable. 
The various pathways, sequences of biochemical conversions which are named 
after the endproducts and in which D-glucuronic acid is the end- or the 
starting product, will be discussed in the following sections (Fig. 1): 
I. The glucuronic acid pathway leading from D-glucose to D-glucuronic acid 
or from D-galactose to D-glucuronic acid (la). The possibility of the formation 
of D-glucuronic acid by hydrolysis of polysaccharides containing D-glucur-
onic acid will also be discussed briefly. 
II. The ascorbic acid pathway leading from D-glucuronic acid to L-ascorbic 
acid. For certain mammals, namely man, monkey and guinea pig, L-ascorbic 
acid is a vitamin since one of the enzymes essential in the L-ascorbic acid 
pathway is lacking. This implies that in the discussion of this pathway mainly 
other mammals will be involved. 
III. The glucaric acid pathway leading from D-glucuronic acid to D-glucaric 
acid. This short pathway consists of only two steps with D-glucuronolactone 
as an intermediate. The pathway was identified by Marsh (1963a). 
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IV. The xylulose pathway, leading from D-glucuronic acid to D-xylulose. In 
certain patients the step in this pathway leading from L-xylulose to xylitol is 
absent because of an inborn error in metabolism, based on an enzyme defect. 
The consequence is an overflow of L-xylulose which appears in the urine of the 
patient (essential pentosuria). 
The xylulose pathway is linked via D-xylulose-5-phosphate with the pentose 
phosphate pathway (VI). The pentose phosphate pathway leads to D-hexose 
phosphate, which in its turn can be taken up in the glucuronic acid system. 
Herewith a cycle of biochemical conversions is closed, implying that the various 
pathways mentioned can be considered as a part or as side-ways of what is 
called in the literature the glucuronic acid cycle. 
V. The glucuronide formation. This conjugation reaction may be linked to the 
glucuronic acid system. The glucuronyl moiety is transferred from uridine 
diphosphate glucuronic acid (UDPGA) to the acceptor (drugs, drug metab-
olites and body-formed compounds such as bilirubin and thyroxin). The con-
jugation reaction possibly constitutes one of the main links between the 
glucuronic acid system and drug metabolism. 
1.1.1 The formation of D-glucuronic acid 
It is assumed that D-glucuronic acid is mainly formed by biosynthesis via 
UDPGA (glucuronic acid pathway). In addition the possibility exists that 
D-glucuronic acid is formed by catabolism of polysaccharides containing this 
compound. 
1.1.1.1 The glucuronic acid pathway 
Although the occurrence of D-glucuronic acid as a physiological substance 
was revealed in 1879 (Schmiedeberg and Meyer), an insight in the nature of the 
intermediate steps of the biosynthesis of this substance has been gained only 
during the last decade. The isolation of UDPGA was of essential importance 
in this respect (Dutton and Storey, 1954; Smith and Mills, 1954). The enzymes 
and products involved in this biosynthesis are presented in Fig. 2. 
Uridine diphosphate glucose dehydrogenase 
One of the steps linking intermediates of glycolysis with D-glucuronic acid 
metabolism was established with the discovery (Strominger et al., 1957) that the 
liver contains an enzyme capable of oxidizing uridine diphosphate glucose 
(UDPG) to UDPGA in the presence of nicotinamide adenine dinucleotide 
(NAD). This soluble enzyme, the UDPG dehydrogenase, acts on its substrate 
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in two clearly separated steps. In the first step only the uracil moiety of UDPG 
appears to be oxidized at the expense of NAD to produce an as yet uncharacter-
ized substance (XUDPG). In the second step this substance is further oxidized 
with NAD and in the course of this reaction the oxidized uracil moiety is 
restored to its original configuration, while the carbon atom 6 of the D-glucose 
moiety is oxidized to a carboxyl group (Simonart et al., 1966). It seems that 
uridine diphosphate glucose (UDPGJ 
NAD — . * Hj 0 
UDPG dehydrogenase 
XUDPG 
NAD 
UDPG dehydrogenase 
nucleotide 
pyrophosphataae 
uridine diphosphate 
glucuronic acid (UDPGA) 
-UMP UDP ^ 
acceptor 
UDP g-lucuronyl-
tranaferase 
D- glucuronic acid-l-phosphate 
H20>j 
phosphataa ρ ^ 
D- glucuronic acid 
pakhwoyA 
β D glucoeiduronic acid 
H20-J 
ß-glucuranidaae 
^•»· acceptor 
D- glucuronic acid 
pathway В 
FIG. 2 The glucuronic acid pathway. 
Note It is not established whether D-glucuronic acid formation in vivo takes place 
via pathway A or via pathway B. 
these reactions are not reversible. The UDPG dehydrogenase is specific for the 
substrate UDPG; D-glucose and D-glucose-i-phosphate cannot be used as 
substrates by the enzyme. The pH optimum of the purified enzyme is 8.7. 
It has been demonstrated that the UDPG dehydrogenase isolated from 
bovine liver is inhibited competitively by UDPGA (K15 χ io-5M), by uridine 
diphosphate xylose (K.14X io-8M) (Neufeld and Hall, 1965) and by uridine 
diphosphate galactose. Moreover, an uncompetitive inhibition by uridine di­
phosphate (UDP) has been reported (Salitis and Oliver, 1964). The question 
whether these inhibiting compounds exercise a regulatory function in the 
glucuronic acid pathway awaits further experiments. 
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The formation of D-glucuronic acid from UDPGA in the liver has been 
demonstrated clearly with tracer studies (Evans et al., i960; Pogell and Leloir, 
1961; Conney and Burns, 1961). In vitro two possible pathways (A and B, 
Fig. 2) have been demonstrated ; whether these pathways play a role also in vivo 
is not sure. The intermediate enzymatic steps involved in vivo have not yet been 
established with certainty. 
Nucleotide pyrophosphatase and phosphatase 
The pathway A is catalyzed by a nucleotide pyrophosphatase and a phos­
phatase. The first enzyme catalyzes the conversion of UDPGA into D-glucur­
onic acid-1-phosphate and uridine monophosphate (UMP). The phosphatase 
converts D-glucuronic acid-1-phosphate into D-glucuronic acid and inorganic 
phosphate (Pi). Using rat kidney microsomes and starting from UDPGA as a 
substrate Ginsburg et al. (1958) were the first to show the formation of D-
glucuronic acid-i-phosphate and D-glucuronic acid. The formation of D-
glucuronic acid-i-phosphate and D-glucuronic acid from UDPGA could also 
be demonstrated with the aid of rat liver microsomes (Pogell and Leloir, 1961 ; 
Conney and Burns, 1959,1961). 
Recently, the purification of pyrophosphatase from the rat liver was per­
formed. The pyrophosphatase is present in the microsomal fraction and in the 
nuclei; the supernatant shows little pyrophosphatase activity. Schliselfeld et al. 
(1965) and Ogawa et al. (1966) studied purified pyrophosphatase obtained from 
the nuclei and from the microsomal fraction respectively. In both cases the 
purified enzyme had its highest activity at alkaline pH (the microsomal 
enzyme at pH 9.1 ; the enzyme obtained from the nuclei at pH 8.5). Little sub­
strate specificity was observed; for instance, the substrates UDPG, UDP-N-
acetylglucosamine and NAD were also hydrolyzed. It is remarkable that the 
microsomal fraction from guinea pig liver shows little or no pyrophosphatase 
activity (Pogell and Leloir, 1961). 
The phosphatase activity of the rat liver, tested with D-glucuronic acid-i-
phosphate as a substrate is very low, this in contrast with the phosphatase 
activity obtained from the rat kidney (Pogell and Leloir, 1961; Conney and 
Burns, 1961 ; Takanashi et al., 1966). The kidney phosphatase which hydrolyzes 
D-glucuronic acid-1-phosphate is mainly present in the microsomal fraction. 
This enzyme was purified by Takanashi et аЦідбб); according to these authors 
it is identical with a nonspecific alkaline phosphatase (EC 3.1.3.1). Whether the 
liver phosphatase, which hydrolyzes D-glucuronic acid-1-phosphate, is in­
volved in the glucuronic acid pathway requires further investigation. In view of 
the low activity of this enzyme it is not clear whether the pyrophosphatase and 
phosphatase are involved in the D-glucuronic acid formation. 
II 
UDF glucuronyltransferase and ß-glucuronidase 
As pointed out by Pogell and Leloir (1961) the combination of microsomal 
UDP glucuronyltransferase and microsomal ß-glucuronidase may be involved 
in the formation of D-glucuronic acid by the liver. 
UDP glucuronyltransferase catalyzes the transfer of the glucuronyl moiety 
from UDPGA to the acceptor (Fig. 2). The properties of the glucuronyl trans-
ferase and the glucuronide formation will be discussed further in Section 1.1.5. 
The enzyme ß-glucuronidase hydrolyzes the glucuronide under the formation 
of the free D-glucuronic acid and the acceptor. The enzyme has a low specificity. 
It is strongly inhibited by D-glucaro-(i-»^-lactone and to a lesser degree by 
D-glucuronic acid (product inhibition; Levvy, 1952). Whether these inhibitors 
are of physiological significance is not clear (Marsh, 1964; Fishman, 1964). 
In the study of Pogell and Leloir (1961) on the influence of UDP-N-acetyl-
glucosamine on the enzymatic formation of D-glucuronic acid, D-glucuronic 
acid-1-phosphate and glucuronide by rat liver microsomes, a strong indication 
is found that both UDP glucuronyltransferase and ß-glucuronidase are of real 
importance for the D-glucuronic acid formation, at least in vitro. From this 
study it follows that UDP-N-acetylglucosamine is an activator of UDP glucur-
onyltransferase in vitro. It appears that this compound enhances the formation 
of D-glucuronic acid from UDPGA and simultaneously decreases the formation 
of D-glucuronic acid-1-phosphate from the same substrate. The possible ex-
planation might be the following: the pathway A (Fig.2) is inhibited because 
UDP-N-acetylglucosamine competes with UDPGA for the pyrophosphatase 
whereas simultaneously the pathway В is stimulated by the activated UDP 
glucuronyltransferase. 
If the combination of UDP glucuronyltransferase and ß-glucuronidase plays 
a role in the physiological D-glucuronic acid formation, the presence of an 
endogenous acceptor for the glucuronyl moiety is required. Up till now such 
an acceptor could not be detected. It follows that a function of UDP glucuronyl-
transferase and ß-glucuronidase in the D-glucuronic acid formation in vivo is 
not established (see also Miettinen and Leskinen, 1963). 
1.1.1.2 The formation of D-glucuronic acid by catabolism of polysaccharides 
D-glucuronic acid is found copolymerized in 1:1 ratio with substituted 
2-amino-2-deoxy-D-gIucose in compounds as heparin, chondroitin sulfate-A 
and -C, and hyaluronic acid (Whistler and Rowell, 1966). Besides D-glucuronic 
acid biosynthesis, catabolism of such compounds may be a source for D-glucu-
ronic acid in the cell. 
Enzymes for the breakdown of D-glucuronic acid containing polysaccharides 
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are present in the liver. It was found by Hutterer(i965) that enzymes of liver 
lysosomes show hyaluronidase activity. This investigator observed that the 
system used degrades hyaluronic acid, chondroitin sulfate-A and -C into oligo-
saccharides. Aronson and Davidson(i965) have isolated and partially purified 
hyaluronidase from rat liver lysosomes. After incubation of hyaluronidase with 
hyaluronic acid, oligosaccharides were formed which appeared to be identical 
to those resulting from degradation of hyaluronic acid by testicular hyal-
uronidase. ß-Glucuronidase and ß-acetylaminodeoxyglucosidase act alter-
nately on the oligosaccharides (Weissmann et al., 1964). ß-Acetylaminodeoxy-
glucosidase in rat liver is only found in the lysosomes (Sellinger et al., i960); 
ß-glucuronidase can be of microsomal and lysosomal origin (de Duve et al., 
1955). As may be clear from the foregoing, the combined actions of lysosomal 
enzymes may lead to the liberation of D-glucuronic acid from polysaccharides. 
It is not sure whether this route of D-glucuronic acid formation has a physio-
logical significance. Recent results suggest that lysosomes are able to engulf 
hyaluronidase substrates, which are then removed probably by degradation 
(Aronson and Davidson, 1967). 
It was postulated by Laborit (1964) that D-glucuronic acid-containing poly-
saccharides present in the cell, may be degraded and that the remaining D-
glucuronic acid is metabolized further via the xylulose pathway. 
1.1.2 The ascorbic acid pathway 
Experiments with labeled D-glucuronolactone and L-gulonolactone applied 
to rats revealed that an important proportion of these substances is converted 
to L-ascorbic acid (Horowitz and King, 1953; Burns and Evans, 1956). These 
findings were supported by the results of Isherwood et al. (1954), who have 
demonstrated that formation of L-ascorbic acid in intact rats is increased after 
administration of D-glucuronolactone and L-gulonolactone. These observations, 
together with other considerations, led to the postulate that D-glucuronolactone 
and L-gulonolactone are intermediates in the pathway leading from D-glucose 
to L-ascorbic acid. 
The data mentioned above could be used in the identification of the enzymes 
concerned in the biosynthesis of L-ascorbic acid (Fig. 3). 
Glucuronolactone reductase 
The reduction of D-glucuronic acid to L-gulonic acid and of D-glucurono-
(6 -> 3)-lactone (D-glucuronolactone) to L-gulono-(i->4)-lactone (L-gulono-
lactone) respectively is catalyzed by a nicotinamide adenine dinucleotide phos-
phate (NADP)-linked glucuronolactone reductase. The enzyme is found in 
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different organs of various species. Its occurrence is not related to the ability 
of these tissues to synthesize L-ascorbic acid. The presence of the enzyme has 
been shown for the first time by Hassan and Lehninger(i956) in liver extract. 
Mano et al.(i96i) purified the liver enzyme. They found that the enzyme is not 
bound to the microsomes and has its optimal activity at pH 9.6 to 10.0. The 
enzyme catalyzes both reduction as well as oxidation reactions. For the re­
duction reaction with aldehydes as hydrogen acceptors it shows little specific­
ity; as hydrogen donors on the other hand the enzyme accepts only L-hexonic 
acids or their lactones. 
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FIG. 3 The ascorbic acid pathway. 
Note It is not established whether L-ascorbic acid formation in vivo takes place via 
pathway A or via pathway B. 
L-gulonolactone oxidase 
The L-gulonolactone oxidase is involved in the enzymatic conversion of L-
gulonolactone to 2-oxy-L-gulonolactone, which is followed by a spontaneous 
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enolization to L-ascorbic acid. The description of the enzyme was given by 
Chatterjee et al. (i960) and Isherwood et al. (i960). Recently Brush and May 
(1966) published a kinetic study on the mechanism of action of this enzyme. 
From their data it becomes probable that the mechanism involved is a so-called 
'ping-pong' mechanism. The characteristic distinguishing this mechanism for 
enzyme-catalyzed oxidation-reduction reactions from other ones is that the 
enzyme itself is reduced by the first substrate prior to reacting with and reducing 
the second substrate, instead of catalyzing a direct oxidation-reduction reaction 
between the two substrates (Fig. 3). Using a solubilized enzyme from rat liver 
microsomes, Kanfer et al.(1959) and Ashwell et al.(i96i) showed that only 
those compounds that have the hydroxyl group on C-2 in the levo configuration 
(as in L-gulono-, L-galactono-, and L-mannonolactone) are oxidized to an 
analogue of L-ascorbic acid. It is essential that the substrate is in the ester 
or lactone form (Isherwood and Mapson, 1961). The optimal pH for oxidase 
activity is between 6.5 and 7.0. 
Lactonases 
For the biotransformation of D-glucuronic acid to L-ascorbic acid the pre-
sence of a lactonase is needed (Chatterjee et al., 1959). In the liver of all mammals 
studied urono- and aldonolactonase were found to be present. These enzymes 
catalyze the equilibrium between the lactone and acid form. Whether a net 
conversion of acid to lactone takes place or the reaction goes in the opposite 
direction depends on the circumstances; in the absence of a 'trapping agent' for 
the lactone such as, for instance, hydroxylamine, the enzymatic equilibrium 
is in favour of the acid form. 
The uronolactonase is present in the microsomal fraction of the liver cells 
(Winkelmann and Lehninger, 1958; Yamada et al., 1959). The enzyme has a 
high specificity. It accepts D-glucuronolactone as a substrate but L-gulono-
lactone and D-gulonolactone are not converted (Mano et al.,1961). Possibly, 
the formation of D-glucuronolactone as catalyzed by this enzyme is a step in 
the biosynthesis of L-ascorbic acid. In that case the synthesis might follow 
pathway A (Fig. 3). 
The soluble enzyme aldonolactonase (Yamada, 1959) is capable of catalyzing 
the interconversion between L-gulonic acid and its lactone. The enzyme has a 
low specificity. Some lactones such as D-glucuronolactone and D-gulono-
lactone are also accepted as substrates. It is not sure whether aldonolactonase 
plays a role in the biosynthesis of L-ascorbic acid. The enzyme accepts L-gulonic 
acid, which implies that the L-ascorbic acid biosynthesis might follow the 
pathway via D-glucuronic acid and L-gulonic acid. It is not clear whether in 
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that case L-gulonolactone formation would be an obligatory step or whether 
only the formation of a L-gulonyl-aldonolactonase complex is needed. Stirpe 
and Comporti (1965) studied the L-ascorbic acid formation using a 10.000 g 
supernatant of rat liver as a catalyzing system and D-glucuronolactone as a 
substrate. The supernatant was supplied with NAD and adenosine triphosphate 
(ATP). The lactonase activity in the incubate is found to be so high that the 
substrate was hydrolyzed already before the L-ascorbic acid formation was 
appreciably started. L-gulonolactone is also quickly hydrolyzed under these 
circumstances. A tentative explanation which fits to these experiments has been 
given by Isherwood et al. (i960). They suggest that a L-gulonyl-enzyme complex 
formed transitorily from the free acid and the aldonolactonase is oxidized by 
the L-gulonolactone oxidase, possibly with transference of the L-gulonyl 
moiety (Fig. 3, pathway B). 
1.1.2.1 Why are certain mammals unable to synthesize L-ascorbic acid? 
The formation of L-ascorbic acid in mammals takes place in the liver (Chat-
terjee et al.,1961). Man, monkey and guinea pig are not able to synthesize 
L-ascorbic acid and are dependent on an exogenous supply of this substance 
which for them therefore is a vitamine. Burns and Evans (1956) studied the role 
of L-gulonolactone as a precursor of L-ascorbic acid synthesis in rats and 
guinea pigs. In contrast with the appreciable conversion of labeled L-gulono­
lactone to L-ascorbic acid in rats no detectable conversion was observed in 
guinea pigs. Further it was found that cellular fractions of guinea pig liver are 
unable to convert L-gulonolactone to L-ascorbic acid. This indicates that this 
conversion may be postulated as the site for the missing link in the synthesis of 
L-ascorbic acid in this species. Chatterjee et аЦідбі) performed a comparative 
study on the presence in mammalian liver of the enzymes of the ascorbic acid 
pathway. They found that those species which are unable to synthesize L-ascor­
bic acid (man, monkey and guinea pig) possess all the enzymes needed for the 
conversion of D-glucuronic acid to L-gulonolactone but that the enzyme L-gul­
onolactone oxidase is absent. Baker et al. (i960,1962) reported an increased L-
ascorbic acid excretion after giving humans D-glucuronolactone to eat, but these 
results could not be confirmed by Chatterjee et аЦідбі). 
і.і.З The glucaric acid pathway 
The formation of D-glucaric acid represents another pathway of D-glucuronic 
acid metabolism (Marsh, 1964). In the biosynthesis of D-glucaric acid from 
D-glucuronic acid two enzymatic steps are involved. The first one consists in 
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the lactonization of D-glucuronic acid by urono- or aldonolactonase (see 
Section 1.1.2); the second one consists in the oxidation of D-glucuronolactone 
to D-glucaric acid. 
Inhibitors of ß-glucuronidase are known to be present in mammalian urine. 
Marsh (1963a) demonstrated that a substance is present in boiled urine which, 
although non-inhibiting under alkaline conditions, acts as a ß-glucuronidase 
inhibitor after acidic treatment. The fact that the inhibiting action is abolished 
again by the subsequent alkaline treatment suggests that the inhibitor is a 
lactone. It was known already that acidic treatment of D-glucaric acid leads to 
the formation of a lactone, which has a strong inhibiting effect on ß-glucuronid-
ase (Levvy, 1952). As mentioned before, this type of inhibition is observed in 
human urine and in urine of other mammalian species (Marsh, 1963a). Using 
the inhibiting action as a test it was possible to isolate D-glucaric acid bis-
phenylhydrazide in a crystalline and pure form from human urine (Marsh, 
1963a; Aarts, 1965; see also Section 4.3.1). 
An indication for the source of urinary D-glucaric acid is given by the fact 
that the acid-potentiated inhibition, an indicator of the D-glucaric acid content, 
in mammalian urine increases considerably after oral ingestion of D-glucurono-
lactone. Under normal conditions an inhibition equivalent to about io mg 
D-glucaric acid is detected in 24-hr urine of humans. After giving a dose of 5 g 
of D-glucuronolactone this response increases to the hundredfold. On the basis 
of these data the enzyme system for the formation of D-glucaric acid was 
identified (Fig. 4). 
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D-glucuronolactone dehydrogenase 
This NAD-linked enzyme converts D-glucuronolactone (I) (Fig. 4) to a deriv­
ative of D-glucaric acid. Results of Marsh(i966) are consistent with the hypo­
thesis that the (i -»4), (6 -^-dilactone (II) is formed. This substance decomposes 
spontaneously to the (1 -* 4)- and the (6 -* 3)-monolactone (III, IV) and the free 
acid (V). Results of Sadahiro et 31.(1966) are in agreement with the hypothesis 
that the enzyme acts upon the free aldehyde of the (6 -• 3)-lactone of D-glucur­
onic acid. The enzyme in question appears to be distinct from glucurono-
lactone reductase, L-gulonolactone oxidase, glucose dehydrogenase and glu-
cose-6-phosphate dehydrogenase. It does not accept D-glucuronic acid as a 
substrate (Marsh, 1964). The enzyme is present in the liver of all mammals 
examined (rat, mouse, guinea pig and man). In the rat the enzyme is found in 
preparations of liver, kidney and testis; in preparations of spleen, uterus, 
thyroid gland, lung, duodenum and in serum no enzyme activity is detectable. 
The enzyme activity in liver preparations is high in all species examined; the 
enzyme activity in kidney preparations is high in the rat, appreciable in the 
guinea pig and very low in mouse and man (Marsh, 1963b). 
Purified D-glucuronolactone dehydrogenase from rat liver has an activity 
optimum at a pH of about 6.5. If the enzyme is incubated with D-glucaric acid 
or its lactones and NADH2, no D-glucuronolactone is formed, so that no 
reversal of the reaction can be demonstrated. 
Matsui et 31.(1965) observed that after administration of D-mannurono-
lactone to humans a quantity of D-mannaric acid, equivalent to about 20 percent 
of the dose of the lactone, is found in the urine. They made the suggestion that 
the conversion of D-mannuronolactone to D-mannaric acid might be catalyzed 
by D-glucuronolactone dehydrogenase. Sadahiro et 31.(1966) purified D-glu­
curonolactone dehydrogenase from guinea pig liver. The final purification was 
performed by passing the enzyme extract through a diethylaminoethyl(DEAE)-
cellulose column. It was found for the fractions obtained from chromatography 
that the ratio of the conversion rates of D-glucuronolactone 3nd D-mannu­
ronolactone remains constant during the purification steps. Further no differ­
ence in heat stability was observed for the two conversions and з competitive 
substrate inhibition W3S found if both substrates are combined. These results 
suggest that a single enzyme is responsible for the dehydrogenstion of D-glu­
curonolactone and D-mannuronolactone. 
Sadshiro and coworkers (1966) also found зп indic3tion tlmt D-ribose and 
D-ribose-5-phosphate зге substrates for the dehydrogenase in question. More­
over, the experimental results obtained in DEAE-cellulose chromatography 
showed thst the protein реэк of D-glucuronolactone dehydrogenase can not be 
distinguished from that of aldehyde dehydrogenase (EC 1.2.1.3). It is known 
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that the latter enzyme is not very specific (Racker, 1949). In view of the fore-
going the question arises whether the enzyme D-glucuronolactone dehydro-
genase is possibly identical with this aldehyde dehydrogenase. 
It is not known whether the glucaric acid pathway has a physiological signific-
ance. The pathway might be of significance if it results in the formation of the 
(i->4)-lactone of D-glucaric acid, which is known to be a specific inhibitor of 
ß-glucuronidase (see before). So far the presence of this lactone in biological 
fluids could not be demonstrated. This does not necessarily argue against its for-
mation, since under physiological conditions the lactone would be hydrolyzed 
rapidly (Lewy, 1952). 
1.1.4 The xylulose pathway 
This pathway, which is part of the glucuronic acid cycle, leads from D-
glucuronic acid to D-xylulose (Fig. 5). It has been shown by Enklewitz and 
Lasker(i935) that the administration of D-glucuronolactone to patients with 
pentosuria causes a considerably enhanced level of L-xylulose in the urine. This 
suggests that this pentulose is derived from D-glucuronolactone. Touster et al. 
(1955) obtained similar evidence in healthy persons. In further studies with 
labeled compounds it could be demonstrated that the carbon atom 6 of D-
glucuronolactone is lost in the conversion, whereas the carbon atom 1 of the 
lactone becomes carbon atom 5 in L-xylulose (Touster et al., 1957). 
Subsequently it was found that L-xylulose can be formed from D-glucuronic 
acid as well as from L-guIonic acid, but that fewer steps are involved in the 
conversion starting from L-gulonic acid. 
L-gulonate dehydrogenase and keto-L-gulonate decarboxylase 
As mentioned before the formation of L-gulonic acid from D-glucuronic acid 
is catalyzed by glucuronolactone reductase (Section 1.1.2). The conversion of 
L-gulonic acid into L-xylulose (Fig. 5) is catalyzed by NAD-linked L-gulonate 
dehydrogenase and keto-L-gulonate decarboxylase (Ashwell et al., 1959; Smiley 
and Ashwell, 1961). The localization of this L-xylulose-forming system in rat 
liver is still under study. Ishikawa and Noguchi(i957) and Chatterjee et al. 
(i960) reported the conversion of L-gulonic acid to L-xylulose in the soluble 
fraction prepared from this organ. On the other hand experiments of Stirpe 
and Comporti (1965) indicate that the presence of the microsomal fraction is 
needed for the formation of L-xylulose. 
L-xylulose reductase and D-xylulose reductase 
Two enzymes were found to be involved in the conversion of L-xylulose to 
D-xylulose. They are both present in the mitochondria (Hollmann and Touster, 
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Note The xylulose pathway, the glucuronic acid pathway and the pentose phosphate 
pathway form a cycle which is called the glucuronic acid cycle. 
1956,1957). They have been identified as a NADP-linked L-xylulose reductase 
of high substrate specificity catalyzing the interconversion between L-xylulose 
and xylitol and as a NAD-linked D-xylulose reductase with little substrate 
specificity. The latter enzyme may convert xylitol to L-xylulose as well as to 
D-xylulose; the latter product, however, is mainly formed. 
The pentose phosphate pathway in the glucuronic acid cycle 
The fact that an interconversion of L-xylulose and D-xylulose via xylitol was 
found to exist, raised the possibility that D-glucuronic acid metabolism via the 
xylulose pathway is linked to the pentose phosphate pathway, thus closing a 
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cycle. The link requires a Phosphokinase, catalyzing the phosphorylation of 
D-xylulose to D-xylulose-5-phosphate which is a key intermediate in the pentose 
phosphate pathway. 
Xylulokinase 
Indeed the enzyme xylulokinase was reported to be present in calf liver (Hick-
mann and Ashwell, 1958). Thus the experimental base was laid for the closure 
of the glucuronic acid cycle, a cyclic pathway of D-glucose metabolism via 
D-glucuronic acid, L-xylulose and the pentose phosphate pathway (Burns and 
Kanfer,i957)(Fig.5). 
Further evidence for the physiological occurrence of the glucuronic acid 
cycle was needed. It was found that L-xylulose incubated with liver slices in an 
appropriate medium disappears while xylitol is formed (Touster et al., 1954, 
1956). In view of this finding McCormick and Touster(i957) administered 
labeled xylitol to rats and guinea pigs. Their experiments showed that xylitol is 
an efficient precursor of liver glycogen in rat and guinea pig. Administration of 
xylitol-i-C14-5-C13 to rats led to a labeling pattern in glycogen which is in 
accord with metabolism via the xylulose pathway and the pentose phosphate 
pathway (McCormick and Touster, 1957; Eisenberg et al., 1959). 
Essential pentosuria 
Essential pentosuria is an inborn error in metabolism found in Jewish and 
Arab people (Hiatt, i960). The condition is characterized by a high level of 
L-xylulose in the urine. The evidence that an individual with this metabolic 
error lacks the L-xylulose reductase is convincing (Touster, 1959) although an 
enzyme assay in the liver of patients with pentosuria has not been performed. 
The role of the xylulose pathway is not fully elucidated. There is indirect 
evidence that little carbohydrate is actually metabolized through this pathway 
(Hiatt and Lareau, 1958). The failure to convert L-xylulose to xylitol in individu-
als with pentosuria is quite harmless. So the pathway is not essential for the or-
ganism. It is conceivable that the large number of oxidation-reduction reactions 
in the pathway helps to regulate tissue coenzyme levels (Touster and Shaw, 1962). 
In this connection it is remarkable that in the xylulose pathway NAD is always 
used in the dehydrogenations whereas NADPH2 is always used in the reductive 
steps. Laborit(i964) postulated that the xylulose pathway may be involved in 
the disposal of D-glucuronic acid formed by the degradation of the poly-
saccharides belonging to the cell. In the experimental animals a high proportion 
of exogenous D-glucuronolactone is rapidly catabolyzed to CO2 and H2O, part 
of it is converted to D-hexoses and then incorporated into glycogen (Douglas 
and King, 1953; Butler and Packham, 1955; Burns and Evans, 1956; Eisenberg 
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et al., 1959). Since the xylulose pathway known so far is the only route for 
catabolism of D-glucuronolactone or for conversion to D-hexoses and thus to 
glycogen, this fact suggests that this pathway serves the elimination of surplus 
of D-glucuronic acid in the cell, irrespective of its source. 
7.7.5 Glucuronide formation 
In the following section only those aspects of the glucuronide formation, 
which have a special bearing on our study will be discussed in greater detail. 
For a more representative introduction into this subject the reader may be 
referred to several review articles published by Dutton(i962,1966) and Holl-
mann(i964). 
Many drugs and drug metabolites are eliminated from the body in the form 
of glucuronides. In order to be conjugated these compounds should have 
a reactive group, e.g. a hydroxyl, amino, sulfhydryl or carboxyl group. Drugs 
containing such a group function as acceptors. Glucuronide formation occurs 
by transfer of the glucuronyl moiety from UDPGA to the acceptor (Fig. 6). 
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no. 6 The glucuronide formation. 
Note The glucuronyl moiety in uridine diphosphate glucuronic acid occurs in a-
position, but in the glucuronide in ß-position. 
The enzymes responsible for the transference are called UDP glucuronyl-
transferases (Dutton and Storey, 1954). The conjugation involves a Walden 
inversion, since the conjugated compounds are ß-D-glucosiduronic acids, where-
22 
as the glucuronyl moiety in UDPGA has the α-configuration. The transferase 
reaction is not reversible. 
Glucuronidation takes place especially in the liver. Originally it was supposed 
that the microsomal UDP glucuronyltransferase activity in the liver is dependent 
on one enzyme with a low specificity and a wide pH optimum. This enzyme was 
thought to conjugate endogenous substrates such as bilirubin, thyroxin and 
steroid hormones as well as drugs and drug metabolites, substrates which 
normally are not present in the organism. More recent findings give a strong 
evidence that in the liver more than one transferase is present (Isselbacher et al., 
1962; van Leusden, 1963; Dutton, 1966b; Tomlinson and YafTe, 1966; Gram et 
al., 1968). Some of these findings come from developmental studies using liver 
tissues of fetal and very young animals. In these experiments a distinct increase 
of the transferase activity during development is found to occur. Measured 
with different phenols as substrates, quite different developmental rates of 
transferase activity are found (Tenhunen, 1965; Dutton, 1966b). The same holds 
with respect to phenols compared with bilirubin (Tomlinson and Yaffe.igóó). 
An obvious explanation of these results is found in the supposition that several 
UDP glucuronyltransferases exist. 
Definite proof of the presence of more than one transferase is complicated 
by the fact that the transferase(s) in the liver cell is (are) connected with the 
endoplasmic reticulum. In this connection it may be remarked that in another 
tissue, viz. the ileal mucosa of man, the existence of two different transferases 
could be readily demonstrated. In these cells a soluble transferase catalyzing 
only the conjugation with aliphatic hydroxyl groups occurs. This enzyme is 
different from a microsomal transferase in the mucosa which catalyzes con-
jugations with aromatic hydroxyl groups as well as with aliphatic hydroxyl 
groups (Dahm et al., 1966). 
If it is true that also in the liver different UDP glucuronyltransferases occur, 
it is conceivable that these different enzymes will serve different purposes. 
A function with respect to the elimination of potentially harmful substances is 
obvious. According to certain data (Section 1.1.1.1; Miettinen and Leskinen, 
1963) a second function for UDP glucuronyltransferase is possible, viz. in the 
formation of D-glucuronic acid. It has been postulated that D-glucuronic acid 
is formed from UDPGA in the following way: first the glucuronyl moiety of 
UDPGA is transferred to an endogenous acceptor under the influence of UDP 
glucuronyltransferase, and subsequently the formed glucuronide is hydrolyzed 
by ß-glucuronidase to give free D-glucuronic acid. 
Since the glucuronidation as a way of detoxification of potentially harmful 
substances utilizes UDPGA, a substance taking a central position in the 
glucuronic acid system (Section 1.1.1.1), it may be linked to this system. The 
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question arises whether the UDPGA used in the various pathways of this sy-
stem and that used for glucuronidation of substances to be eliminated comes 
from a common UDPGA pool in the liver or whether the UDPGA used for the 
glucuronidation and that used in the glucuronic acid system are formed in 
separated biochemical systems, although according to the same biochemical 
principles. 
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CHAPTER 2 
STIMULATING EFFECT OF DRUGS ON CARBOHYDRATE 
METABOLISM VIA THE GLUCURONIC ACID SYSTEM 
REVIEW OF THE LITERATURE 
2.1 Introduction 
In this chapter investigations reported in the literature on the stimulation of 
carbohydrate metabolism via the glucuronic acid system caused by drugs, will 
be summarized and discussed. Brief reviews on this topic were written by 
Burns and Shore(i96i) and Touster and Shaw(i962). 
2.2 Characterization of the stimulation 
With the term stimulation of the glucuronic acid system (see Figs, ι and 7) is 
meant the stimulation by drugs or chemicals in general of metabolism in the liver 
of glycolytic intermediates via the pathways of the glucuronic acid system as 
outlined in Section 1.1. The experimental data in the literature are in agreement 
with the postulate that this stimulation is initiated in the glucuronic acid path-
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glucuromdee D-glucaricacid L- aecorBic acid 
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undine diphosphate 
glucuronic acid(UDPGA) 
uridine diphoephale .^ undine diphosphate 
galackoee -* glucose CUDPG) 
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no. 7 D-hexose metabolism via uridine diphosphate glucuronic acid (UDPGA). 
Note In the urine of drug-treated animals enlarged amounts of the underlined pro­
ducts have been detected. 
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way leading from D-hexose to D-glucuronic acid (Conney et al.,1961). The 
stimulation results in an enhanced excretion in the urine of endproducts from 
the various pathways of the glucuronic acid system. 
The observations of the drug-induced increased excretion of products from 
the glucuronic acid system such as L-xylulose and L-ascorbic acid by man and 
rat respectively, are of much older date (Enklewitz and Lasker, 1935; Lon-
genecker, 1940) than the identification of the enzyme systems involved in the 
formation of these products (Chapter 1). The increased excretion of D-glucur-
onic acid by rats treated with barbital as a stimulating drug is a more recent 
observation (Burns et al., 1957). 
As will be shown in the discussion of our own results (Chapters 4 and 5) the 
stimulation of the glucuronic acid pathway by drugs also results in an increased 
excretion of D-glucaric acid by man and other mammals. 
There are indications that stimulation of the glucuronic acid system is not 
confined to mammals. It has been shown recently that treatment of fishes with 
aminophenazone or barbital results in an enhanced level of L-ascorbic acid in 
the liver and that the hepatic enzyme systems involved in the L-ascorbic acid 
biosynthesis in the fish are of the same nature as those occurring in mammalian 
liver (Salseduc, 1968). The conclusion may be that, as in the rat, in the fish 
also stimulation of the glucuronic acid system occurs during drug treat-
ment. 
The investigation of the glucuronic acid system got an impetus from the 
observation that stimulation of this system by drugs and the inherent increased 
excretion of L-ascorbic acid coincide with the induction of an increased activity 
of drug-metabolizing enzyme systems (Conney and Burns, 1959). This co-
incidence of the stimulating influence on drug metabolism and the stimulating 
influence on the glucuronic acid system could be confirmed for different groups 
of drugs (Table 1). The stimulating drugs are chemically and pharmacologically 
unrelated. It is not necessary that the stimulating compound is metabolized 
itself. Barbital, although very slightly metabolized (Ebert et al., 1964) is never-
theless a strong stimulator. Neither is it necessary that the drugs involved or 
metabolites of them are conjugated to a large extent with D-glucuronic acid 
(Burns et al., 1957). 
The increased excretion of L-ascorbic acid in the urine after drug treatment 
was especially studied in the rat. The quantity of L-ascorbic acid excreted during 
treatment of the animals with various stimulating drugs (summarized in Table 1) 
amounts to 50-fold of the normal excretion. Certain groups of compounds, 
such as phenols, salicylates, sulphonamides and hormones are weak stimulators. 
Examples of drugs that do not stimulate the L-ascorbic acid excretion are 
the readily water-soluble compounds acetazolamide and 2,4-dinitrophenol 
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and the slightly water-soluble compounds caffeine and theobromine. Only if 
applied in relatively high doses, certain hormones bring about an increase in the 
L-ascorbic acid excretion, as a rule, however, not to a larger extent than the 
2-fold of the normal excretion. As was reported for androgens and anabolic 
steroids by Vanha-Perttula(i963) and for the growth hormone by Salomon and 
Stubbs(i96i) the stimulating effect of these compounds becomes manifest only 
after a few days of application. This in contrast to the stimulating effect of the 
drugs, mentioned in Table I. 
2.s The biochemical basis of the stimulating action of drugs on the glucuronic acid 
system 
2.3.1 Results obtained in in vivo experiments 
L-ascorbic acid biosynthesis 
In the investigations on the biochemical background of the stimulating action 
of drugs on the L-ascorbic acid biosynthesis emphasis was put on those drugs 
which act as strong stimulators. As such, the sedatives barbital and chloretone, 
the antipyretic aminophenazone and the carcinogen 3-methylcholanthrene can 
be mentioned. As said before, active stimulating drugs can increase the ex-
cretion of L-ascorbic acid by rats tremendously. Upon this fact Longenecker 
et al.(1940) based the following conclusion: 'In view of the fact that without 
any other L-ascorbic acid intake the quantities excreted each day are far in 
excess of the total body stores, the phenomenon obviously involves an in-
creased rate of synthesis unless one postulates a normal, very rapid turnover 
that might be blocked by a second step with resultant accumulation of L-
ascorbic acid'. By applying radio-active isotopes, it was possible to obtain 
definite proof for the increased biosynthesis. By these means, Burns et al. (1953) 
and Conney et 31.(1961) determined the body pool, the turnover rate (expressed 
as the amount synthesized or the amounts metabolized and excreted each day) 
and the excretion of L-ascorbic acid in rats during treatment with the stimulating 
drugs chloretone, pentobarbital or 3-methylcholanthrene. In untreated rats the 
body pool was about io mg L-ascorbic acid per 100 g body weight; the amounts 
metabolized and excreted were found to be 2.0 mg and 0.5 mg per 100 g body 
weight per day respectively. Compared with the untreated animals, under the 
influence of drug treatment the body pool increased with a factor 2, the turn-
over rate with a factor 5 to 10, the quantity metabolized with a factor 5, and the 
quantity excreted with a factor 5 to 40. 
After it was proved that as a result of the stimulation an increased bio-
synthesis of L-ascorbic acid takes place, the question arose at which step of the 
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sequence of enzymatic reactions leading from D-hexose to L-ascorbic acid, 
stimulation is initiated. 
D-glucuronic acid biosynthesis 
An indication of the D-glucuronic acid pathway (Fig. 2 and in Fig. 1 : I and 
la) as the important sequence where initiation takes place was found in the 
observation of Burns et al. (1954) that application of barbital to rats not only 
results in an enhanced L-ascorbic acid excretion but also in an enhanced D-
glucuronic acid excretion. These data and the observations that during treatment 
with the stimulating drugs barbital, chloretone and 3-methylcholanthrene an 
increased conversion of D-glucose-1-C14 into radio-active L-ascorbic acid as 
well as into radio-active D-glucuronic acid takes place (Burns and Evans, 1956; 
Conney et al., 1961), point to the glucuronic acid pathway as the system in which 
stimulation is initiated. It is shown by Evans et al.(i960) that D-galactose-1-С14 
is incorporated into D-glucuronic acid, L-gulonic acid and L-ascorbic acid in 
barbital-treated rats, even to a higher degree than D-glucose-1-C14. The labeled 
carbon atom of D-galactose undergoes considerably less randomization. So 
evidence is presented that D-galactose is a more direct precursor of the acids 
than is D-glucose. In view of the evidence that D-galactose is a more direct 
precursor of UDPG (Siu and Wood, 1959) than D-glucose, the results of the 
in vivo experiments given by Evans et al. (i960) are in accord with an enhanced 
carbohydrate metabolism via the nucleotides UDPG and UDPGA during 
stimulation. Chloretone does not stimulate the incorporation of D-glucurono-
lactone-1-C14 and L-gulonolactone-1-C14 into L-ascorbic acid (Burns and 
Evans, 1956). These results suggest that the primary effect of chloretone and 
probably of stimulating drugs in general, is to increase the synthesis of D-
glucuronic acid in the cell, which is then utilized for the synthesis of L-ascorbic 
acid. 
The fact that both D-glucose and D-galactose are converted into L-ascorbic 
acid more rapidly under the influence of drug treatment indicates that the 
probable site of action is located in the enzymatic steps which the D-glucose 
route and the D-galactose route have in common (Fig. 7). The enzymes connected 
with these steps e.g. UDPG dehydrogenase, nucleotide pyrophosphatase, phos­
phatase, UDP glucuronyltransferase and ß-glucuronidase (Fig. 2) require fur-
ther attention in this respect. See further Section 2.3.2. 
L-xylulose biosynthesis 
During treatment of pentosuria patients with bomeol, aminophenazone or 
Phenazone, an increased excretion of L-xylulose in the urine is observed within 
24 hours after the first dose (Enklewitz and Lasker, 1935). Aminophenazone 
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and phenazone strongly increase the L-ascorbic acid excretion in the rat; 
borneol does so to a lesser degree (Longenecker et al., 1940). The increased ex-
cretion of L-xylulose can be interpreted as the stimulating influence of borneol, 
aminophenazone and phenazone on the glucuronic acid pathway, similar to 
that observed for barbital, chloretone and 3-methylcholanthrene, which, as was 
indicated before, have as a primary effect an increase in the synthesis of D-
glucuronic acid from D-glucose. In healthy individuals treated with drugs the 
increased activity in the xylulose pathway does not result in the appearance of 
extra pentose in the urine. In patients with pentosuria the pathway is blocked 
at the point where the conversion of L-xylulose to xylitol takes place (Section 
1.1.4), so that in such patients the stimulation results in an increased excretion of 
L-xylulose in the urine. 
D-glucaric acid biosynthesis 
Since the stimulation of the glucuronic acid pathway, as mentioned before, 
results in an increased excretion of L-ascorbic acid and, under particular con-
ditions, of L-xylulose, it might be expected that also an increased formation 
and excretion of another product of the glucuronic acid system, i.e. D-glucaric 
acid, will take place. Marsh and Reid(i963) obtained indications for this sup-
position. These investigators treated rats with barbital and chloretone and 
observed that in the urine obtained during drug treatment the reaction on 
D-glucaric acid is more positive. 
The reaction on D-glucaric acid is based on the acid-potentiated inhibition 
of ß-glucuronidase. It is known that heating of D-glucaric acid at 1000C for 40 
minutes at a pH of about 3 results in the formation of the D-glucaro-(i-^-lac-
tone, a strong inhibitor of the enzyme ß-glucuronidase (Section 4.3.1.). There 
are no indications of other substances in the urine, which after such a treatment 
act as inhibitors for this enzyme. The acid-potentiated inhibition by urine is 
strongly increased after drug treatment. It is proposed that the increased excre-
tion of D-glucaric acid in the urine after drug treatment is the result of an in-
creased formation of this acid in the liver, based on a stimulation of the 
glucuronic acid pathway (Marsh and Reid, 1963). 
Is de novo enzyme synthesis involved in the stimulation of the glucuronic acid 
system by drugs? 
It has been put forward that the stimulation of the glucuronic acid pathway 
is the result of the enhanced level of hepatic enzymes involved in the formation 
of D-glucuronic acid. An argument for this supposition was the observation in 
rats treated with the stimulating drugs barbital and 3-methylcholanthrene that 
ethionine, an inhibitor of protein synthesis, prevents the response in the urinary 
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excretion of L-ascorbic acid (Touster et al., i960; Neumann et al., 1963; Holl-
mann and Touster, 1962). However, the prevention was only found to be partial 
(de Matteis, 1964; Kato, 1967). Available evidence now indicates that the in-
hibition of protein synthesis in the liver by ethionine is a secondary result of a 
decrease in the concentration of ATP (Villa Trevino et al., 1963). This decrease 
would also explain the strong decrease in the levels of D-fructose-i,6-diphos-
phate, D-glucose-6-phosphate and NAD after ethionine treatment (Bartels and 
Hohorst, 1963; Stekol, 1963). The effect of ethionine on the response to drugs 
could then be explained from the decreased availability of glycolytic inter-
mediates and NAD for the conversion into UDPGA, rather than from in-
hibition of enzyme synthesis. The observation of de Matteis(i964) that actino-
mycin D does not inhibit the stimulating effect of 2-allyl-2-isopropylacetamide 
on L-ascorbic acid excretion by rats indicates that de novo enzyme synthesis is 
not involved in the stimulation. 
Involvement of hormones in the stimulation of the glucuronic acid system 
Because of the apparent lack of a relationship between chemical structure or 
pharmacodynamic activity and the capacity of drugs to enhance the L-ascorbic 
acid excretion. Burns et al. (1957) considered the possibility that the drugs might 
act in an unspecific indirect way. Their finding that in hypophysectomized rats 
no stimulation of the L-ascorbic acid excretion takes place after chloretone or 
barbital treatment points in the direction of certain hormonal control processes 
as possible sites of initiation. These results, however, could not be confirmed 
by other investigators (Salomon and Stubbs, 1961; Hollmann and Touster, 
1961; Klinger et al., 1965). The observations, however, still leave open the 
possibility of the stimulation of the glucuronic acid system by the action of the 
drugs via certain hormonal processes. In Section 7.1.1 these aspects will be 
discussed in further detail and extended with the results of new experiments. 
The fact that in nephrectomized rats during drug treatment the level of L-
ascorbic acid in the blood is strongly increased (Burns et al., i960; Martin, 1961) 
indicates that renal mechanisms are not involved. 
2.3.2 Results obtained in in vitro experiments 
It is a plausible assumption that the increased excretion of the products of 
the glucuronic acid system is the result of an enhanced synthesis of these pro-
ducts in the liver. A convincing argument for this point of view is found in 
the fact that in mammals the liver is the organ where L-ascorbic acid is syn-
thesized (Chatterjee et al.,1961). Data for direct experimental proof for the 
enhanced biosynthesis of the various products of the glucuronic acid system in 
the perfused liver of drug-treated animals were not found in the literature. 
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Effect of stimulating drugs on enzyme activity 
Efforts to stimulate the L-ascorbic acid synthesis in liver preparations were 
unsuccessful up to now. The application of stimulating drugs to liver homogen­
ates gave no indication whatsoever of an increased activity of the enzymes in­
volved in the glucuronic acid system, nor of an enhanced L-ascorbic acid syn­
thesis. In fact the stimulating drugs such as chloretone and barbital are able to 
inhibit certain of the enzymes involved in the glucuronic acid system. The enzyme 
glucuronolactone reductase is found to be inhibited non-competitively by 
barbital (Mano et al.,1961). The formation of D-glucuronic acid-1-phosphate 
from UDPGA is also inhibited by barbital (Hollmann and Touster, 1962). The 
enzyme D-glucuronolactone dehydrogenase is inhibited non-competitively by 
barbital, pentobarbital, thiopental and chloretone (Marsh, 1963c). The con­
centrations of the various drugs which cause an enzyme inhibition in vitro are 
of the same order as those occurring in the plasma of the animals during the 
stimulation experiments. As a matter of fact the effectiveness of the drug con­
centrations concerned in in vitro and in in vivo experiments is not necessarily 
comparable. The results mentioned might, however, indicate that the enzymatic 
steps inhibited by the direct action of the various drugs are probably not rate-
limiting as far as the conversions in the glucuronic acid system are concerned. 
The information about the influence of drugs on the breakdown of L-ascor­
bic acid in liver tissue is not complete. It has been shown by Conney et аЦідбі) 
that the stimulating drugs 3-methylcholanthrene, chloretone and pentobarbital 
in vivo markedly shorten the half-life time of L-ascorbic acid in the rat. Koch 
and Klinger(i963) report that in liver homogenates of rats, which were treated 
for 4 days with barbital, a retarded disappearance of added L-ascorbic acid 
takes place, although the L-ascorbic acid level originally present in the homo-
genate does not decrease under the same experimental conditions. They report 
an accelerated disappearance of exogenous as well as endogenous L-ascorbic 
acid after treatment with hexobarbital. Taking into account the small number 
of experiments performed, it is doubtful whether definite conclusions can be 
drawn from the experiments of Koch and Klingen 
UDPG dehydrogenase 
In Section 2.3.1 the possibility that the stimulation of the glucuronic acid 
system by drugs is based on an increased synthesis of enzymes has been put 
forward. Application of drugs to liver tissue preparations as was described 
before, does not result in any stimulation. The study of enzyme activity in the 
liver preparations of animals treated with drugs gave interesting results. Conney 
et al. ( 1961) reported that in liver homogenates of rats treated orally with 
chloretone for 7 days an increased conversion of D-galactose-l-C14 to D-
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glucuronic acid-1-С14 takes place. In more detailed studies on the effect of 
treatment with chloretone on the formation of D-glucuronic acid and L-
ascorbic acid by liver homogenates an enhanced activity of the enzyme UDPG 
dehydrogenase was reported by these investigators. Neither the activities of 
liver microsomal pyrophosphatase and phosphatase, the latter tested with D-
glucuronic acid-1-phosphate as a substrate, nor the activities of the enzymes 
involved in the conversion of D-glucuronolactone and L-gulonolactone into 
L-gulonolactone and L-ascorbic acid respectively, appeared to be increased 
after treatment with chloretone. The activity of L-gulonolactone oxidase was 
even found to be decreased. This might indicate that the increased activity of 
UDPG dehydrogenase — the only activity found to be enhanced after pretreat­
ment with chloretone — is primarily involved in the stimulation of the glucur­
onic acid pathway by drugs. Hollmann and Touster (1962) also described an 
increased activity of UDPG dehydrogenase in liver homogenates from guinea 
pigs and rats treated during 4 days with chloretone or barbital. Zeidenberg et 
31.(1967) observed that in rats treated daily with phénobarbital the increased 
activity of the UDPG dehydrogenase does not manifest itself clearly before 
the treatment has lasted for 3 or more days. Under the same circumstances 
the activity of UDP glucuronyltransferase was also found to be enhanced after 
only a few days of treatment. As will be discussed in more detail in the experi-
mental sections (see also Aarts, 1966), pretreatment of rats or guinea pigs with 
barbital for a short period, 1 to 3 days, did not result in an increase in the activ-
ity of UDPG dehydrogenase in the liver homogenates. 
UDP glucuronyltransferase 
The possible significance of the increase of the activity of the UDPG de-
hydrogenase after drug treatment for the stimulation in the glucuronic acid 
system cannot be generalized, since for certain stimulating drugs such as 
aminophenazone and the polycyclic carcinogens, no increase in the activity of 
the enzyme concerned could be detected (Inscoe and Axelrod, i960; Touster et 
al., 1961). These drugs, however, were found to be able to increase the activity 
of UDP glucuronyltransferase. 
The UDP glucuronyltransferase is involved in the transfer of D-glucuronic 
acid from the donor UDPGA to the acceptor drugs and drug metabolites under 
the formation of glucuronides (Section 1.1.5). It has been put forward that the 
increased activity of UDP glucuronyltransferase might also lead to an enhanced 
formation of D-glucuronic acid and L-ascorbic acid from UDPGA (Touster 
et al., 1962). As discussed in Sections 1.1.1 and 1.1.5 it is questionable whether 
an UDP glucuronyltransferase is involved in that part of the glucuronic acid 
system, which leads from UDPGA to D-glucuronic acid. 
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From the foregoing it is clear that the definite proof of the significance of in-
creased activities of UDPG dehydrogenase and UDP glucuronyltransferase for 
the stimulation of the glucuronic acid system has not been established. 
Further investigations in this respect are required (Section 5.4 and Chapter 6). 
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CHAPTER 3 
MATERIALS A N D M E T H O D S 
3.1 Animals 
Wistar rats and guinea pigs maintained on Hope Farms Laboratory Diet, 
with free access to water were used. The guinea pigs received an extra supply 
of 20 mg L-ascorbic acid per day; the rats received L-ascorbic acid-free food. 
3.2 Analytical methods 
Preparation and storage of tissue 
Immediately after killing the animals by a blow on the head, the tissues to 
be used were removed, cooled in ice and homogenized with the Ultra-turrax 
homogenizer TP 18/2. The homogenized tissue was kept at 40 if it was to be used 
without delay and stored at a temperature below o0 if it was to be used later. 
Preparation and storage of urine 
The urine for determination of L-ascorbic acid was collected in a 10 % oxalic 
acid solution. For other determinations urine was collected as such. Urine was 
stored at 40 or below 0° depending on the period of time before analysis (see 
above). 
L-ascorbic acid in urine 
L-ascorbic acid was determined by the 2,6-dichlorophenolindophenol 
method (Oliiver, 1954). 
L-ascorbic acid in tissue 
The method of Schaffert and Kingsley(i955) was applied. 
D-glucaric acid in urine 
D-glucaric acid was assayed with the aid of the inhibiting action of its 
(i-+4)-lactone on ß-glucuronidase (Section 4.3.1). In the assay Phenolphthalein 
glucuronide is used as substrate. If the D-glucaric acid content has to be 
assayed in urine which contains amounts of glucuronides coming from drugs 
or drug metabolites an interference in the D-glucaric acid assay may occur. 
For that reason the following procedure was followed if glucuronides were 
expected to be present in the urine. The urine was adjusted to pH 7 and heated 
at 100° for 20 min. After readjustment at pH 7, if necessary, the urine was incu-
bated with ß-glucuronidase (Sigma type I, active at pH 7,1000 U/ml urine) for 
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48 hours at 37° to eliminate possibly interfering glucuronides. After inactivation 
of the ß-glucuronidase by heating for 5 min at 1 ooc, the urine was extracted twice 
with a double volume of ethyl acetate and assayed by the procedure of Marsh 
(1963a). 
The method given above was applied if patients or animals had been treated 
with the following drugs : thiopental, aminophenazone, phenylbutazone, Pheny-
toin, tolbutamide, borneol and salicylic acid. 
If very little glucuronide was expected to be present in the urine, as is the case 
for barbital, nikethamide and DDT, the urine was adjusted to pH 7 and heated 
to 1000 for 20 min. Then the urine was extracted twice with a double volume of 
ethyl acetate and assayed by the procedure of Marsh (1963a). 
The urines of control animals and drug-treated animals were treated in the 
same way. 
D-glucaric acid in tissue 
The tissue homogenate was centrifuged at 9000 g for 20 min. The supernatant 
was deproteinized and a suitable portion was used for the D-glucaric acid assay 
as described by Marsh (1963b). 
D-glucose in urine (qualitative) 
The color test with Clinistix reagent strips was used. 
D-glucuronic acid in urine 
Dische's carbazole reaction modified by Yuki and Fishman (1963) for differ-
ential analysis was applied. 
Glucuronides in urine 
Dische's carbazole reaction modified by Yuki and Fishman (1963) was 
applied. 
D-mannaric acid in urine 
The total quantity of D-glycaric acids (in this case D-mannaric acid plus 
D-glucaric acid) was measured with the method of Ishidate et al. (1965). The 
quantity of D-glucaric acid in urine was determined as described above. The 
quantity of D-mannaric acid was calculated by subtracting the quantity of 
D-glucaric acid from the total quantity of D-glycaric acids determined. 
3.3 Enzymatic assays 
Immediately after killing the animal the liver was removed, cooled in ice and 
homogenized in 4 volumes of 0.15 M KCl in a Potter-Elvehjem grinder. Homo-
genates were centrifuged for 30 min at 9000 g and the supernatants were used 
for all assays. 
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Demethylation 
The rate of demethylation was determined with the procedure described by 
Smith et 31.(1963) with slight modifications. GIucose-6-phosphate dehydrogen-
ase (5 Romberg units of G 6-OH 15303 Boehringer) was added, aminophena-
zone was used as a substrate, and the incubation time was 1 or 3 hours. 
D-glucuronolactone dehydrogenase 
D-glucuronolactone dehydrogenase was determined according to Marsh 
(1963b). 
Tyrosine aminotransferase 
Tyrosine aminotransferase was determined according to Kenney (1959) 
except that no pyridoxal phosphate was added during incubation. Under the 
circumstances in the course of this study the addition of the compound is not 
essential. 
UDPG dehydrogenase 
UDPG dehydrogenase was determined according to Strominger et 31.(1957). 
Proteins 
Proteins were estimated by the procedure of Lowry(i95i), using bovine 
serum albumin (Sigma) as a standard. 
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CHAPTER 4 
THE INFLUENCE OF DRUGS ON THE EXCRETION OF 
D-GLUCARIC ACID IN MEN AND GUINEA PIGS 
4.1 Introduction 
The stimulation of the glucuronic acid system by drugs becomes especially 
manifest in an increased excretion of L-ascorbic acid in the animals treated. 
The question arises whether the stimulation after drug treatment also occurs in 
man. As known, man lacks the ability to synthesize L-ascorbic acid (Section 
1.1.2.1) and therefore an increase in the excretion of this acid cannot be ex-
pected and cannot serve as an indication of the stimulation under discussion. 
The observation of the increased excretion of L-xylulose in patients with 
pentosuria after treatment with drugs such as borneol, aminophenazone and 
Phenazone indicates that also in man drug treatment results in a stimulation of 
the glucuronic acid system; however, in healthy individuals this stimulation 
will not manifest itself by an increased excretion of L-xylulose in the urine, 
since then the L-xylulose formed is processed further in the glucuronic acid 
cycle (Section 1.1.4). In order to detect a stimulation of the glucuronic acid 
system in man the endproduct of one of the other pathways should be taken 
into consideration. 
The question arises whether D-glucuronic acid can be considered as an end-
product. The acid is normally excreted in the urine of mammals. Although it is 
excreted in greater quantities after treating rats or guinea pigs with a stimulating 
drug such as barbital (Burns et al., 1957), it is still questonable whether the 
increased excretion of D-glucuronic acid is suitable as a criterion for the 
enhanced activity in the glucuronic acid system. 
According to the results of balance experiments (Südhof and Schellong, 1953 ; 
Fretwurst and Ahlhelm, 1953) and experiments with radio-active products 
(Butler and Packham, 1955), D-glucuronolactone administered orally to 
mammals can be metabolized almost completely, so that practically no D-
glucuronic acid administered in the lactone form appears in the urine. The 
products formed from D-glucuronolactone are L-ascorbic acid, D-glucaric acid, 
glycogen, CO2 and H2O (Sections 1.1.2, 1.1.3, 1.1.4). D-glucuronolactone ad-
ministered to patients with hepatitis or liver cirrhosis and to dogs with an Eck fis-
tula is metabolized to a lesser degree than under normal conditions (Hollmann, 
1954). The latter data indicate that the metabolism of D-glucuronolactone or D-
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glucuronic acid primarily takes place in the liver (Hollmann, 1964). As for the D-
glucuronolactoneand D-glucuronic acid formed in the liver, it may also be expect-
ed that in the normal liver they are easily converted into L-ascorbic acid, D-glucar-
ic acid and glycogen so that only a small fraction of them may appear in the urine. 
If D-glucuronic acid as such or as a constituent of food is applied orally to 
mammals a definite excretion of the acid in the urine is observed. Exogenous 
D-glucuronic acid as opposed to exogenous D-glucuronolactone, probably 
because of its high polarity, is not or only slightly taken up by the liver (Eisen-
berg, 1957) but excreted quickly by the kidney. The varying quantities of D-
glucuronic acid in the urine after intake of different kinds of food (Remmer, 
1959; Hänninen, 1966) can be explained by the varying quantities of D-glucur-
onic acid in the food. 
Another reason why the D-glucuronic acid excretion is less suitable as a 
criterion for the stimulation of the glucuronic acid system is the fact that many 
drugs and their metabolic products are conjugated to D-glucuronic acid. The 
conjugated forms (glucuronides) are excreted with the urine or bile. The quantities 
of these glucuronides are mainly dependent on the quantity of acceptor (drugs 
or drug metabolites) available for the UDPGA. Taking into account the 
unstable character of these glucuronides and the presence of ß-glucuronidase 
in the gut and in the urine, it is difficult to differentiate between the D-glucuronic 
acid in the urine originating from glucuronide disjunction or that originating 
directly from the glucuronic acid pathway in the liver. 
The question arises whether the glucuronide excretion as such can serve as a 
criterion. The biochemical link between the glucuronidation of drugs and drug 
metabolites and the rate of turnover in the glucuronic acid system is in no way 
clear as yet (Section 1.1.5). For the glucuronide formation the presence of 
suitable acceptors such as drugs and drug metabolites is of predominant 
significance. This implies that the glucuronide excretion cannot serve as a 
suitable parameter for the activity in the glucuronic acid system. 
Another endproduct of the glucuronic acid system to which little attention 
has been paid in the past, viz. D-glucaric acid, may offer a better opportunity. 
The conversion of D-glucuronic acid to D-glucaric acid takes place via D-
glucuronolactone as an intermediate. Under normal conditions D-glucaric acid 
is excreted by man in a quantity of about io mg per 24 hours. D-glucurono-
lactone, applied orally to man is converted partially to D-glucaric acid (Marsh, 
1963a; Okada et al., 1964). A dosis of 5 g D-glucuronolactone results in an ex-
cretion of about 1 g D-glucaric acid in the urine. On the basis of these data it 
may be expected that an enhanced metabolism via D-glucuronic acid during 
stimulation of the glucuronic acid system, may as well result in an enhanced 
formation and an attendant excretion in the urine of D-glucaric acid. Up to 
38 
now little attention has been paid to the formation and excretion of D-glucaric 
acid under the influence of drugs. More extensive investigation of this aspect 
of the drug-induced stimulation of the glucuronic acid system is required. 
4.2 The influence of barbital on the formation and the excretion in the urine of 
D-glucaric acid in guinea pigs 
4.2.1 The influence of barbital on the urinary excretion of D-glucaric acid in 
guinea pigs 
Animal experiments can serve as a basis for the studies aimed at the investig­
ation of the excretion of D-glucaric acid in patients. For this purpose the guinea 
pig is the most suitable animal since besides man and monkey, it is the only 
mammal known to lack the ability to synthesize L-ascorbic acid (Section 1.1.2.1). 
Barbital is chosen as a stimulating drug, since this compound has been used in 
many studies concerning the glucuronic acid system, especially with respect to 
the formation and excretion of L-ascorbic acid in the rat. 
D-glucaric acid . 
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3-, 
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FIG. 8 Effect of cumulative doses of barbital on the urinary excretion of D-glucaric 
acid in guinea pigs. 
A group of 14 female guinea pigs, weighing 300-400 g, was used. The animals were 
injected with saline i.p. at zero time, and sodium barbital i.p. at 24 hr. Urine was 
collected in two consecutive 24-hr periods. The individual D-glucaric acid excretions 
after barbital treatment are represented by closed circles ; mean and S.D. of the D-glu­
caric acid excretions before barbital treatment are represented by an open circle with 
vertical line. A positive trend between the increase in D-glucaric acid excretion and 
the dose of barbital is found (Terpstra trend test, two-sided; Ρ value <o.ooi). 
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First the influence of various doses of barbital applied intraperitoneally 
(i.p.) on the D-glucaric acid excretion was studied. As shown in Fig. 8 a higher 
dose of the drug results in an increase in the quantity of D-glucaric acid excreted. 
Then the time course of the increased D-glucaric acid excretion after a single dose 
of barbital was investigated. On the basis of the result reported in Fig. 8, a dose of 
sodium barbital of 150 mg/kg was chosen. Already within 24 hours after ap­
plication of the drug the D-glucaric acid excretion increased (Fig. 9). The in­
crease is still significant on the 4th day after application and gradually levels off 
to the original value. 
As mentioned before, both the enhanced excretion of L-ascorbic acid and the 
enhanced activity of the drug-metabolizing enzyme systems in the liver take 
place in the drug-treated rat (Table 1). The drug-metabolizing enzyme systems 
sodium barbital • 
mg/ kg per day 
D-glucaric acid 
μ moles 
4 -
Ô days 
FIG. 9 Effect of a dose of barbital on the urinary excretion of D-glucaric acid in guinea 
pigs. 
A group of 8 female animals, weighing 300-400 g, was injected with saline i.p. and 
after 24 hr with sodium barbital i.p. Urine was collected in 24-hr periods. Means with 
S.D. are shown. The urines of the 24-hr periods after treatment were compared 
with that of the 24-hr period before treatment. Significant differences are shown by 
closed symbols (P< 0.05; Wilcoxon signed-rank test). 
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involved are bound to the endoplasmic reticulum. They belong to the group 
of mixed-function oxidases, which need as co-factors NADPH2 and oxygen. 
The terminal step in this oxidizing system is formed by the cytochrome P-450 
(Ernster and Orrenius, 1965). 
In an orientating experiment the effect of barbital upon the excretion of 
D-glucaric acid in the urine as well as upon the activity of liver tissue of metabo-
D glucaric acid 
/nnoles (average value) 
sodium barbital 
mg/kg per day 
treated group A 
treated group В 
control group С 
control group D 
1 0 0 
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FIG. 10 Excretion of D-glucaric acid in urine and demethylation activity in the liver of 
guinea pigs treated with barbital. 
Female animals, weighing 230-280 g, were used. Animals of each group A and В 
(5 and 5 respectively) were injected with sodium barbital 75 mg/kg i.p. twice daily 
during the ist, 2nd and 3rd day; animals of groups С and D (5 and 3 respectively) 
were injected with saline i.p. Groups A and С were killed after the 4th day, groups В 
and D after the 14th day and the livers of each group were homogenized for estima­
tion of the demethylation activity in each liver supernatant (9000 g). 
The activity was tested with aminophenazone as a substrate. 
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lizing drugs was measured in guinea pigs. For the measurement of the drug-
metabolizing activity the demethylation of aminophenazone by liver homogenate 
was measured. As shown in Fig. io, the D-glucaric acid excretion in the urine 
as well as the demethylation activity in the liver increased after treatment of the 
guinea pigs with barbital. 
4.2.2 Experiments to study the relation between the enhanced excretion of D-
glucaric acid in the urine and the stimulation of the glucuronic acid system in 
the liver 
D-glucuronic acid synthesized to a greater extent in the liver is the most 
probable source for the enhanced formation and excretion of D-glucaric acid. 
The formation and excretion of D-glucuronic acid is known to be enhanced 
after drug treatment (Chapter 2). However, theoretically there are other possible 
causes of an enhanced D-glucaric acid excretion. 
It might be that the increased excretion of D-glucaric acid after drug treat­
ment is the result of a depletion of a D-glucaric acid pool in the organism, 
or the result of an inhibition of the catabolic degradation of D-glucaric acid 
caused by the drug treatment. If the total body pool of D-glucaric acid in the 
animal (guinea pig) is compared with the extra quantity of D-glucaric acid ex­
creted under the influence of the drug treatment, it is found that this quantity 
per period of 24 hours is significantly greater than the body pool (Table 2). 
TABLE 2 Body pool of D-glucaric acid in untreated guinea pigs, and the amount of 
D-glucaric acid in 24-hr urine of untreated and barbital-treated guinea pigs. * 
D-glucaric acid 
μιηοΐββ 
body pool urinary excretion in 24 hr** 
Untreated (5) 0.38 ± 0.28 
Treated (6) 
before treatment 0.48 ± o. 10 
after treatment 3.2 ± 1 . 6 
increase: 2.8 ± 1 . 6 
* Of a group of 11 female guinea pigs, weighing 200-240 g, 6 animals were given single 
injections of sodium barbital 150 mg/kg i.p., and 5 animals were used for determina­
tion of the body pool of D-glucaric acid. 
** Urine collection was started 24 hr before injection and immediately after injection. 
Means with S.D. are presented. 
Note The increase in the D-glucaric acid excretion (per 24 hr) is higher than the 
body pool (P = 0.03 ; two-sided Wilcoxon test). 
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Definite proof for the absence of an inhibition of D-glucaric acid catabolism 
after drug treatment could not be given; however, a variety of experimental 
arguments could be obtained pleading for the direct relation between the en­
hanced carbohydrate metabolism via D-glucuronic acid in the liver during drug 
treatment and the enhanced formation and excretion of D-glucaric acid. D-
glucuronolactone dehydrogenase involved in the conversion of D-glucurono-
lactone to D-glucaric acid is found to be present in the liver of mammals. The 
activity of this enzyme in the liver is high as compared to that in the other tis­
sues. For the rat the presence of the enzyme was detected in liver, kidney 
and testis (Section 1.1.3). In other tissues such as uterus, thyroid gland, lung, 
duodenum and in plasma no significant activity was found. The enhanced ex­
cretion of D-glucaric acid in the urine after barbiturate treatment of rats, re­
ported by Marsh and Reid (1963) could be confirmed, while it was also shown 
that after this treatment the D-glucaric acid level in liver tissue increased 
(Table 3). As reported in Chapter 2, definite proof is available for the enhanced 
TABLE 3 Effect of barbital treatment* on the amount of D-glucaric acid in rat liver. 
D-glucaric acid/g liver Ρ value 
тцтоіез 
Treated: 
9 hr after injection of drug 25.9 ± 5.8 (6) < 0.01 
20 hr after injection of drug 9.7 ± 6.8 (6) >o.io 
Control: 4.1 ± 1.6 (6) 
* Of a group of 18 female rats, weighing 180-200 g, 12 animals were given single 
injections of sodium barbital 150 mg/kg i.p. at zero time. The control animals were 
given saline at zero time and killed at 9 hr. The treated animals were killed at 9 hr 
or at 20 hr. 
Means with S.D. are presented. Numbers in parenthesis indicate number of animals 
on which mean is based. Ρ values were obtained by applying the two-sided Wilcoxon 
two-sample test. 
synthesis of L-ascorbic acid in the liver of rats after treating them with drugs. 
This implies that after barbital treatment the L-ascorbic acid (Klinger and 
Koch, 1965a) as well as the D-glucaric acid content of the liver increased 
(Table 3). Taking into account the data that D-glucuronolactone is metabolized 
mainly in the liver (Section 4.1) and that D-glucuronolactone dehydrogenase 
occurs mainly in the liver, while in barbital-treated rats the D-glucaric acid 
level in the liver is strongly enhanced, it is likely that the D-glucaric acid syn­
thesis in the liver is responsible for the enhanced level of D-glucaric acid in the 
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urine as caused by barbital. As will be shown later, in man barbiturate treat­
ment also results in an enhanced excretion of D-glucaric acid in the urine. The 
activity of D-glucuronolactone dehydrogenase in human liver is high, while it 
is very low in the human kidney (Section 1.1.3). Also on the basis of these 
various data it is feasible that in man as well as in rat and guinea pig the in­
crease in the D-glucaric acid excretion after drug treatment is based on an en­
hanced synthesis of it in the liver. 
TABLE 4 D-glucuronolactone dehydrogenase activity of guinea pig liver homogenates 
at various times after administration of barbital. 
Time after 
administration* 
hr 
5 
9 
24 
72 
D-glucuronolactone dehydrogenase activity per mg protein 
io 2 цтоіез/ііг 
control 
3-4 ± 0.9 (6) 
2.8 ± 1.6 (6) 
3.4 ± 0.8 (6) 
3.0 ± 0.7 (6) 
treated 
2.7 ± 0.9 (6) 
4.2 ± 1.6 (6) 
4-9 ± 2.6 (11) 
2.7 ± 1.0 (6) 
Ρ value 
>0.25 
>0.I0 
>0.I0 
>0.25 
* Female guinea pigs, weighing 300-400 g, were given single injections of sodium 
barbital 150 mg/kg i.p. at zero time. The 72-hr group were given three injections: 
at zero time, at 24 hr and at 48 hr ; the control animals were given saline. 
The figures and Ρ values are calculated as indicated in Table 3. 
Taking into account the high probability that the increased levels of D-
glucaric acid in the liver and in the urine after treatment with barbiturates are 
due to an enhanced formation of this acid via D-glucuronic acid in the liver, 
the following question arises. Is this enhanced formation due to a drug-induced 
enhanced formation of D-glucuronic acid resulting again in an enhanced met­
abolism via the glucaric acid pathway, as is proposed by Marsh and Reid 
(1963), or to an enhanced utilization of D-glucuronic acid based on a stim­
ulating effect of barbital in the glucaric acid pathway? As shown in Table 4, 
the D-glucuronolactone dehydrogenase activity in the liver of guinea pigs is not 
found to be increased after drug treatment. In Table 5 the influence of barbital 
on the in vivo conversion of D-glucuronolactone into D-glucaric acid is pre­
sented. It may be seen that during barbital treatment no increase of the D-
glucaric acid excretion is observed in D-glucuronolactone-loaded rats. The 
dose of D-glucuronolactone is chosen so high that it largely surpasses the 
concentration of this substrate in the liver under normal conditions or during 
drug treatment. This results, as is shown, in a strong increase in the D-glucaric 
acid excretion in the urine and therefore in a strong increase of its formation. 
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TABLE 5 Influence of barbital on the urinary excretion of D-glucaric and D-mannaric 
acid in guinea pigs treated with D-uronolactones. * 
Urinary excretion — цтоіев/іг hr 
Compound Oral dose D-glucaric acid 
цтоіев without barbital with barbital Ρ value 
о Ο.Ι2 ± 0.05(6) 0.45 ± 0.21(8) <o.oi 
300 19.1 ± 7.7 (7) 17-3 ± 2.4 (7) >o.25 
750 42.8 ± 14.9 (6) 43.0 ±11.3 (6) >0.25 
1600 101.8 ± 31.7 (7) I0I.6 ± 19.9 (7) >0.25 
660 0.39 ± 0.24 (5) 
D-mannaric acid 
660 33.6 ± 44 (5) 29.8 ± 7.1 (5) >o.25 
* Male guinea pigs, weighing 250-300 g, were given single injections of sodium bar­
bital 150 mg/kg i.p. at zero time. The animals were given twice D-glucuronolactone: 
at zero time and at 6 hr. D-mannuronolactone was given in a single dose. The control 
animals were given saline i.p. 
The figures and Ρ values are calculated as indicated in Table 3. 
These experiments (Tables 4 and 5) give no indication whatsoever of an en­
hancement under the influence of barbital in the conversion of D-glucur­
onolactone into D-glucaric acid, the second step in the conversion of D-gluc-
uronic acid into D-glucaric acid. 
This conclusion is further confirmed by studying the conversion of D-
mannuronolactone into D-mannaric acid. It has been shown by Sadahiro et al. 
(1966) that also in this conversion D-glucuronolactone dehydrogenase very 
probably is involved (Section 1.1.3). No enhancement is found for the con­
version of D-mannuronolactone into D-mannaric acid in the guinea pig during 
barbital treatment (Table 5). 
As may be seen from Table 5, the capacity to convert D-glucuronolactone to 
D-glucaric acid is very high. After application of high doses of D-glucurono­
lactone the D-glucaric acid excretion in the urine is about 100 цтоіез per 
12 hours, while without application these quantities are smaller than 1 цтоіе. 
During barbital treatment the quantity excreted per 24 hours is 1 to 5 цтоіев 
(Tables 2 and 5; Figs. 8, 9 and 10). This indicates that under normal conditions 
and even after barbital treatment only a small fraction of the conversion capa­
city is used, so that an enhancement of this capacity during drug treatment will 
only mean an even greater increase of a tremendous reserve capacity already 
present. 
D-glucuronolactone 
>» 
»» 
D-mannuronolactone 
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4-3 The urinary excretion of D-glucaric acid in men after the use of drugs 
The amount of barbiturate per kg body weight given to guinea pigs in the 
experiments such as described (Section 4.2) is generally very much higher than 
the clinical dose used in man. One of the reasons for this difference is the fact 
that experimental animals, especially the smaller species such as mouse, rat and 
guinea pig, tend to eliminate drugs more rapidly than humans. The question 
arises whether also the relatively low clinical therapeutic doses used in man also 
cause a stimulation of the glucuronic acid system. For this purpose the urinary 
excretion of D-glucaric acid in humans after the use of suitably chosen drugs 
can be studied. The chosen drugs such as thiopental, phénobarbital, phenytoin, 
phenylbutazone and aminophenazone, are known to cause an enhanced for-
mation of L-ascorbic acid in experimental animals. In addition the urine of 
diabetic patients treated with tolbutamide and the urine of volunteers taking 
salicylic acid were analyzed. Tolbutamide and salicylic acid enhance the ex-
cretion of L-ascorbic acid in rats to a much lower degree than the drugs men-
tioned earlier. 
TABLE 6 Urinary excretion of D-glucaric acid in patients* undergoing thiopental 
anaesthesia. 
D-glucaric acid 
mg/24-hr urine Ρ value 
Before first thiopental injection 6.5 ± 5.7 0.03 
During and after thiopental anaesthesia 22.3 ± 18.9 
* Orthopoedic operations in 11 patients were concerned. As premedication was given 
atropine (0.25-0.50 mg), meperidine (50 mg) and promethazine (50 mg) s.c.The total 
amount thiopental given varied from 500 tot 800 mg. Anaesthesia proceeded for 
2.5 to 4.0 hr. 
Means with S.D. are presented. The Ρ value was obtained by applying two-sided 
Wilcoxon signed-rank test. 
In the study on the influence of thiopental the D-glucaric acid level was determ­
ined in the two 24-hr urine portions produced before and after administration 
of the first dose (Table 6). The later samples were found to contain higher levels 
of D-glucaric acid. Since the urine was obtained from patients treated surgically 
the possibility should be considered that this rise is not only caused by the thio­
pental, but may be partly due to the premedication. In the study on the influence 
of the other drugs mentioned a comparison with urine collected before treatment 
was not possible since the patients had already been under drug treatment for 
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TABLE 7 Effect of drugs on the urinary excretion of D-glucaric acid in human subjects. * 
Drug administered. 
daily dose 
Aminophenazone, 
1800-2400 mg 
Phenylbutazone, 
400-600 mg 
None 
Phénobarbital and 
Phenytoin, 100-300 mg 
and 90-225 mg 
Tolbutamide, 
500-2000 mg 
Salicylic acid, 1500 mg 
None 
Group 
polyarthritis 
rheumatica 
polyarthritis 
rheumatica 
polyarthritis 
rheumatica 
epilepsy 
diabetes 
healthy 
healthy 
Period of drug 
administration 
two weeks or 
longer 
two weeks or 
longer 
two months or 
longer 
two months or 
longer 
10 days 
D-glucaric acid 
mg/24-hr urine 
39.1 ± 23.4(10) 
11.3 ± 3·9(ιο) 
8.7 = 2.6 ( 6) 
62.5 ± 38.6 (14) 
5.5 ± 3.2 (10) 
5-5 ± 2.0 ( 5) 
6.5 ± 3-3(17) 
Ρ value 
<0.00I 
<0.0I 
0.22 
<0.00I 
>0.25 
>0.25 
* The figures and Ρ values are calculated as indicated in Table 3. 
some time; thus the urine of healthy persons (men and women1) was used to 
obtain reference values for the D-glucaric acid excretion (Table 7). In patients 
treated with aminophenazone, phenylbutazone or with a combination of phéno-
barbital and phenytoin the D-glucaric acid excretion was found to be higher 
than in the controls. The interpretation of these data is complicated by the 
possibility that the enhanced excretion might be influenced by the condition of 
the patient. The patients treated with aminophenazone and phenylbutazone 
were suffering from polyarthritis rheumatica. A group of patients with the 
same disease in the same hospital but not subjected to a treatment with drugs 
did not show an enhanced excretion of D-glucaric acid. It may be concluded 
therefore, that polyarthritis rheumatica is not involved in this phenomenon. 
As for the epileptics treated with phénobarbital and phenytoin it seems rather 
improbable that their disease is a factor in an enhanced excretion of D-glucaric 
acid. 
During the intake of salicylic acid by healthy persons no change in the D-
glucaric acid excretion was observed. The same holds for diabetics treated with 
tolbutamide. Tolbutamide is known to be oxidized to a carboxylic acid in the 
liver. This product has a hydrophilic character and is conjugated easily, so that 
1
 Marsh (1963a) reports that the D-glucanc acid excretion in man is about 20% higher 
than in woman, but from his data it cannot be concluded whether this difference is signifi-
cant. In our experiments no significant difference between the D-glucaric acid excretion by 
healthy man and woman was observed. 
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it is eliminated rapidly. The same holds for salicylic acid. It seems possible 
therefore, that salicylic acid and tolbutamide do not cause an enhanced D-
glucaric acid excretion since the therapeutic doses were not sufficient to reach 
a concentration high enough to stimulate the glucuronic acid system. The half-
life time in man for salicylic acid and tolbutamide is 5 to 6 hours (Südhof et al., 
1958; Levy, 1963). The half-life time for aminophenazone, phenylbutazone and 
phénobarbital, drugs which cause an enhanced D-glucaric acid excretion, is 3 
to 6 hours, 72 hours, and 48 to 96 hours respectively (Brodie and Axelrod, 1950; 
Burns et al., 1953). In the case of aminophenazone, besides the drug itself, the 
metabolite 4-aminoantipyrine may also have a stimulating effect on the glucur-
onic acid system. 
Another possibility might be that an enhancement of the D-glucaric acid 
formation requires an excessive stimulation of the glucuronic acid pathway 
(Section 5.3.2). For the latter point of view argues the fact that even high doses 
of salicylic acid do not cause an enhanced D-glucaric acid excretion in the rat 
(Table 13) while the administration of salicylic acid to this animal is shown to 
cause only a slightly enhanced excretion of L-ascorbic acid (Longenecker et al., 
1940). As will be shown, after administration of tolbutamide in the rat a slightly 
enhanced excretion of L-ascorbic acid can be observed too, while an enhanced 
D-glucaric acid excretion is not observed (Table 10). 
4.3.1 Definite proof for the enhanced D-glucaric acid excretion in man after drug 
treatment by means of a semi-quantitative isolation of urinary D-glucaric acid 
The enzymatic determination of D-glucaric acid used in this study (Marsh, 
1963a) is based on the inhibition of ß-glucuronidase by the (1-»^-lactone of 
D-glucaric acid (Fig. 11). In this determination one part of the urine is heated 
after acidification and another part after neutralization. In the first sample 
about 30 % of the D-glucaric acid present is converted into the (1 -• 4)-lactone, 
in the other sample the (1-^-lactone, if present at all, will be converted into 
the acid. The difference in inhibitory action between the acid-treated and 
neutralized urine fraction is a measure for the amount of D-glucaric acid 
present. The potentiation by acid treatment is essential for the specificity of this 
method. Apart from D-glucaric acid, D-galactaric acid is the only substance 
naturally occurring known to show this acid-potentiated inhibition. However, 
an amount of D-galactaric acid, a 50-fold larger than that of D-glucaric acid, is 
needed in order to get the same degree of inhibition (Levvy, 1952) (Fig. 11). 
Moreover, Marsh (1963a) and Okada(i964) found no indications of the 
presence of acid-potentiated inhibitory substances in the urine apart from 
D-glucaric acid. Notwithstanding these data definite proof for the enhanced 
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D-glucaric acid excretion during drug treatment requires isolation and identific-
ation. A more detailed study of the acid-potentiated inhibition in the urine of a 
drug-treated patient was made therefore. The aim was twofold : 
I. Corroboration of the correctness of the enzymatic method of Marsh by 
showing the absence of acid-potentiated inhibitory substances in the urine other 
than D-glucaric acid. 
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FIG. II Inhibition of ß-glucuronidase by various compounds. 
A, D-glucaro-(i->4)-lactone; B, D-glucaric acid boiled for 30 min at pH 3.5; C, 
D-galactaric acid boiled for 1 hr at pH 2 ; D, freshly prepared D-glucaric acid solu-
tion. From Levvy (1952). 
2. Demonstration of the enhanced excretion of D-glucaric acid by isolation and 
identification. 
An isolation procedure for D-glucaric acid has been given by Marsh (1963a). 
This procedure includes the removal of endogenous glucuronides by extraction 
with ethyl acetate, precipitation of the acid as a lead salt which subsequently 
is decomposed with H2S, and isolation of the acid with phenylhydrazide from a 
solution treated with charcoal. Marsh started with 56 1 urine containing 
11.2 mg/1 D-glucaric acid as estimated by the enzymatic assay and isolated 22 % 
of the total amount. Since the procedure of Marsh has a non-quantitative 
character and does not answer the question whether other substances which 
show an acid-potentiated inhibition, might be present in urine of drug-treated 
individuals, a different procedure for the isolation was followed in the present 
study. 
The method of gradient elution from an ion-exchange column was applied, 
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followed by a further fractionation by paper chromatography. With this method 
which was described by Whiting and Coggins (i960) for sugar acids in fruits, a 
qualitative as well as a quantitative approach is possible. Finally part of the 
main fraction of the acid-potentiated inhibitor was treated with phenylhydra-
zide. The crystalline solid which deposited was weighed and identified as the 
bisphenylhydrazide of D-glucaric acid. 
Isolation and identification 
Urine was analyzed for acid-potentiated inhibition. This inhibition is ex-
pressed as an amount of'apparent D-glucaric acid', meaning that the inhibitory 
action after acid potentiation would correspond with the presence of the in-
dicated amount of D-glucaric acid if this substance is accepted to be the only 
cause of the inhibition. A 24-hr urine sample was collected from a patient 
chronically under treatment with phénobarbital and phenytoin (150 mg and 
300 mg respectively every day). The amount of apparent D-glucaric acid was 
determined to be 89 mg. The urine was cooled, filtered and passed through a 
column of Dowex 50-WX4 (H^form, 100/200 mesh, capacity 1250 meq). The 
effluent was evaporated under vacuum at 400 to a rest of about 200 g and 
further concentrated with freeze-dry technique to give a rest of 70 g with a total 
acid content of 210 meq. The material was extracted with ethyl acetate for 
acid-potentiated inhibitor (in mg D-glucaric acid) 
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FIG. 12 Elution of acid-potentiated inhibitors from a column of Dowex I-Xz (acetate 
form). 
The acid-potentiated inhibitors were obtained from urine of a patient under treatment 
with phénobarbital and phenytoin. 
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5 hours in a continuous liquid-liquid extractor at 25o. To reduce the content of 
strong acids the aqueous solution was passed through a column of Dowex I-X2 
(acetate form, 100/200 mesh, capacity 70 meq) and the effluent was again con­
centrated to give a rest with a total acid content of 76 meq. It was checked that 
no acid-potentiated inhibitor remained on the columns. 
The gradient elution 
As the following step in the analysis, the material was passed through a 
column (diameter 2.5 cm, height 40 cm) of Dowex I-X2 (acetate form, 100/200 
mesh, capacity 190 meq). The column was washed until the effluent obtained 
was neutral. The effluent displayed no inhibitory action. Then acetic acid 
solutions with concentrations increasing from ο N to 6 N were successively 
passed through the column and 5 min-fractions with a volume of 50 ml each 
were collected. Every fifth fraction was checked on acid-potentiated inhibition. 
In the sequence of fractions acid-potentiated inhibition appeared in two area's 
(Fig. 12). The fractions 48 up to 65 were taken together and concentrated to a 
fraction A of approximately 3 ml. The same was done for the fractions 74 up 
to 99 yielding a fraction B. The amount of apparent D-glucaric acid in the 
fractions A and В was found to be 7.5 mg and 76.5 mg respectively. 
Paper chromatography 
The concentrates A and В obtained were studied further with descending 
chromatography on Whatman no. 1 paper, using the solvent system n-propanol: 
aq. ammonia 25 % (3:2 by vol.). The spots were developed with the aqueous 
acetone-silver nitrate method of Trevelyan et al. (1950) and fixed with 5 % 
sodium thiosulfate. Minute samples of the concentrates were chromatographed 
in two ways. 
Method (a): The samples were chromatographed immediately after spotting 
them on the paper. 
Method (b): The samples were brought on the paper with approximately 
5 mm 3 2 N ammonia and chromatographed after a 24-hr stay in an atmosphere 
saturated with water and ammonia. In this manner possibly occurring lactones 
of D-glucaric acid are converted into the acid. 
With both methods two chromatograms were made. One of each pair of 
chromatograms was developed with the silver nitrate reagent. The area's of the 
non-developed chromatogram of each pair corresponding with the developed 
spots were extracted with water and examined for acid-potentiated inhibition. 
D-glucaric acid and the (1-^-lactone were used as references (Table 8). As 
demonstrated with method (a), the acid-potentiated inhibitors present in 
both concentrates A and В had R F values of 0.22 and 0.30 respectively. If the 
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TABLE 8 RF values of compounds present in the concentrates A and B* obtained after 
gradient elation. 
D-glucaric acid 
Concentrate A Concentrate В without with 
( ι -» 4)-lactone (i -• 4)-lactone 
(a) (b) (a) (b) (b) (a) 
І 0.22 І 0.21 І 0.22 І 0.22 І 0.22 І 0.23 
0.26 0.26 
І 0.30 І 0.30 0.30 І 0.30 
* The concentrates were obtained from urine of a patient under treatment with phéno-
barbital and Phenytoin. 
Method (a) : no pretreatment with 2 N ammonia. 
Method (b) : pretreatment with 2 N ammonia, 
i : Compounds displaying acid-potentiated inhibition. 
Solvent system n-propanol: aq. ammonia 25% (3:2 by vol.). 
Note 1. Both untreated samples of the concentrates contain acid-potentiated inhib-
itors with the same RF values as D-glucaric acid and the (1 ->4)-lactone. 
2. After treatment with ammonia the samples of the concentrates A and В contain 
a non-inhibiting compound with RF value 0.26 and 0.30 respectively. 
inhibitory fractions with RF value of 0.30 of concentrates A and В were ex­
tracted from the paper and chromatographed once more with method (b), an 
acid-potentiated inhibition was found at RF value 0.22, whereas the acid-
potentiated inhibition at R F value 0.30 disappeared. This finding agrees with 
the supposition that the acid-potentiated inhibition at R F value 0.30 is caused 
by a substance with a lactone character. It seemed highly probable that D-
glucaric acid is involved in the acid-potentiated inhibition. If this supposition 
were true, it should be possible to isolate this substance as the bisphenyl-
hydrazide derivative. However, the chromatograms showed that the concen­
trates A and В still contained impurities, so that further purification would have 
to precede a possible isolation. The concentrate A contained an important 
amount of an impurity with an R F value not very different from that of the 
inhibitory compound itself. In connection with this complication and also with 
the fact that concentrate A contained only 7.5 mg 'apparent' D-glucaric acid, 
the inhibitory compound was not isolated from this concentrate. 
Of concentrate В 55.7 % was used for the proposed experiment. In order to 
remove the non-inhibitory impurity (RF 0.30), this fraction was chromato­
graphed two times according to method (b) on 12 sheets (each 45 cm broad) of 
Whatman no. 1 paper. The area of every sheet displaying acid-potentiated in-
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hibition was extracted with water. The combined extracts were evaporated to 
a dry residue. 
Condensation with phenylhydrazide 
The apparent amount of D-glucaric acid present in this residue was 38.5 mg. 
The dry residue was mixed with 2.5 ml water and centrifuged in order to re­
move paper fibres. The supernatant was heated with 0.4 g of phenylhydrazide 
hydrochloride and 0.1 g of anhydrous sodium acetate for 150 min at 1000. 
A yellowish crystalline solid deposited. After cooling overnight at 00 the 
crystallizate was sedimented by centrifuging, and washed with aq. 50 % (v/v) 
ethanol. The dry crystallizate, m.p. 208-210° (decomp.), had a weight of 48.1 mg. 
The supernatant was made alkaline with ammonia and extracted during 5 hours 
with ether in a liquid-liquid extractor in order to remove the phenylhydrazide. 
The apparent D-glucaric acid content of the ammoniacal solution was found 
to be 11.4 mg. Consequently 27.1 mg of apparent D-glucaric acid had dis­
appeared from the solution *. 
The yellowish crystallizate was recrystallized two times from aq.50%(v/v) 
ethanol yielding 21.9mg, m.p.208-2100 (decomp.) (Found: Qss-s; Н.в.з; 
N,i4.2%; Cale, for C18H22N4O6: C,55.4; H,5.7; N,14.4%). There was no depres­
sion of the melting point when the crystals were mixed with authentic D-
glucaric acid bisphenylhydrazide, m.p. 209-210° (decomp.), and the infra-red 
spectra of the respective samples (KBr disk) could be superimposed. Conse­
quently, it was accepted that the crystallizate was the bisphenylhydrazide of 
D-glucaric acid. 
Conclusions 
A 24-hr urine obtained from a patient treated with phénobarbital and Pheny-
toin was studied. From this urine which contained 89.0 mg apparent D-glucaric 
acid, two fractions were obtained, a minor fraction and a main fraction. The 
amount of acid-potentiated inhibitor(s), present in these fractions, corresponded 
to 7.5 mg and 76.5 mg D-glucaric acid respectively. The inhibitor in both 
fractions showed, on application of the paper-chromatographic procedure, a 
behaviour which was identical with that of D-glucaric acid. For this reason it 
seemed probable that this inhibitor was D-glucaric acid. 
From part (55.7 %) of the main fraction 48.1 mg of the bisphenylhydrazide 
of D-glucaric acid (corresponding to 26.0 mg D-glucaric acid) was isolated. 
1
 The condensation of D-glucaric acid with phenylhydrazide will not proceed quantitat-
ively. Under the conditions in question the degree of conversion of pure D-glucaric acid 
amounts to about 70%. 
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Consequently, it may be concluded that the 24-hr urine of the patient in question 
contained at least 46.7 mg D-glucaric acid. According to Marsh (1963a) the 
24-hr urine of healthy humans contains about io mg 'apparent' D-glucaric acid. 
As reported in Table 7 we studied the 24-hr urine of 17 persons and found 
a mean amount of 6.5 mg ± 3.3 mg 'apparent' D-glucaric acid. This agrees 
rather well with the data of Marsh and justifies the conclusion that in the 
patient treated with phénobarbital and phenytoin the D-glucaric acid level was 
considerably enhanced. In the analytical procedure used no indications of the 
presence of acid-potentiated inhibitory substances, apart from D-glucaric acid, 
were obtained. It is concluded therefore that 'the apparent D-glucaric acid 
content' is identical with 'the D-glucaric acid content'. 
4.4 Summary 
In Chapter 2 some arguments were given for the supposition that the en-
hanced excretion of D-glucaric acid during drug treatment is based on the 
stimulation of the glucuronic acid pathway. The finding, reported by Marsh 
and Reid (1963) that during treatment of rats with barbital or chloretone an 
increased excretion of D-glucaric acid takes place, was the only experimental 
argument in this respect. In this chapter an extension of the experimental basis 
for the supposition mentioned is described. It was shown that in man as well as 
in the guinea pig (mammals unable to synthesize L-ascorbic acid) and the rat 
(mammal able to synthesize L-ascorbic acid) an increased excretion of D-gluc-
aric acid takes place during drug treatment. For the guinea pig treated with barb-
ital it was shown that this increase in the excretion is based on an increase in the 
biosynthesis of D-glucaric acid. It has been shown for rats that under such 
circumstances an increased level of L-ascorbic acid is present in the liver 
(Martin, 1961; Klinger and Koch, 1965a). This increased level is found to be 
due to an enhanced biosynthesis of L-ascorbic acid in the liver (Chapter 2). 
In the experiments described here it was shown that a strongly enhanced level 
of D-glucaric acid occurs in the liver of the rat treated with barbital. The fact 
that the enzyme involved in the final step of the D-glucaric acid formation 
occurs mainly in the liver and the fact that D-glucuronolactone is metabolized 
mainly in the liver, makes it probable that the enhanced D-glucaric acid level 
in the liver is due to biosynthesis in this organ. The parallels in the phenomena 
for the L-ascorbic acid and the D-glucaric acid excretion and production and 
the fact that both products have a common root in D-glucuronic acid, makes it 
highly probable that for D-glucaric acid like for L-ascorbic acid the enhanced 
formation after drug treatment is related to the stimulation of the glucuronic 
acid pathway under these circumstances. Now the question arose whether this 
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Stimulation only takes place in the glucuronic acid pathway or also in the 
glucaric acid pathway. In the experiments described in this chapter it was made 
clear that the capacity of the final step in the D-glucaric acid synthesis is not 
enhanced during drug treatment. Concerning the lactonase(s) involved in the 
equilibrium between D-glucuronic acid and D-glucuronolactone no definite 
information is available. Taking into account the data concerning the L-ascorbic 
acid formation and the experiments described in this chapter, the assumption 
that the enhanced excretion and formation of D-glucaric acid is based on an 
enhanced formation of D-glucuronic acid during drug treatment is readily 
acceptable. This implies that it is not unreasonable to consider the enhanced 
excretion of D-glucaric acid in drug-treated animals as an indication of a 
stimulation of the glucuronic acid system. 
The conclusions concerning the D-glucaric acid excretion based on the 
enzymatic method described by Marsh (1963a) must be considered as indirect 
conclusions. We could prove by isolation and chemical identification that during 
drug treatment (phénobarbital and phenytoin) enlarged quantities of D-glucaric 
acid are excreted in man. In the isolation procedure no indications were found 
of the presence in the urine of compounds interfering with the enzymatic assay 
of D-glucaric acid. 
In the rat (see references in Table 1) and in the dog (Burns et al., 1957; Burns 
et al., 1963) drug treatment results in a stimulation of the glucuronic acid system 
as well as in an enhancement of drug metabolism in the liver. As was shown in 
this chapter, in guinea pig barbital treatment results in an enhanced formation 
and excretion of D-glucaric acid and in an enhancement of drug metabolism 
in the liver. Furthermore, it was found that drug treatment (aminophenazone, 
phenylbutazone, thiopental, phenobarbital-phenytoin) causes an increased D-
glucaric acid excretion in man. On the basis of the analogy between the pheno-
mena observed in guinea pig, rat and man, it may be assumed that in man a 
stimulation of the glucuronic acid pathway is the cause of the enhanced D-
glucaric acid excretion. Taking into account that in man also during treatment 
with phenylbutazone or phénobarbital (Cheng et al., 1962; Burns et al., 1965) an 
enhanced metabolism of drugs takes place, it could be concluded that treatment 
with drugs results, as far as man, guinea pig, rat and dog are concerned, in a 
stimulation of the glucuronic acid system as well as in a stimulation of the 
hepatic enzyme systems involved in drug metabolism. 
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CHAPTER 5 
A COMPARISON OF THE EFFECT OF DRUGS ON THE 
FORMATION AND EXCRETION OF L-ASCORB1C ACID 
AND D-GLUCARIC ACID AND A STUDY ON THE 
POSSIBLE RELATIONSHIP BETWEEN STIMULATION OF 
THE GLUCURONIC ACID SYSTEM AND A CHANGE IN 
GLUCURONIDATION UNDER THE INFLUENCE OF DRUGS 
5. ƒ Introduction 
As mentioned in the foregoing chapter, the enhanced D-glucaric acid excre-
tion after drug treatment is not restricted to man or guinea pig but also takes 
place in mammals such as rats, which are able to synthesize L-ascorbic acid. 
A direct comparison of the influence of drugs on D-glucaric acid and L-ascorbic 
acid formation and excretion is as a matter of fact only possible in a study on 
animals which produce D-glucaric acid as well as L-ascorbic acid. The aim is 
to find out whether the changes in D-glucaric acid production and excretion 
follow the same pattern as those for L-ascorbic acid and D-glucuronic acid. In 
this respect also the question arises whether the increase in the excretion of 
D-glucaric acid in man and in mammals in general can be considered as a 
diagnostic sign of an enhanced activity in the glucuronic acid system and of 
an enhanced activity of the drug-metabolizing enzyme systems. Up to now in 
animal experiments and especially in the clinic the main emphasis was laid on 
the stimulation of drug metabolism by drugs (Ernster and Orrenius, 1965; Or-
renius et al., 1965; Wilson and Fouts, 1966; Shuster and Jick, 1966a, b; Kato 
et al., 1966; Peraino et al., 1966; Alfred and Gelboin, 1967; Conney, 1967), 
while little or no attention was paid to the possible relationships between these 
phenomena and the changes in the glucuronic acid system. 
5.2 The effects of barbiturates 
5.2.1 The initial phase of stimulation of the glucuronic acid system in rats and 
dogs after treatment with barbital 
It may be assumed that the stimulation of the glucuronic acid system as 
caused by drugs takes place in the liver cells. As a rule, however, the pheno-
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menon is detected by measuring the enhanced urinary excretion of the products 
of the glucuronic acid system. 
The quantity of L-ascorbic acid excreted per day under normal circumstances 
by the rat and expressed as a percentage of the total quantity synthesized per 
day is estimated as 15 percent (Conney et al., 1961) and 40 percent (Salomon 
and Stubbs, 1961). This indicates that under normal conditions there is a slight 
overproduction of L-ascorbic acid. During treatment with stimulating drugs 
there is a clear overproduction. This overproduction manifests itself not only 
in an increase of the L-ascorbic acid content in the urine but also in that of 
the tissues. Conney et al. (1961) showed that under the influence of strong 
stimulating drugs such as barbital and pentobarbital, the quantity of L-ascorbic 
acid in the animal tissues is about doubled. From the literature it can be con­
cluded that under the influence of stimulating drugs the increase in the L-as­
corbic acid level differs for the various tissues. In this respect the question 
arises in which tissues or biological fluids (urine, blood) the rise in the L-ascor­
bic acid content as a result of stimulation can be detected soonest. 
Martin (1961) reported that during treatment of rats with chloretone the 
L-ascorbic acid level in the liver increased with 50 percent, in the muscular 
tissue with 100 percent and in the urine to a manifold of the original concen­
tration. He also observed that the level in the blood hardly changed. Klinger 
and Koch (1965a) observed in the rat that after treatment with barbital the 
maximum value of the L-ascorbic acid content in the liver, which is about 
140 percent of the normal value, is reached after 5 hours. During the period 
of the enhanced L-ascorbic acid level in the liver no changes in the levels of 
blood, kidney and brain tissue were observed. Treatment with barbital resulted 
in an increase of the L-ascorbic acid level in the adrenals (Klinger and Koch, 
1965b). 
TABLE 9 Effect of barbital treatment* on the amount of L-ascorbic acid in rat liver. 
L-ascorbic acid 
Time after injection pmoles/g liver Ρ value 
hr control treated 
2 0.93 ± 0.10 (6) 0.99 ± 0.06 (6) >o.io 
3 0.89 ± 0.06 (6) 1.03 ± 0.08 (6) <o.oi 
*Male rats, weighing 180-200 g, were given injections of sodium barbital 150 mg/kg 
i.p. at zero time. The control animals were given saline. 
Ρ values were obtained by applying the two-sided Wilcoxon two-sample test. Num­
bers in parenthesis indicate number of animals on which mean is based. Means with 
S.D. are presented. 
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From the experiments of Klinger and Koch (1965a) it can be seen that al-
ready 3 hours after i.p. application of barbital to rats the L-ascorbic acid level 
in the liver is increased. The activity of the drug-metabolizing enzyme systems 
in the liver however, is not yet found to be increased 3 hours after i.p. appli-
cation of phénobarbital (Ernstei and Orrenius, 1965), which indicates that for 
this phenomenon there is a longer latency time than for the response in the 
L-ascorbic acid levels. The question how long the latency time for the enhanced 
L-ascorbic acid and D-glucaric acid formation and for the enhanced drug me-
tabolism is, is of importance in relation to the question whether these phenomena 
are based on de novo synthesis of enzymes. For that reason further experiments 
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FIG. 13 Effect of barbital on the urinary excretion of L-ascorbic acid and D-glucaric 
acid in rats. 
Male rats, weighing 45-60 g, were used. After collecting urine over a 3-hr period a 
group of 8 rats was injected with sodium barbital 140 mg/kg i.p. (see arrow). Urine 
was collected in two consecutive 3-hr periods. L-ascorbic acid and D-glucaric acid 
excretions were determined in the three periods. After collecting urine over a 3-hr 
period a control group of 6 rats was injected with saline i.p. and urine was collected 
over another 3-hr period. L-ascorbic acid excretion was determined in the two periods. 
Means with S.D. are presented. The 3-hr intervals after treatment were compared 
with the 3-hr interval before treatment. Significant differences are represented by 
closed symbols (P < 0.05 ; two-sided Wilcoxon signed-rank test). 
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were designed. From these experiments it was found that 2 hours after drug 
treatment there was no clear indication of an increase in the L-ascorbic acid 
content in the liver, while after 3 hours the increase was significant (Table 9). 
The excretion in the urine of L-ascorbic acid and D-glucaric acid in the 3-hr 
period following the i.p. application of barbital increased significantly (Fig. 13). 
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FIO. 14 Effect of barbiturates (barbital and thiopental) on the urinary excretion of 
L-ascorbic acid and D-glucaric acid in dogs. 
Five male dogs, weighing 18-24 kg, fasted 12 hr. The dogs were catheterized at zero 
time, and at 1 hr control urine was collected. After that the dogs were anaesthetized 
with sodium barbital 175 mg/kg and sodium thiopental 25 mg/kg i.v. The dogs were 
supplemented with 2-5 mg/kg per hr sodium thiopental whenever necessary. If pos-
sible, urine was collected at 2 hr by catheterization. After that urine was collected from 
the cannulated ureters at 30-min periods. Each point in the figure corresponds with 
the urine of an interval that finishes at the indicated time. Each symbol represents one 
dog. The values given at 1 hr and 2 hr are obtained by dividing the amount of L-as-
corbic acid and D-glucaric acid in the i-hr fractions by 2. 
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These results indicate that under the influence of barbital the latency time for 
the stimulation of the glucuronic acid system is shorter than 3 hours, but 
probably longer than 2 hours. One should be aware of the fact that in order 
to find the lag time between the initiation of the stimulation mechanism and 
the manifestation of the eifect, the time required for the absorption of the drug 
should be deducted from the latency time. 
In order to become informed on the changes during the 2-hr period after 
drug application, it is necessary to use animals from which practically contin-
uously quantities of urine, large enough to be analyzed on their L-ascorbic 
acid and D-glucaric acid content, can be obtained. For this reason experiments 
were performed on dogs in which the ureters were cannulated. As stimulating 
drugs a combination of barbital and thiopental was used and applied intra-
venously (i.v.) in order to reduce the time required for resorption and distri-
bution of the drug to a minimum. Moreover, the drugs used served as anaesthet-
ics for the animals. No premedication was used. Under these experimental 
conditions the first measurements could be made about 1 hour after the drug 
application (Fig. 14). From the results presented in this figure it can be seen 
that it takes about 2 hours before a clear increase in the excretion is observed. 
As known from biochemistry the time required for de novo synthesis of hepatic 
enzymes after oral application of various stimuli, such as hormones and sub-
strates, can be as short as 2 hours (Steele, 1966). This implies that the latency 
time of about 2 hours observed for the enhanced formation and excretion of 
the products of the glucuronic acid system in the liver do not exclude the possi-
bility that de novo synthesis of enzymes might be involved. The question about 
this de novo synthesis of enzymes is dealt with in Chapter 6. 
5.2.2 The influence of the dosis of barbital used on the excretion of some products 
of the glucuronic acid system and the time pattern of this excretion in rats 
It is of interest to know, in order to cause enhanced excretions of the various 
products of the glucuronic acid system such as L-ascorbic acid, D-glucaric acid 
and D-glucuronic acid, whether the same doses of stimulating drug are needed 
and whether the time courses of the excretions are similar or different. For 
this purpose we have studied the dose-effect relationship for barbital on rats, 
comparing in one set of experiments the excretion of L-ascorbic acid and 
D-glucuronic acid (Fig. 15) and in the second set of experiments the excretion 
of L-ascorbic acid and D-glucaric acid (Fig. 16). The lowest dose of barbital 
(20 mg/kg) used resulted already in an increased excretion of L-ascorbic acid. 
An enhanced excretion of D-glucaric acid was observed after a dose of 60 mg/kg 
(20 mg/kg on the first and 40 mg/kg on the second day). An enhancement of 
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no. 15 Effect of cumulative doses of barbital on the urinary excretion of L-ascorbic 
acid and D-glucuronic acid in rats. 
Female rats, weighing 180-220 g, were used. A group of 8 animals was injected i.p. with 
saline on day zero and with sodium barbital as indicated in the fìgure on the following 
days. The quantity administered per day was given in a single dose. A group of 8 
control animals was injected with saline every day. 24-hr Urine was collected and 
used for the assay of the L-ascorbic acid and D-glucuronic acid content. Means with 
S.D. are presented. Excretions during and after treatment are compared with excre-
tion before treatment (day zero). Significant differences are represented by closed 
symbols (P ^  0.05 ; two-sided Wilcoxon signed-rank test). 
Note After administration of 20 mg/kg and 40 mg/kg sodium barbital at day 1 and 
2 respectively, the increase in the L-ascorbic acid excretion is significant, while the 
increase in the D-glucuronic acid excretion is not. After finishing the drug treatment 
a similar pattern is observed. 
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the D-glucuronic acid excretion was observed only after a dose of 120 mg/kg 
(20, 40 and 60 mg/kg successively). The first day after stopping the application 
of the drug there is a steep drop in the levels of all 3 products measured, while 
the level of the D-glucuronic acid excretion returns to normal already on the 
second day after stopping the application. On the n t h day after stopping the 
application of barbital, the L-ascorbic acid as well as the D-glucaric acid ex­
cretion appeared to be still slightly increased. For L-ascorbic acid, measure­
ments were made for a still longer period and it was found that even on the 
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FIG. 16 Effect of cumulative doses of barbital on the urinary excretion of L-ascorbic 
acid and D-glucaric acid in rats. 
Female rats, weighing 180-220 g, were used. A group of? animals was injected i.p. with 
saline on day zero and with sodium barbital as indicated in the fìgure on the following 
days. The quantity administered per day was given in a single dose. 24-hr Urine was 
collected and used for the assay of the L-ascorbic acid and D-glucaric acid content. 
Means with S.D. are presented. Excretions during and after treatment are compared 
with excretion before treatment (day zero). Significant differences are represented by 
closed symbols (P < 0.05 ; two-sided Wilcoxon signed-rank test). 
Note The increase in the L-ascorbic acid and D-glucaric acid excretion after admi-
nistration of 20 mg/kg and 40 mg/kg sodium barbital at day 1 and 2 respectively is 
significant. Note also the significant response after finishing drug treatment. 
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30th day after stopping the application this level still did not reach the original 
level. The enhanced excretion of D-glucuronic acid after barbital treatment is 
difficult to interpret because of the high D-glucuronic acid content in the 
urine before treatment. It is probable that a considerable part of this content 
originates from the food ingested by the animals. It is possible that after the 
barbital treatment a response in the D-glucuronic excretion occurs which is of 
the same character as that of the L-ascorbic acid excretion, but that this respon-
se is obscured by the high base level of the D-glucuronic acid excretion. The 
results are in agreement with the suggestion made in Section 4.1 that for the 
detection of an enhanced activity in the glucuronic acid system the excretion 
of L-ascorbic acid and D-glucaric acid is a more sensitive parameter than that 
of D-glucuronic acid. 
What is the cause of the persistent response in the L-ascorbic acid and 
D-glucaric acid excretion after cessation of the drug treatment.'' A gradual 
disposal by the animal of the L-ascorbic acid accumulated in the tissues, may 
be one of the factors. A second possibility is the persistence for some time of 
the enhanced formation of L-ascorbic acid and also of D-glucaric acid due to 
the enlargement of the liver, which is observed during and after drug treatment. 
Barbital, phénobarbital and many other drugs cause a hypertrophy of the liver 
which gradually disappears after cessation of the drug treatment, so that after 
about 14 days, as was described by Kunz et al. (1966a), the original size of the 
organ is reached again. This implies that for the first two weeks after cessation 
of the drug administration the hypertrophy of the liver may be the factor in 
the persistent enhanced excretion of L-ascorbic acid and D-glucaric acid. The 
enhanced L-ascorbic acid excretion, however, is still evident 4 weeks after the 
last dose, and therefore cannot be explained by hypertrophy alone. Another 
aspect is the possibility of an enhanced synthesis of enzymes as caused by 
barbital. This would imply that after cessation of drug treatment, depending 
on the half-life time of these enzymes, a certain persistence in the enhanced 
formation and attendant excretion of L-ascorbic acid and D-glucaric acid might 
be expected. From experiments to be described in Section 6.1.2 it is concluded 
however, that in the stimulation of the glucuronic acid system by barbital, de 
novo synthesis of enzymes does not play a predominant role. Hollmann and 
Neubaur (1967) found indications that the half-life time of the enzymes UDPG 
dehydrogenase and UDPglucuronyltransferase which are involved in the gluc-
uronic acid system, is only a matter of hours. This implies that a lasting 
enhanced level of the enzymes mentioned is not an essential factor for the 
persistence of the enhanced excretions of L-ascorbic acid and D-glucaric acid. 
A main factor may be found in the fact that the animals can only slowly dispose 
of the drug used. Frey et al. (1959) reported that in a man's urine even 27 days 
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after application of barbital, the drug can still be detected. Barbital is very 
slowly metabolized and eliminated. This holds for man as well as for the rat 
(Ebert et al., 1965). After application of 3-methylcholanthrene to the rat an 
enhanced excretion of L-ascorbic acid during some months is reported (Dayton 
et al., 1964). It is known that this compound too persists for a very long time 
in the animal. The conclusion may be that the persistence of the drug in the 
body is the cause of the continuous L-ascorbic acid response occurring weeks 
after the last application of the drug. 
5.2.2.1 Differences in individual levels of L-ascorbic acid excretion in rats under 
standard conditions and during barbital treatment 
In the course of the study it appeared that the individual differences in the 
urinary L-ascorbic acid excretion in untreated rats of equal sex and strain were 
greater than those in the D-glucaric acid excretion. As may be seen in Table 10 
(controls) this fact finds expression in the relatively large standard deviations 
(S.D.'s) of the L-ascorbic acid excretion as compared with the S.D.'s of the 
D-glucaric acid excretion. It appeared that, although the amount of L-ascorbic 
acid excreted in the urine strongly varies between the experimental animals, the 
daily excretion per individual is fairly constant (Fig. 17). Moreover, a positive 
correlation was found between the increase in L-ascorbic acid excretion during 
barbital treatment and the excretion level before treatment. 
According to Chatterjee et al. (1961) the in vitro activity of the hepatic 
L-gulonolactone oxidase, involved in the terminal step of the L-ascorbic acid 
synthesis in rats of the same strain differs greatly from animal to animal. It is 
likely that the same holds for the in vivo capacity to synthesize L-ascorbic acid 
and that this finds its expression in the great differences in the urinary excretion 
levels. 
5.5 The influence of a variety of drugs on the excretion of the products of the 
glucuronic acid system in rats 
5.3.1 Experiments 
For a variety of drugs and compounds, an enhancement of the L-ascorbic 
acid excretion in the rat is reported in the literature (Table 1). As far as the 
D-glucaric acid excretion and the D-glucuronic acid excretion are concerned 
information is restricted to barbital, chloretone and 3-methylcholanthrene. 
Although these compounds are known to cause an enhancement of L-ascorbic 
acid biosynthesis and of drug metabolism, only the first two compounds men-
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FIG. 17 Differences in individual levels of L-ascorbic acid excretion in rats under stan-
dard conditions (lower part of the figure) and during barbital treatment. 
The individual levels of the L-ascorbic acid excretion in the rats described in Fig. 15 
are given. 
Note the constant amount of L-ascorbic acid excreted every day by the control ani-
mals. 
Note also the greater response of the treated animals which have a high base level 
before treatment. There is a positive correlation between the increase in L-ascorbic 
acid excretion after administration of sodium barbital 150 mg/kg (24-hr excretion 
after administration of sodium barbital minus 24-hr excretion at day zero) and the 
base level before treatment (Kendall's rank correlation test). 
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Q TABLE io Urinary excretion of L-ascorbic acid, D-glucaric acid and D-glucuronic acid in rats on the first day of drug treatment. 
L-ascorbic acid** D-glucaric acid** D-glucuronic acid** 
Treatment* μπιο1ε8/24 hr pmoles/24 hr цто1е8/24 hr 
control treated Ρ value control treated Ρ value control treated Ρ value 
Aminophenazone, 7.0 ± 2 . 1 14.8 ± 2.9 0.03 0.33 ± 0.08 0.38 ± 0.06 > o . i o 
125 mg/kg orally (6) (6) 
Borneol, 3.0 ± 1 . 7 7.2 ± 2.0 <o.oi 0.37 ± 0 . 1 0 0.33 ± 0.13 >o.25 
400 mg/kg orally (7) (7) 
Nikethamide, 14.3 ± 6.9 55.6 ± 18.6 <o.oi 0.34 ± 0.09 0.41 ± 0 . 1 2 > o . i o 36.6 ± 10.8 24.1 ± 9.3 0.05 
125 mg/kg orally (6) (6) 
Phenylbutazone, 2.7 ± 0.6 14.8 ± 7.7 <o.oi 0.31 ± 0.04 0.36 ± 0.09 0.10 
125 mg/kg orally (12) (8) 
Sodium barbital, 12.8 + 8.4 32.3 ± 18.4 0.03 0.42 ± 0 . 1 1 2.1 ± 0 . 6 0.01 24.5 ± 7.4 35.3 ± 7.9 0.01 
150 mg/kg i.p. (6) (6) 
Sodium thiopental, 6.3 ± 5.3 15.2 ± 10.3 0.05 0.42 ± 0.09 0.35 ± 0.08 > o . i o 
40 mg/kg i.p. (7) (7) 
Tolbutamide, 6.9 ± 1.9 8.0 ± 2.2 0.03 0.22 ± 0.04 0.21 ± 0.05 >o.25 
125 mg/kg orally (6) (6) 
DDT, 14.3 ± 6.9 67.0 + 23.0 <o.oi 0.34 ± 0 . 0 9 0.35 ± 0.12 >o.25 36.6 ± 10.8 33.9 ± 6.8 >o.25 
30 mg/kg orally (6) (6) 
D-glucuronolactone, 6.2 ± 1.1 19.6 ± 4.8 <o.oi 0.39 ± 0.08 12.2 ± 5.6 <o.oi 
4000 mg/kg orally (8) (8) 
(about 4500 pinoles per rat) 
* Female rats, weighing 180-220 g, were used. Aminophenazone, borneol, sodium barbital, tolbutamide and DDT were given in 
single doses; sodium thiopental, nikethamide and phenylbutazone were given in 2 doses: at zero time and at 8 hr. D-glucurono­
lactone was given in 4 doses: at zero time, at 4 hr, 8 hr and 12 hr. 
** Collection of urine was started after the first dose. 
The figures and Ρ values are calculated as indicated in Table 9. 
tioned were effective, and 3-methylcholanthrene was ineffective with respect to 
the enhancement of the D-glucaric acid excretion (Marsh and Reid, 1963). 
With respect to the D-glucuronic acid excretion only barbital was very active. 
In order to extend the information on the influence of several drugs on the 
excretion of D-glucaric acid, L-ascorbic acid and D-glucuronic acid one or 
two doses of the drug were given to rats within a 24-hr period. For purposes 
of comparison the effect of D-glucuronolactone was also studied. D-glucurono­
lactone is a precursor of L-ascorbic acid and D-glucaric acid (Sections 1.1.2 
and 1.1.3). The 24-hr portions of urine produced after the first application of 
the drugs were analyzed; the D-glucuronic acid content of the urine was studied 
only as far as those drugs are concerned which themselves are not or only 
slightly involved in the formation of glucuronides. The results are presented 
in Tables 10 and 11. 
TABLE 11 Urinary excretion of L-ascorbic acid and D-glucaric acid in rats* treated 
with low doses of D-glucuronolactone 
Day 
1 
2 
3 
4 
5 
D-glucuronolactone 
administered** 
daily dose 
umoles per rat 
0 
12.5 
25 
50 
225 
L-ascorbic acid 
6.5 ± 2.4 
6.2 ± 2.5 
7-8 ± 2.9 
8.4 ± 2.9 
8-4 ± 33 
Urinary excretion 
umoles/24 hr 
Ρ value 
>0.25 
0.03 
0.03 
0.08 
D-glucaric acid 
0.18 ± 0.06 
0.22 ± 0.09 
0.34 ± 0.04 
0.46 ± 0 . 1 0 
0.82 ± 0.20 
Ρ value 
>0.25 
0.02 
0.02 
0.03 
* 7 Female rats, weighing 180-220 g, were used. 
* * D-glucuronolactone was given orally in 4 doses : at zero time, at 4 hr, 8 hr and 12 hr. 
After collecting a 24-hr urine on the ist day, the rats were given D-glucuronolactone 
on the following days. 
Means with S.D. are shown. The 24-hr intervals after treatment were compared with 
the 24-hr interval before treatment (two-sided Wilcoxon signed-rank test). 
From Table 10 it can be seen that with the exception of barbital, no increase 
in the D-glucaric acid and D-glucuronic acid excretion is observed, although the 
L-ascorbic acid excretion is increased for all drugs. During nikethamide treat­
ment the excretion of D-glucuronic acid is even lowered. The conclusion might 
be that neither the excretion of D-glucuronic acid nor the excretion of D-gluc­
aric acid are suitable as an indicator of an enhanced activity in the glucuronic 
acid system. The L-ascorbic acid excretions both after drug treatment and after 
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loading with high doses of D-glucuronolactone are of the same order. This 
does not apply to the excretion of D-glucaric acid. After treatment with 
drugs, in no case is such a high D-glucaric acid excretion reached as after 
D-glucuronolactone loading. After administration of low doses of D-glucurono­
lactone the D-glucaric acid excretion is relatively more pronounced than the 
L-ascorbic acid excretion (Table u ) . The differences in L-ascorbic acid and 
D-glucaric acid excretion obtained with exogenous D-glucuronolactone as 
compared to the situation in drug-treated and in untreated animals will be dealt 
with more extensively in the discussion (Section 5.3.2). 
One should be well aware of the fact that the data of Table 10 are obtained 
with rats, animals which apparently easily synthesize L-ascorbic acid. It is pos­
sible that the lack of an enhanced formation and excretion of D-glucaric acid 
and D-glucuronic acid has to be ascribed to the ease with which the interme­
diates of the glucuronic acid pathway find their way along the ascorbic acid 
pathway and the xylulose pathway. The experiments of Marsh (1963a) and 
Okada et al. (1964) indicate that D-glucuronolactone applied to the rat results 
in a relatively slight formation of D-glucaric acid, if compared with species 
that cannot synthesize L-ascorbic acid. These results could be confirmed by us 
with respect to rats and guinea pigs (compare Table 5 with Table 10). If endo­
genous D-glucuronic acid synthesized to a high extent during drug treatment, 
is processed further according to the same species-dependent pattern of D-gluc­
uronolactone, it may be expected that men and guinea pigs give a stronger 
D-glucaric acid response upon drug treatment than rats. The investigation 
of some of the drugs found to be ineffective with respect to the D-glucaric 
acid response in rats would have to be made in e.g. guinea pigs in order to 
TABLE 12 Urinary excretion of D-glucaric acid in guinea pigs* under treatment with 
aminophenazone or thiopental. 
Aminophenazone, 
125 mg/kg orally 
Sodium thiopental, 
40 mg/kg i.p. 
control 
0.37 ± 0 . 1 1 
(8) 
0.29 ± 0.12 
(6) 
D-glucaric acid 
цтоІе5/24 hr 
treated 
0.49 ± 0 . 1 8 
(6) 
0.41 ± 0.24 
(6) 
Ρ value 
>0.25 
>0.I0 
*Female guinea pigs, weighing 300-400 g, were used. 
Conditions of this experiment were similar to those of Table 10. 
Collection of urine was started after the first injection and after the oral dose. 
The figures and Ρ values are calculated as indicated in Table 9. 
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get more information on this point. Table 12 summarizes the results obtained. 
In the guinea pig no significant increase in the D-glucaric acid excretion is 
obtained in the 24-hr urine collected after application of high doses of amino-
phenazone or thiopental. To a certain degree this is unexpected. A plausible 
explanation is that the endogenous D-glucuronic acid is metabolized primarily 
via the xylulose pathway in mammals such as the guinea pig and man, species 
that cannot synthesize L-ascorbic acid. 
In man an enhanced D-glucaric acid excretion is observed after application 
of aminophenazone and thiopental, however, in these experiments the drugs 
concerned have been applied for ten days or longer (Table 7). F r o m the 
foregoing it appears clearly that animal experiments have to be performed 
in which a more chronic treatment with the stimulating drugs is applied. 
In the next series of experiments rats were treated for three days with bar­
bital, aminophenazone, nikethamide or phenylbutazone. The excretions were 
studied in 24-hr urine which in the case of D-glucaric acid was pooled (Fig. 18). 
These experiments make clear that under these circumstances barbital again is 
very effective as a stimulator for the D-glucaric acid excretion, while as far as 
TABLE 13 Urinary excretion of D-glucaric acid in rats on the fourth day of treatment 
with drug, and liver weight of rats after the fourth day of treatment. 
D-glucaric acid * * Liver weight * * * 
Treatment* Mmoles/24 hr 
control treated Ρ value control treated Ρ value 
Aminophenazone, 0.31 ± 0 . 0 7 0.51 ± 0 . 1 6 0.03 5.0 ± 0.5 5.9 ± 0.7 0.03 
125 mg/kg (6) (6) 
Nikethamide, 0.26 ± 0 . 1 5 0.98 ± 0.33 <o.oi 4.7 i 0.4 5.0 ± 0.2 0.10 
125 mg/kg (6) (6) 
Phenylbutazone, 0.31 ± 0.04 0.46 ± 0.04 <o.oi 4.71^0.3 6.0 ± 0.8 <o.oi 
125 mg/kg (6) (6) 
Borneol, 0.20 ± 0.07 0.69 ± 0.39 0.01 4.7 ± 0.5 5.3 ± 0.5 0.06 
400 mg/kg (7) (8) 
Salicylic acid, 0.26 ± 0.15 0.35 ± 0 . 2 1 >o.25 4.7 ± 0.4 5.5 ± 0.4 <o.oi 
400 mg/kg (6) (7) 
Sodium thiopental, 0.20 ± 0.07 0.35 ± 0 . 1 7 0.07 4.7 ± 0.5 5.5 ± 0.3 <o.oi 
40 mg/kg (7) (7) 
DDT 0.28 ± 0.04 0.28 ± 0.07 >o.25 4.7 ± 0.3 5.3 ± 0.4 0.01 
30 mg/kg (6) (6) 
* Female rats, weighing 180-220 g, were used. The drugs were given orally in 2 doses 
at zero time and 8 hr. 
* * Collection of urine was started at 72 hr. 
*** Liver weight was determined at 96 hr. 
The figures and Ρ values are calculated as indicated in Table 9. 
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FIG. 18 Effect of repeated administration of several drugs on the excretion of L-ascorbic 
acid and D-glucaric acid in rats. 
Groups of 5 female rats, weighing 180-200 g, were treated orally. Urine was collected 
in 24-hr periods. At day zero control urine was collected. As far as L-ascorbic acid 
is concerned means with S.D. are presented; as far as D-glucaric acid is concerned 
means determined in the pooled urine are presented. 
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the other drugs are concerned there is a slight indication of an enhanced 
D-glucaric acid excretion. All the drugs have a strong influence on the L-as-
corbic acid excretion. In order to get more definite information another series 
of experiments was performed with rats treated for 4 days with aminophena-
zone, nikethamide, phenylbutazone, salicylic acid, DDT, thiopental and bor-
neol. In this case the individual 24-hr urine portions were analyzed. The results 
summarized in Table 13 show that a significant increase of the D-glucaric acid 
excretion is observed only after treatment with aminophenazone, nikethamide, 
phenylbutazone and borneol. However, with the exception of salicylic acid, all 
the drugs used are known to be effective stimulators of the L-ascorbic acid 
excretion in the rat. 
An important aspect to be considered after more chronic drug treatment in 
relation to the enhanced formation of products of the glucuronic acid system 
is liver growth. As said before (Section 5.2.2), after drug treatment an increase 
in the weight of the liver is observed. This enlargement of the liver is mainly 
due to a hypertrophy of the liver cells (Kunz et al., 1966a). Increase of the 
number of cells (hyperplasia) has only been observed after prolonged treatment 
(3-6 months) with certain of the halogen-alkyl anaesthetics. As a matter of 
fact the enlargement of the quantity of liver tissue as such might be the cause 
of the increase in the production of L-ascorbic acid and D-glucaric acid and 
therefore of the increase of the excretion of these products after chronic treat-
ment with the drugs. However, nikethamide and also carcinogenic hydrocar-
bons do not cause liver enlargement (Kirchberg, 1966). In our own experi-
ments the drug treatment resulted in several cases in an enlargement of the 
weight of the liver. The experimental results summarized in Table 13 show that 
in rats pretreated with nikethamide or borneol no significant increase in the 
weight of the liver is observed, while there is nevertheless a clear increase in 
the excretion of D-glucaric acid. In rats treated with DDT or salicylic acid, 
on the other hand, there is a significant increase of the liver weight, while an 
enhanced excretion of D-glucaric acid is not observed. So there is no direct 
relation between the increase in the liver weight and the enhancement of the 
D-glucaric acid excretion during drug treatment. The increase of the weight of 
the liver as such therefore is not the main cause of the increase in the excretion 
of D-glucaric acid. It is assumed that the differences in the response to the 
various drugs as far as the excretion of D-glucaric acid is concerned are due 
to differences in the effect of these drugs on the glucuronic acid system (Section 
5.3.2). 
5.3.2 Discussion 
In radio-active tracer studies Evans et al. (i960) and Conney et al. (1961) 
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showed that treatment of rats with barbital, chloretone and 3-methylcholan-
threne brings about an enhanced conversion ofD-hexose into the products of 
the glucuronic acid system such as D-glucuronic acid, L-gulonic acid and 
L-ascorbic acid (Section 2.3.1). A closer analysis of their data shows that there 
is a difference between the response during treatment with barbital and the 
response during treatment with chloretone and 3-methylcholanthrene. During 
treatment with barbital there is an increase in the urinary excretion of labeled 
L-ascorbic acid as well as labeled D-glucuronic acid, while during treatment 
with chloretone and 3-methylcholanthrene a similar increase in the L-ascorbic 
acid excretion but little increase in the excretion of labeled D-glucuronic acid 
takes place. Dayton et al. (1965) also report that during treatment of rats with 
chloretone or with 3-methylcholanthrene little increase in the excretion of D-
glucuronic acid occurs, while during treatment with barbital a clear increase 
takes place. No biochemical interpretation of these differences in the responses 
could be given up to now (Dayton et al., 1965; Marsh and Reid, 1963). 
Differences in the excretion of D-glucuronic acid and L-ascorbic acid during 
treatment with various drugs were also mentioned in relation to the experi-
ments described in Section 5.3.1. These experiments confirm the results of 
Burns et al. (1957), Nitze and Remmer(i962) and Dutton et al. (1965) in which 
was shown that in animals treated with barbital the D-glucuronic acid ex-
cretion is enhanced. The observation of Dutton et al. (1965) that not all drugs 
stimulating drug metabolism, e.g. chloretone and 3-methylcholanthrene, cause 
a strong increase in the D-glucuronic acid excretion, is extended by the results 
of our own experiments, in which it was found that during treatment of rats 
with nikethamide and DDT the excretion of D-glucuronic acid was not in-
creased, while the excretion of L-ascorbic acid was (Table 10). 
After drug treatment the response in the L-xylulose excretion in pentos-
uriacs resembles that of L-ascorbic acid in the rat. Within 24 hours after ad-
ministration of the first dose of borneol or aminophenazone both the excretion 
of L-xylulose in the pentosuriac and the L-ascorbic acid excretion in the rat 
are enhanced. 
As far as the excretion of D-glucaric acid is concerned, it can be concluded 
that the enhancement after treatment with barbital is much greater than that 
observed with the other drugs investigated (Table 10; Fig. 18). In the experi-
ments of Marsh and Reid (1963) an indication is found for an increase in the 
D-glucaric acid excretion during barbital and chloretone treatment and little 
or no increase during 3-methylcholanthrene treatment. In general it can be said 
that with low doses of the drug (Figs. 15, 16) or application of short duration 
(Table 10; Fig. 18) the response in the L-ascorbic acid excretion is much clearer 
than the response in the D-glucaric acid and D-glucuronic acid excretion. With 
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high doses of the drugs after prolonged treatment (4 days) responses are ob­
served in the L-ascorbic acid as well as in the D-glucaric acid excretion, while 
the D-glucuronic acid excretion is not studied in detail under these circumstan­
ces (Figs. 15; Table 13). These differences in the responses as far as the 
stimulation of the glucuronic acid system by various drugs is concerned are 
not in accordance with the supposition that the enhanced excretion of D-glucur­
onic acid, D-glucaric acid and L-ascorbic acid are related in a direct and un­
complicated way to an enhanced formation of D-glucuronic acid in the liver. 
In efforts to interpret the findings from the literature and those obtained in 
the experimental part of this chapter, the following points should be taken into 
consideration. Under normal conditions the D-glucaric acid levels in the liver 
and in the urine of the rat are very low. The content in the liver is about a 
200-fold smaller than the L-ascorbic acid content (Compare Table 3 with 
Table 9; the L-ascorbic acid contents in the liver of males and females are of 
the same order: Koch and Klinger, 1963). The quantity of D-glucaric acid 
excreted in urine is about a 10- to 40-fold lower than that of L-ascorbic acid 
(Table io). After application of high doses of D-glucuronolactone to the rat and 
the guinea pig the D-glucaric acid excretion increases about 30-fold and more 
than a 200-fold respectively (Tables 5 and 10), while the L-ascorbic acid ex­
cretion in the rat is only increased about 3-fold. Also after low doses of 
D-glucuronolactone the D-glucaric acid excretion is more pronounced than the 
L-ascorbic acid excretion (Table n ) . The data indicate that without D-glucur­
onolactone feeding little carbohydrate is metabolized via the glucaric acid 
pathway and that a higher turnover rate of D-glucuronolactone in the ascorbic 
acid pathway than in the glucaric acid pathway is not the cause of the big 
difference between D-glucaric acid excretion and L-ascorbic acid excretion in 
untreated animals. 
D-glucuronic acid formed in the liver is the precursor of L-ascorbic acid and 
D-glucaric acid (Sections 1.1.2 and 1.1.3). For the low excretion of D-glucaric 
acid as compared with L-ascorbic acid two obvious explanations can be given: 
1. The lactonization of endogenous D-glucuronic acid is insufficient, conse­
quently no D-glucuronolactone is available for the terminal step of the glucaric 
acid pathway. But the condition is that L-ascorbic acid is synthesized via 
D-glucuronic acid and L-gulonic acid (Pathway В in Fig. 3) and not via 
D-glucuronolactone (Pathway A in Fig. 3). 
2. The lactonization is not rate limiting for D-glucaric acid formation but D-
glucuronolactone dehydrogenase, the terminal enzyme of the glucaric acid path­
way, is localized different from the glucuronic acid pathway and the ascorbic 
acid pathway. Of the enzymes catalyzing the conversions from D-glucuronic 
acid into L-ascorbic acid the terminal enzyme L-gulonolactone oxidase is spe-
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cifically involved in the L-ascorbic acid synthesis. It is not found in relation 
to any other biochemical in vivo conversion. However, D-glucuronolactone 
dehydrogenase seems not to be specific for the glucaric acid pathway. It may 
be that this enzyme is identical to aldehyde dehydrogenase (EC 1.2.1.3), an 
hepatic enzyme involved in the conversion of a variety of aldehydes into carb-
oxylic acids (Section 1.1.3). D-glucuronolactone occurs in solution also in 
the free aldehyde form. The question arises whether the formation of D-glucaric 
acid has a specific biochemical significance or whether it should be considered 
as a more or less incidental process which takes place if a sufficient amount 
of D-glucuronolactone is available in the neighbourhood of the unspecific 
aldehyde dehydrogenase. In the latter case the glucaric acid pathway is not 
an intrinsic part of the glucuronic acid system. 
It is postulated that the drug-induced stimulation of the glucuronic acid 
system starts in the glucuronic acid pathway (Section 2.3). The ascorbic acid 
pathway as well as the xylulose pathway are linked to the glucuronic acid 
pathway. The increased supply with substrate i.e. D-glucuronic acid results in 
an enhanced conversion via the pathways just mentioned. This postulate has 
been extended by Marsh and Reid (1963). They suggest that the increased 
supply of D-glucuronic acid caused by drug treatment also leads to an enhanced 
conversion via the glucaric acid pathway. The enhanced D-glucaric acid excre-
tion, however, occurs less generally than the enhanced L-ascorbic acid excre-
tion (see before), indicating that the enhanced D-glucaric acid formation occurs 
less generally than the enhanced L-ascorbic acid formation. The latter pheno-
mena can be explained as follows. Only if the supply of the substrate D-glucur-
onic acid surpasses a certain level, it is also converted via the glucaric acid 
pathway. The higher supply is reached after a single administration of very 
effective drugs (barbital, chloretone) or after repeated administration of less 
effective drugs (borneol, phenylbutazone, nikethamide and aminophenazone). 
The question remains why the very lipid-soluble compounds DDT and thio-
pental, strong stimulators of the L-ascorbic acid excretion, after repeated ad-
ministrations do not cause an enhanced D-glucaric acid excretion in the rat. 
The higher supply of endogenous D-glucuronic acid in order to effect an enhan-
ced D-glucaric acid excretion is needed because of the slight lactonization of 
the D-glucuronic acid (see discussion under 1 ; in the xylulose pathway no lact-
onase is involved) or because of the missing link between the glucuronic acid 
pathway and the glucaric acid pathway ; in that case the glucaric acid pathway 
is not an intrinsic part of the glucuronic acid system (see discussion under 2). 
The fact that a strongly enhanced D-glucuronic acid excretion in urine 
occurs only during barbital treatment can be explained as follows: D-glucur-
onic acid has to be considered as an intermediate and not as an endproduct of 
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the glucuronic acid system. A high supply of D-glucuronic acid is required in 
order to get a D-glucuronic acid concentration which is sufficient for a con-
siderable diffusion of the acid from the liver cell to the extracellular space. 
Barbital treatment results in a strong stimulation of the glucuronic acid system, 
which means a high endogenous D-glucuronic acid supply. 
5.4 On the possible relationship between the drug-induced stimulation of the 
glucuronic acid system and a drug-induced change in glucuronidation 
As mentioned earlier (Section 2.3.2) the activity of rat liver UDP glucuronyl-
transferase is found to be enhanced after treatment of the animal with certain 
stimulating drugs (aminophenazone, barbital, polycyclic hydrocarbons). The 
activity was measured in vitro, while body-foreign compounds were used as 
acceptors. It has been put forward that this enhanced activity might result in 
a stimulation of the glucuronic acid system on the one hand (Touster et al., 
1962) and lead to an increased glucuronidation on the other. In this hypothesis 
it is implied that an UDP glucuronyltransferase plays a role in the glucuronic 
acid pathway and that this enzyme would be able to transfer the glucuronyl 
moiety to exogenous acceptors such as drugs and drug metabolites and to a 
hypothetical intermediary acceptor (Section 1.1.1.1). The correctness of these 
assumptions, however, has not been proved (Section 1.1.5). If indeed in both 
types of processes just indicated the same UDP glucuronyltransferase plays a 
role it would be expected that the enhanced activity of the UDP glucuronyl-
transferase would occur simultaneously with the enhancement of the in vivo 
activity of the glucuronidating system and that of the glucuronic acid system. 
It has been shown recently that stimulation of the glucuronic acid system is 
evident within 24 hours after administration of the stimulating drugs barbital 
(Section 5.2.1), phénobarbital and aminophenazone (Hollmann and Neubaur, 
1967). This may be concluded from the enhanced excretion of L-ascorbic acid 
and also of D-glucaric acid in the case of barbital. In the period of time ment-
ioned no increase of UDP glucuronyltransferase can be detected (Zeidenberg 
et al., 1967; Hollmann and Neubaur, 1967). The increase in the UDP glucuro-
nyltransferase activity can only be detected after treatment with drugs during 
several (3-4) days. The detection of the UDP glucuronyltransferase was per-
formed with the aid of exogenous acceptors such as drugs and drug metabo-
lites. The data indicate that an enhanced activity in the glucuronic acid 
system during drug treatment, which is detectable already after 2 or 3 hours, 
does not directly correlate with the enhanced activity of the UDP glucuronyl-
transferase involved in the glucuronidation of drugs. The conclusion is that 
two different transferases are involved or that in the activation of the glucur-
onic acid system no transferase is involved at all. 
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UDPGA is a common precursor of the glucuronidation and the various path-
ways in the glucuronic acid system. As a result of the stimulating action of drugs 
the supply with UDPGA may be enhanced with as a result an enhanced utiliz-
ation of this substance in the various pathways including the glucuronidation. 
The in vivo study of the influence of drugs, known to stimulate the glucuronic 
acid system, on the glucuronidation has been performed in experimental ani-
mals treated with such drugs during several days. The experiments of Remmer 
(1962) indicate that an enhanced glucuronidation of sulfadimethoxine occurs 
in rats after treatment with phénobarbital. Under the same circumstances an 
enhanced glucuronidation of N-acetyl-p-aminophenol has been observed (Buch 
et al., 1967). The experiments of Yaffe et al. (1966) suggest that the glucuronide 
forming capacity in hyperbilirubinemic children can be enlarged by treatment 
with phénobarbital. 
Besides an enhanced supply of UDPGA caused by the stimulating drugs, 
an enhanced activity of UDP glucuronyltransferase or liver growth may also 
be involved in the enhanced glucuronidation under these circumstances. As 
discussed before, within the first 24 hours after administration of the stimul-
ating drug (barbital, phénobarbital, aminophenazone) no enhanced UDP 
glucuronyltransferase activity can be observed and no liver growth occurs 
(Kunz et al., 1966a), whereas the stimulation of the glucuronic acid system, 
especially the L-ascorbic acid synthesis, is already evident. In order to get 
information on a possible connection between the stimulation of the glucuronic 
acid system and the enhanced glucuronidation on the level of UDPGA forma-
tion, the phenomena in question have been studied during the first 24 hours 
after administration of the stimulating drug. The possible influence of the 
enhanced UDP glucuronyltransferase activity, as measured in vitro with an 
exogenous compound as acceptor, and of liver growth can be left out of con-
sideration. 
Rats were treated with the exogenous glucuronic acid acceptor salicylamide 
in combination with certain drugs which stimulate the glucuronic acid system. 
It has been shown by Hänninen (1966) that salicylamide does not cause an 
enhanced L-ascorbic acid excretion in the 8-hr period after application of the 
drug. This indicates that stimulation by salicylamide of the glucuronic acid 
system does not occur in this period yet. For that reason the glucuronidation 
of salicylamide during 8 hours after the application of this glucuronide-forming 
compound was studied. Administration of barbital, DDT and nikethamide, 
which are known to stimulate the glucuronic acid system (Table 10), hardly 
results in any glucuronide formation. For that reason these compounds were 
used in these experiments. The rats were given barbital and nikethamide 1 hour 
before salicylamide administration and DDT 15 hours before salicylamide ad-
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TABLE 14 Effect of some stimulators of the glucuronic acid system on glucuronidation 
of salicylamide in rats. 
Conjugated D-glucuronic acid L-ascorbic acid 
Treatment* Mmoles/8-hr urine** Mmoles/8-hr urine** 
control treated Ρ value control treated Ρ value 
Sodium barbital, 230 ± 40 158 ± 18 <o.oi 4.9 ± 1.7 14.8 ± 4.8 <o.ooi 
150 mg/kg (6) (6) 
Nikethamide, 198 ± 1 1 180 ± 46 >o.25 4.8 ± 1.9 27.1 ± 4.3 <o.ooi 
125 mg/kg (7) (7) 
DDT, 271 ± 27 209 ± 17 <o.oi 8.4 ± 3.5 13.6 ±8.4 0.05 
30 mg/kg (6) (6) 
* Male immature rats, weighing 125-150 g, were given orally sodium barbital, ni­
kethamide or DDT at zero time. Salicylamide was suspended in 0.1% tragacanth 
solution. Salicylamide was given 600 mg/kg (about 600 цтоіез per rat) at 1 hr to the 
sodium barbital- and nikethamide-treated rats and at 15 hr to the DDT-treated rats. 
Control animals were given the solvents concerned. 
* * Collection of urine was started immediately after administration of salicylamide. 
The figures and Ρ values are expressed as indicated in Table 9. 
ministration. No indication was found that an enhanced glucuronidation of 
salicylamide takes place under the influence of the stimulating drugs (Table 14). 
Treatment with barbital and DDT even inhibited that glucuronidation. Yet 
the treatment of the experimental animals with the stimulating compounds in 
question causes a stimulation of the glucuronic acid system already during the 
first hours after application. This can be concluded from the increase of the 
urinary L-ascorbic acid excretion (Table 14) and in the case of barbital from 
the increase of the urinary D-glucaric acid excretion (Fig. 13). The data in­
dicate that during this period a stimulation of the glucuronic acid system 
occurs, whereas the glucuronidation is not enhanced. These results in comb­
ination with data from the literature show that the stimulation of the glucuronic 
acid system and the enhanced glucuronidation, both occurring after treatment 
with drugs, have a different time course and do not appear to be directly related. 
It has recently been shown that a lowered UDP glucuronyltransferase activ­
ity occurs shortly after the treatment of rats with aminophenazone (Hollmann 
and Neubaur, 1967) and a lowered UDPG dehydrogenase activity shortly after 
the administration of barbital to rats (Hollmann and Neubaur, 1967) and 
guinea pigs (see Table 16). The lowered glucuronidation which could be observed 
immediately after barbital administration might be easily explained if shortly after 
barbital treatment also a lowered UDP glucuronyltransferase activity resulting 
jrom a lower level or from an inhibition of this enzyme by barbital would occur. 
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It might be proposed that the lowered glucuronidation is caused by a high 
utilization of UDPGA through the stimulated glucuronic acid system resulting 
in a lowered supply of UDPGA for the glucuronidation. In that case one has 
to postulate that stimulation of the glucuronic acid system takes place in the 
steps which lead from UDPGA to D-glucuronic acid. If this supposition holds 
true one might expect that not only after barbital and DDT treatment, but also 
after nikethamide treatment a lowered glucuronidation occurs. 
5.5 Summary 
The first subject dealt with in this chapter concerns the length of the latency 
period between administration of barbiturate and occurrence of an enhanced 
production and/or excretion of D-glucaric acid and L-ascorbic acid in rats and 
dogs. It was found that in rats no increase of the hepatic L-ascorbic acid level 
can be observed 2 hours after i.p. injection of barbital, whereas after a period 
of 3 hours an increase in this level is evident. It was also observed that in rat the 
urine obtained during the first 3 hours after i.p. injection of barbital, contains 
an increased amount of D-glucaric acid and L-ascorbic acid. In view of these 
data the conclusion seems justified that already within the first 3 hours after 
i.p. application of barbital the glucuronic acid system is stimulated. It was 
known already that a time interval of at least 3 hours separates the i.p. injection 
of phénobarbital from the moment that an increase in drug metabolism on the 
basis of a de novo enzyme synthesis becomes evident (Ernster and Orrenius. 
1965). Although both a stimulation of the glucuronic acid system and an in-
creased drug metabolism in question are found after the application of the same 
kind of compounds, the experiments discussed above indicate that in the liver 
the first-mentioned stimulation can be detected earlier than the increase in drug 
metabolism. 
In the experiments on dogs a combination of barbital and thiopental was 
given intravenously ; so in these cases the barbiturates served as stimulator and 
as anaesthetic. The urine was collected directly from the cannulated ureters. 
The experiments showed that the urinary D-glucaric acid and L-ascorbic acid 
levels are found to be increased within the first 2 hours after barbiturate applic-
ation. The stimulation may be caused either by an enhanced enzyme synthesis 
for which a period of 2 hours (dog) to 3 hours (rat) is sufficiënt (Section 5.2.1), 
or by a completely different type of mechanism, not dependent on a de novo 
enzyme synthesis (see in this respect Chapter 7). 
So far, the fact that drug treatment causes an enhanced excretion of 
D-glucaric acid had been described only as far as the rat is concerned (Marsh 
and Reid, 1963). The fact that the same phenomena can be observed in man, 
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guinea pig (Chapter 4) and dog (this chapter) shows that the phenomena in 
question are not confined to a single species. 
In rats given cumulative doses of barbital it appears that in order to 
obtain an enhanced D-glucuronic acid excretion, higher drug levels are needed 
than those needed to obtain an enhanced excretion of L-ascorbic acid and 
D-glucaric acid. After stopping drug application much less L-ascorbic acid, 
D-glucaric acid and D-glucuronic acid is excreted than during the application. 
After the final dose of barbital, the enhanced D-glucuronic acid excretion is 
observed for only one day more, whereas the enhanced excretion of the other 
two acids is observed for more than a week. The pretreatment level of the 
D-glucuronic acid excretion was very high. It has to be considered that a small 
D-glucuronic acid response (of the same order as the L-ascorbic acid response) 
possibly occurring after drug treatment, may be obscured because of the high 
base level of urinary D-glucuronic acid. The response in D-glucaric acid ex-
cretion tends to coincide with that of L-ascorbic acid. The increase in excretion 
of both substances, although small, is still observed on the n t h day after 
stopping the barbital application. This prolonged small increase may be related 
to a prolonged action of the drug; the elimination of barbital from the body 
is a slow process. 
During this study it was found that in individual untreated rats the amount 
of L-ascorbic acid excreted from day to day in the urine is rather constant. The 
amounts excreted by difTerent rats of the same strain, however, can vary con-
siderably. It was observed that a positive correlation exists between the barb-
ital-induced increase of L-ascorbic acid excretion and the pretreatment level of 
excretion. 
Not only the effect of barbital, but also the effect of some other drugs on the 
urinary D-glucaric acid and L-ascorbic acid excretion of the rat was studied. 
It was found that all compounds tested cause an increase in L-ascorbic acid 
excretion, whereas an enhanced D-glucaric acid excretion is less common. In 
the cases that both effects were observed the increase in L-ascorbic acid excret-
ion occurred earlier than the other response and could be brought about by 
a single dose of the drug in question, whereas an increased excretion of D-glucar-
ic acid became evident only after treatment with the drug during 3 to 4 days. 
In this respect barbital forms an exception. The same holds for chloretone 
(Marsh and Reid, 1963). 
After treatment of rats during 4 days with some of the compounds studied, 
the weight of the liver was found to be increased. This increase in weight is 
supposed to be caused by a hypertrophy of the liver (Section 5.3). The enhanced 
urinary excretion of L-ascorbic acid and D-glucaric acid, which occurs after 
some days of drug treatment, might be related to this liver growth. The experi-
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ments described in this chapter, however, give an indication that the growth 
of the liver does not play a definite role in the enhanced excretion of the acids 
in question. 
The enhanced excretion of L-ascorbic acid as found in the rat can be con-
sidered as a criterion of the stimulation of the glucuronic acid system. This 
does not hold for the enhanced excretion of D-glucaric acid, since in some 
cases an enhanced L-ascorbic acid excretion is found, whereas the D-glucaric 
acid excretion has not or hardly changed. From the experimental results ob-
tained with rats the conclusion seems justified that the finding of an enhanced 
D-glucaric acid excretion in this species implies that a strong stimulation has 
taken place. Possibly, the same holds true in man and guinea pig. 
The influence of drugs on the urinary D-glucaric acid excretion in man 
(Chapter 4) is largely analogous to the effects observed in the animal experi-
ment (this chapter). As for the barbiturates an enhanced excretion of D-glucaric 
acid is found in man (phénobarbital) as well as in rat, guinea pig and dog (barb-
ital). The influence of aminophenazone and phenylbutazone on the D-glucaric 
acid excretion in man is also analogous to that found in the rat, whereas sa-
licylic acid (a week stimulating drug) has no effect in this respect in either 
species. It may be stressed that drugs like aminophenazone and borneol, which 
are known to cause an enhanced excretion of L-xylulose in pentosuriacs 
(Enklewitz and Lasker, 1935) also cause an increase of the D-glucaric acid 
excretion in rats. Furthermore, all the drugs mentioned here cause an enhanced 
excretion of L-ascorbic acid in rats. 
The fact that after the application of a single dose of some drugs a clear 
response in the L-ascorbic acid excretion is observed, whereas the excretion 
of D-glucaric acid remains unaltered, probably means that a stimulation of the 
glucuronic acid pathway has not necessarily the same consequences for all 
metabolic pathways involved in a further metabolism of D-glucuronic acid. In 
this context it should be stressed that, according to the experiments of Sadahiro 
et al. (1966), hepatic D-glucuronolactone dehydrogenase, which catalyzes the 
terminal step in the D-glucaric acid formation, may be identical with the rather 
unspecific enzyme aldehyde dehydrogenase (EC 1.2.1.3). This possibility and 
the fact that under normal conditions carbohydrates are hardly metabolized 
into and excreted as D-glucaric acid, suggest that, in contrast to the ascorbic 
acid pathway and the xylulose pathway, the glucaric acid pathway is not an 
intrinsic part of the glucuronic acid system. On this basis an uncomplicated 
explanation can be given of the different effects of drugs on the ascorbic acid 
pathway on the one hand and on the glucaric acid pathway on the other hand. 
An alternative explanation is that the L-ascorbic acid biosynthesis proceeds 
via D-glucuronic acid and L-gulonic acid in which case D-glucuronolactone is 
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not an obligatory intermediate for the L-ascorbic acid synthesis, and that a 
lactonization of D-glucuronic acid to D-glucuronolactone occurs to a low de-
gree. As discussed in Section 1.1.3 the D-glucaric acid is formed via D-glucuro-
nolactone. 
Another pathway, possibly linked to the glucuronic acid system is that leading 
to the formation of glucuronides. The question arises whether there is a func-
tional link between the enhanced glucuronidation of drugs and drug metabo-
lites, and the stimulation of the glucuronic acid system, as both are observed 
after administration of compounds of the same nature. A theoretical possibility 
would be that both phenomena are dependent on an enhanced activity of 
the same UDP glucuronyltransferase. On the basis of both data found in 
the literature and the results of our own experiments, this is rather unlikely. 
An alternative is that both the enhanced glucuronidation and the enhanced 
formation of the endproducts of the glucuronic acid system are dependent 
on an enhanced formation of UDPGA in the liver cell. This does not lead to a 
simple solution either, since it was found that in animals to which a stimulating 
drug and also a glucuronide acceptor (salicylamide) had been given, no 
enhanced glucuronidation could be observed during a period of time which 
was sufficient for the development of a clear stimulation of the glucuronic acid 
system. If barbital and DDT are used as stimulating drugs, the glucuronidation 
may even be depressed. 
In view of the foregoing it would not seem probable that one and the same 
mechanism is responsible for the stimulation of the glucuronic acid system and 
the enhanced formation of glucuronides, which becomes evident only after some 
days of treatment with the stimulating drugs. The enhanced formation of glucur-
onides might be explained by an increase in activity of the UDP glucuronyl-
transferase and also by liver growth. In contrast with the stimulation of the 
glucuronic acid system, these changes are not found within the first 24 hours 
after administration of the stimulating drug. 
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CHAPTER 6 
A STUDY ON THE POSSIBLE ROLE OF DE NOVO ENZYME 
SYNTHESIS IN THE DRUG-INDUCED STIMULATION 
OF THE GLUCURONIC ACID SYSTEM 
6.1 Introduction 
The stimulating effect of drugs on the biosynthesis of L-ascorbic acid, L-
xylulose and D-glucaric acid is probably due to an increased formation of the 
common intermediate D-glucuronic acid from D-hexose (Sections 2.3 and 
4.2.2). As a matter of fact, the suggestion has been made that this increased 
formation might be the result of a drug-induced elevation of the level of 
certain liver enzymes involved in the glucuronic acid system. 
In studies on the effect of stimulating drugs administered in vivo on rat liver 
enzymes involved in the glucuronic acid system, such as UDPG dehydrogenase 
and UDP glucuronyltransferase, enhanced activities were found which are pos-
sibly due to de novo synthesis of these enzymes (Chapter 2). Chloretone (Holl-
mann and Touster, 1962; Conney et al., 1961) and barbital (Conney et al., 1961) 
cause an enhanced UDPG dehydrogenase activity. Stimulation of UDPG de-
hydrogenase activity by 3,4-benzpyrene reported by Arias et al. (1963) was not 
confirmed by other investigators (Hollmann and Touster, 1962). Carcinogenic 
hydrocarbons and aminophenazone have no influence on UDPG dehydroge-
nase activity, but enhance UDP glucuronyltransferase activity. The postulate 
that an increased level of UDP glucuronyltransferase would imply an enhance-
ment of the metabolism of carbohydrate via the glucuronic acid system is not 
supported by further observations (Section 5.4). The question whether the en-
hanced activity of UDPG dehydrogenase could be responsible for the stimula-
tion of the glucuronic acid system by chloretone or barbital has not been 
definitively answered. Further experiments in this respect are required. 
The investigations described in this chapter are aimed at the elucidation of 
three questions: 
1. What is the function of an enhanced UDPG dehydrogenase activity in the 
stimulation of the glucuronic acid system? 
2. Is de novo enzyme synthesis, that is synthesis of new enzyme molecules from 
amino acids, involved in the stimulation of the glucuronic acid system? 
3. The results obtained from the experiments described in this chapter raise 
82 
the question as to whether the enhanced excretion ofD-glucaric acid resulting 
from the stimulation of the glucuronic acid system can be considered a criterion 
for the occurrence of drug-stimulated enhanced drug metabolism. This question 
will be discussed in this chapter too. 
6.1.1 Evaluation of the function of the enhanced UDPG dehydrogenase activity 
of the liver in the stimulation of the glucuronic acid system 
As mentioned before (Section 6.1) further experiments have to be performed 
in order to determine whether an enhancement of the UDPG dehydrogenase 
activity of the liver, as observed in vitro, plays an essential role in the pheno-
menon indicated as stimulation of the glucuronic acid system (Section 2.3.2). 
It is known that the enhanced activity of the liver enzyme systems involved in 
drug metabolism as observed after treatment of experimental animals with 
certain drugs, is dependent on a de novo enzyme synthesis (Ernster and Orre-
nius, 1965). The notion that a comparison between the influence of certain 
drugs on the activity of a drug-metabolizing enzyme system on the one hand 
and on the UDPG dehydrogenase activity on the other hand might be import-
ant, is based on the following considerations. First there is the fact that both 
the stimulation of the glucuronic acid system and of an enhanced drug meta-
bolism can be observed after administration of drugs of the same type. 
Secondly, the glucuronic acid system may be linked to the glucuroni-
dation, which takes part in drug metabolism. UDPG dehydrogenase catalyzes 
the formation of UDPGA which is an intermediate in glucuronidation and in 
the glucuronic acid system (Fig. 1). Thirdly, it is important to know whether 
an enhancement of the UDPG dehydrogenase activity as a result of drug ad-
ministration (Section 6.1) is of the same order as the enhancement of the activ-
ity of a drug-metabolizing enzyme system in which a de novo synthesis is 
involved. The enzyme system responsible for the demethylation of aminophena-
zone was chosen as a drug-metabolizing enzyme system to be studied. In the 
experiments in question it was further determined whether barbital has an 
influence on the hepatic tyrosine aminotransferase activity. This aspect of the 
barbital action will be discussed in Section 7.1.1. 
Rats and guinea pigs were used as experimental animals. The enzyme activ-
ities were measured 24 hours after the administration of the stimulating com-
pound, in this case barbital. After barbital administration the 24-hr urine por-
tions were collected. The levels of D-glucaric acid and L-ascorbic acid (in the 
rat only) were determined in these urine portions. Since the urinary levels of 
D-glucaric acid and L-ascorbic acid were found to be enhanced, it was con-
cluded that stimulation of the glucuronic acid system had occurred (Table 15). 
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TABLE 15 Effect of barbital treatment** on enzyme activities of guinea pig and rat liver homogenates and on urinary excretion of 
D-glucaric acid or L-ascorbic acid in rats or guinea pigs. 
Enzyme activity 
per mg protein 
Guinea pigs* 
control treated 
Ρ value 
Rats* 
control treated Ρ value 
UDPG dehydrogenase 
units 
Demethylation 
i o 3 цтоІев/Ьг 
Tyrosine 
aminotransferase 
units 
Urinary excretion*** 
цто1е5/24 hr 
21.3 ^ 8.1 (6) 25.7 ± 11.1 (11) >0.25 
12.1 ± 2 . 3 (6) 27.3 ± 4.5(11) <o.oi 
9-2 ± 1 . 7 (6) 10.4 ± 5.2 (11) >0.25 
16.5 ± 2.4 (6) 18.2 ± 6.1 (6) 0.25 
10.3 ± 2 . 1 (6) 18.4 ± 4.6(6) <o.oi 
7.8 ± 1.5 (6) 6.8 ± 1.1 (6) > o . i o 
L-ascorbic acid 
D-glucaric acid 0.60 ± 0.32 (6) 5.7 ± 2.2 (11) <o.oi 
12.8 ± 8.4 (6) 
0.42 ± 0 . 1 1 (6) 
32.3 ± 18.4 (6) 
2.1 ± 0.6(6) 
O.O3 
<0.0I 
* Female guinea pigs, weighing 300-400 g, and female rats, weighing 180-200 g, were used. 
** The animals were given sodium barbital 150 mg/kg i.p. 24 hr before killing; control animals were given saline i.p. 
*** Collection of urine was started immediately after injection. 
Means with S. D. are shown. Numbers in parenthesis indicate number of animals on which each mean is based. Ρ values were obtain­
ed by applying the two-sided Wilcoxon two-sample test. 
This stimulation is accompanied with an enhanced demethylation activity of 
the 9000 g supernatants of the liver homogenates obtained by killing the animals. 
Since enhanced drug metabolism has been shown to be based on de novo syn­
thesis of enzymes, this finding implies that an enhanced de novo synthesis of 
the microsomal enzyme systems involved in drug metabolism has taken place. 
On the other hand no enhanced activity of the UDPG dehydrogenase could 
be observed. The absence of an increase in the UDPG dehydrogenase activity 
after treatment with barbital was an unexpected finding. 
The half-life time of UDPG dehydrogenase is assumed to be about 4 hours 
(Hollmann and Neubaur, 1967). As shown by Steiner (1964) the induction of 
UDPG-glycogen glucosyltransferase — as caused by feeding of starved rats — 
reaches its maximal value after 3 hours and has disappeared after 20 hours. If 
a possible induction of the UDPG dehydrogenase activity after barbital treat­
ment would follow a similar pattern, the absence of an increased activity of 
this enzyme after 24 hours would be understandable. We, however, also studied 
the UDPG dehydrogenase activity in guinea pigs at various times from 5-72 
hours after barbital administration (Table 16). In no case the activity was 
TABLE 16 UDPG dehydrogenase activity of guinea pig liver homogenates at various 
times after administration of barbital. 
Time after 
administration* 
hr 
5 
9 
24 
72 
UDPG dehydrogenase activity per mg protein 
units 
control 
28.5 ± 2.9 (6) 
15-7 ± 8.0 (6) 
21.3 ± 8.1 (6) 
23-5 i 4-8 (6) 
treated 
24.5 ± 3.8 ( 6) 
23-0 ± 5.З ( 6) 
25.7 ± II .I (II) 
23.8 ± 3.6 ( 6) 
Ρ value 
0.05 
0.09 
>0.25 
>0.25 
* Female guinea pigs, weighing 300-400 g, were given single injections of sodium 
barbital 150 mg/kg i.p. at zero time. The 72-hr group was given three injections at 
zero time, at 24 hr and at 48 hr ; the control animals were given saline. 
The figures and Ρ values are calculated as indicated in Table 15. 
found to be enhanced; after a 5-hr period it even appeared to be decreased. 
Recently such an inhibiting effect of barbital in the rat was reported by Holl-
mann and Neubaur (1967). These authors ascribe this effect to a primary in­
hibition of protein synthesis. They too were unable to detect an increase in the 
hepatic UDPG dehydrogenase activity for various periods up to 48 hours after 
administration of barbital to rats. 
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TABLE 17 Effect of chloretone treatment* on UDPG dehydrogenase activity of rat liver homogenates and on L-ascorbic acid excretion 
in rat urine. 
UDPG dehydrogenase activity per mg protein L-ascorbic acid excretion** 
Treatment units pmoles/24 hr 
III control treated Ρ value III control treated Ρ value 
I 150 mg/kg orally, i 6 . i ± 3 . 6 ( 7 ) 30.8 ± 13.3 (6) 0.03 3.5 ± 2.5 (7) 39.9 ± 2 1 . 6 (6) <o.oi 
daily for 6 days 
II 150 mg/kg orally, 16.1 ± 3.6 (7) 18.8 ± 6.5(8) >o.25 3-5 + 2.5(7) 23.3 ± 8.6(8) <o.oi 
single dose 
* Female rats, weighing 180-220 g, were used. Groups I and II were killed 24 hr after the last dose and 20 hr after the single dose 
respectively. The animals in groups I and II were compared with control animals (group HI), which were killed at the same time. 
** Collection of urine was started immediately after the last dose. 
Figures and Ρ values are calculated as indicated in Table 15. 
According to Conney et al. (1961) and Hollmann and Touster (1962) the 
UDPG dehydrogenase activity is enhanced after pretreatment with chloretone. 
These investigators administered the drug daily to rats during 7 days. It was 
thought important to investigate whether also after treatment with a single dose 
of chloretone an enhanced UDPG dehydrogenase activity would occur. The 
following experiment was performed (Table 17). From three groups of rats 
group I was treated daily for 6 days with chloretone, group II received a single 
dose of this drug, whereas group III served as a control. In group II the enzyme 
activity was determined 20 hours after the dose of chloretone, in group I 
24 hours after the last dose. Moreover, the amount of urinary L-ascorbic acid, 
excreted during 24 hours and 20 hours in the groups I and II respectively, was 
determined. The measured enzyme activities and urinary excretions were com-
pared with those of the control group (III). As may be concluded from the 
increased L-ascorbic acid excretion, a stimulation of the glucuronic acid system 
occurs after repeated administration of chloretone as well as after a single dose 
of this drug. An enhanced activity of the UDPG dehydrogenase, however, was 
only observed in the chronically treated animals (group I). From these data it 
may be concluded that the stimulation in the L-ascorbic acid production observed 
within the first 24 hours after administration of the drug is not dependent on 
an enhanced UDPG dehydrogenase activity. The D-glucaric acid excretion is 
also considerably enhanced within 24 hours after administration of chloretone 
to rats (Marsh and Reid, 1963). Since the early responses of L-ascorbic acid 
and D-glucaric acid as compared with the responses obtained after continuous 
treatment are quite considerable already, it is unlikely that an increase in the 
UDPG dehydrogenase activity plays an important role in the overall pheno-
menon of the drug-induced stimulation of the glucuronic acid system. 
6.1.2 Is a de novo protein synthesis involved in the drug-induced stimulation of 
the glucuronic acid system? 
From experiments described in Section 5.2.1 it appears that in rats stimu-
lation of the glucuronic acid system occurs within 3 hours after barbital ad-
ministration. From experiments with dogs (Section 5.2.1) it also appears that 
stimulation occurs within 2 hours after administration of barbiturates. It has 
been shown in the Sections 5.4 and 6.1.1 that de novo synthesis of UDP glucur-
onyltransferase and UDPG dehydrogenase respectively, is not involved in the 
stimulation occurring within a few hours after drug administration. The pos-
sibility has to be considered that although no indication has been found in 
this direction (Section 2.3.2) other enzymes are involved in the stimulation and 
that de novo synthesis of these enzymes occurs in the first few hours after ad-
ministration of a barbiturate. 
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In order to evaluate the role of such a de novo synthesis the effects of inhib-
itors of protein synthesis were studied. The inhibitors used were puromycin 
and actinomycin D. Puromycin inhibits the transfer of the amino acids from 
soluble ribonucleinic acid (RNA) to protein (Yarmolinsky and de la Haba, 
I959)· It has been shown that the inhibition of protein synthesis by puromycin 
occurs practically immediately (15 min after i.p. injection) (Guidice et al., 1964). 
Actinomycin D is supposed to inhibit deoxyribonucleinic acid (DNA)-directed 
RNA synthesis (Traketellis et al., 1964). For actinomycin D it has been shown 
that 30 min after i.p. injection protein synthesis is inhibited (Nakazato et al.,1965). 
In our experiments the question was studied whether puromycin and actino-
mycin D influence the stimulation of the glucuronic acid system, as caused by 
barbital. 
Rats were injected with puromycin or actinomycin D in quantities high 
enough to prevent protein synthesis within the first 6 hours after barbital ad-
ministration. Enhanced urinary excretion of L-ascorbic acid and D-glucaric 
acid was used as an indication for the occurrence of stimulation (Table 18). The 
data show that puromycin and actinomycin D do not prevent the effect of 
barbital. It has been shown by de Matteis (1964), that in actinomycin D-treated 
rats the stimulating effect of 2-allyl-2-isopropylacetamide on the L-ascorbic acid 
excretion is still very pronounced, while the porphyria-inducing effect of the 
same drug — an effect which is dependent on de novo enzyme synthesis — is 
abolished. The results obtained indicate that de novo synthesis is not involved 
in the stimulation of the glucuronic acid system, as caused by drugs such as 
barbital and 2-allyl-2-isopropylacetamide. Assuming that the stimulating drugs, 
although they have different chemical structures and pharmacological proper-
ties, act by the same mechanism, the same holds for stimulation caused by 
other drugs. 
6.1.3 The enhanced excretion of D-glucaric acid in animals during treatment with 
drugs as an indication of an enhanced drug-metabolizing capacity of the liver 
According to Burns et al. (1963) an enhanced excretion of L-ascorbic acid 
in rats during treatment with certain drugs may be considered as an indication 
of enhanced drug metabolism in the liver. This enhanced excretion of L-ascorbic 
acid is caused by an accelerated metabolism of carbohydrates via D-glucuronic 
acid (Chapter 2). Since man does not synthesize L-ascorbic acid, it is a relevant 
question whether another product formed via D-glucuronic acid and excreted 
in the urine might serve as an indication of the stimulation of the glucuronic 
acid system and/or induction of enhanced drug metabolism in patients. Theor-
etically D-glucaric acid might serve as such an indicator (Section 4.1). The 
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TABLE 18 Barbital-stimulated urinary excretion of L-ascorbic acid and D-glucaric acid in rats treated with puromycin and actino-
mycin D. 
Treatment* 
I Barbital with 
puromycin (6) 
II Barbital with 
actinomycin D * * (6) 
III Barbital (8) 
3 hr Before experiment 
цто1е5/з hr 
L-ascorbic acid 0.68 ± 0.38 
D-glucaric acid 0.044 ± 0.009 
L-ascorbic acid 0.60 ± 0.41 
D-glucaric acid 0.029 ± 0.006 
L-ascorbic acid 0.80 ± 0.43 
D-glucaric acid 0.035 ± 0.008 
First 3 hr during 
experiment 
Mmoles/3 hr Ρ value 
Second 3 hr during 
experiment 
цтоіев/з hr Ρ value 
1.67 ± 0.53 
0.143 ± 0.036 
1.02 ± O.3I 
O.049 ± O.OI7 
2.11 ± І.4З 
О.О96 ± О.О45 
О.ОЗ 
O.O3 
O.06 
>0.I0 
0.03 
0.03 
3.66 ± 0.95 
O.I74 ± 0.022 
5.23 ± 2.64 
0.165 ± 0.104 
3-75 ± 1-43 
0.222 ± 0.066 
0.03 
0.03 
0.03 
0.03 
0.03 
0.03 
* Male weanling rats, weighing 45-60 g, were divided into three groups. After collecting urine over a 3-hr period the rats were 
treated as follows : 
Group I was injected with sodium barbital 140 mg/kg i.p. at zero time, together with puromycin 30 mg/kg. The puromycin injections 
were repeated every hour. 
Group II was injected twice with actinomycin D 800 pg/kg i.p. at zero time and at 3 hr. The group was injected with sodium bar­
bital 140 mg/kg i.p. at 30 min. 
Group III was treated as group I except that puromycin was omitted. Urine was collected in two consecutive 3-hr periods. 
** Treatment of a group of six rats with only actinomycin D did not influence significantly urinary excretion of the acids during 
the first 6 hr after injection. 
Numbers in parenthesis indicate number of animals in each group. Means with S.D. are shown. Ρ values were obtained by applying 
the two-sided Wilcoxon signed-rank test. The two 3-hr intervals after treatment were compared with the 3-hr interval before treat­
ment. Comparison of the excretion of the acids of groups I and II with group III did not show significant differences (P value < 0.05) 
in the second 3-hr interval and in the control 3-hr interval (two-sided Wilcoxon two-sample test). 
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basic assumption is, that the enhanced drug metabolism and the enhanced me-
tabolism of carbohydrates via the glucuronic acid system are functionally tied 
up or at least correlated in time. Further analysis, however, leads to the fol-
lowing results. 
i. In animal experiments an enhanced carbohydrate metabolism via D-glucur-
onic acid manifests itself much more clearly in an enhanced excretion of 
L-ascorbic acid than in a change in the excretion of D-glucaric acid. Some 
drugs which stimulate drug metabolism, such as barbital (Table io) and chlore-
tone (Marsh and Reid, 1963), cause already after a single dose an enhanced 
excretion of D-glucaric acid in the rat, whereas other stimulating drugs such 
as aminophenazone, borneol, nikethamide and phenylbutazone have such an 
effect only after a repeated administration during some days. A third group of 
stimulating drugs such as DDT (Table 13) and 3-methylcholanthrene (Marsh 
and Reid, 1963) does not cause a clear change in D-glucaric acid excretion, 
even after repeated dosing during several days. An important enhancement of 
the urinary L-ascorbic acid excretion in the rat follows a single dose of any of 
these drugs. 
2. Contrary to the enhanced drug metabolism, the stimulation of carbohydrate 
metabolism via D-glucuronic acid appears not to be caused by a de novo 
enzyme synthesis (Section 6.1.2), which indicates that different basic processes 
are involved. 
Recapitulating, an enhanced D-glucaric acid excretion does not necessarily 
follow the administration of stimulators of drug metabolism, whereas the bio-
chemical mechanisms involved in an enhanced drug metabolism and in an 
enhanced D-glucaric acid excretion have little in common. It is even question-
able whether the synthesis of D-glucaric acid and that of L-ascorbic acid are 
related in the same way with the glucuronic acid pathway (Section 5.3.2). 
Therefore, the supposition that the enhanced excretion of D-glucaric acid might 
be considered an indication of an increased drug-metabolizing capacity in the 
liver does not seem to be justified. This holds for animal experiments and theie 
is no reason to suppose that the same would not hold too for the clinical use 
of drugs. 
6.2 Summary 
Several investigators put forward the possibility that an enhanced de novo 
synthesis of liver UDPG dehydrogenase caused by drugs might be responsible 
for the enhanced biosynthesis and excretion of products of the glucuronic acid 
system. In the present study this possibility was further tested. First it was 
determined whether the activity of liver UDPG dehydrogenase is enhanced 
after treatment with barbital, a drug which strongly stimulates the glucuronic 
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acid system, and whether this enhancement is in the same order of magnitude 
as the increase in activity of an inducible drug-metabolizing enzyme system. 
It has also been investigated whether the activity of D-glucuronolactone dehy-
drogenase, the enzyme concerned in the terminal step of the glucaric acid path-
way, is enhanced. The oxidative demethylation of aminophenazone was meas-
ured since the responsible enzyme is a good example of an inducible drug-
metabolizing enzyme system, in which enhanced de novo synthesis is involved. 
After barbital treatment of rats and guinea pigs no enhanced UDPG dehy-
drogenase activity was observed, whereas the demethylation activity was en-
hanced and stimulation of the glucuronic acid system was evident. From the 
foregoing it follows that an increase of the UDPG dehydrogenase activity is 
not the primary cause of the stimulation of the glucuronic acid system. On the 
other hand an enhanced UDPG dehydrogenase activity, which occurs after 
drug treatment during several days, may be involved in causing an enhanced 
excretion of products of the glucuronic acid system. A single dose of chloretone 
as well as the administration of this drug during several days causes an enhanced 
excretion ofL-ascorbic acid, indicating that the glucuronic acid system is stim-
ulated ; the activity of UDPG dehydrogenase, however, is enhanced only after 
treatment with this drug during several days. 
As discussed earlier (Section 5.4) an enhanced UDP glucuronyltransferase 
activity, which is measured with the aid of exogenous substances as acceptors, 
appears not to be primarily involved in the stimulation of the glucuronic acid 
system. 
The stimulation caused by barbital is not prevented by treatment with ac-
tinomycin D or puromycin. A similar observation was made by de Matteis 
(1964), who observed that actinomycin D does not prevent the stimulating ef-
fect of 2-allyl-2-isopropyIacetamide on the formation of L-ascorbic acid. If, as 
is probable, most stimulating drugs, although they have different chemical 
structures and pharmacological properties, act by the same mechanism as far 
as enhancement of drug metabolism is concerned, the same may hold true for 
stimulation of the glucuronic acid system. The results obtained with drugs as 
actinomycin D and puromycin, which inhibit the protein synthesis, indicate 
that, contrary to the stimulation of drug metabolism, the stimulation of the 
glucuronic acid system is not dependent on a de novo enzyme synthesis. 
The question was asked whether the enhanced urinary D-glucaric acid ex-
cretion occurring in animals during drug treatment can be used as an indication 
of an existing enhanced drug-metabolizing capacity in the liver of man or 
animal involved. In view of the results of the experiments discussed in this 
chapter and of the experiments described in Chapter 5, the answer in this 
question can only be negative. 
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CHAPTER 7 
THE BASIC CHEMICAL PROCESSES POSSIBLY INVOLVED 
IN THE STIMULATION OF THE GLUCURONIC ACID 
SYSTEM AS CAUSED BY DRUGS 
7./ Introduction 
In this chapter the emphasis will be put on the possible, primary biochemical 
processes involved in the stimulation of the glucuronic acid system as caused 
by drugs. The following aspects will be studied : 
1. Are hormonal processes involved in the stimulating effect of drugs on the 
glucuronic acid system ? 
2. It is known that a variety of drugs cause stimulation of the pentose phos­
phate pathway. The stimulation of this pathway is accompanied by liver growth 
and follows a change in the NADP redox state in the cytoplasm of the liver 
cells. A comparison of the stimulation of the pentose phosphate pathway with 
that of the glucuronic acid system is made. This comparison may be useful 
for further analysis of the stimulation of the glucuronic acid system by drugs. 
7.1. ί The involvement of hormones in the stimulation of the glucuronic acid system 
With respect to a hormonal action several possibilities can be considered: 
The hormones are administered to the animals acting directly on the glucuronic 
acid system or the hormones are of endogenous origin and released under the 
influence of the drug. In the latter case the drugs stimulate the glucuronic acid 
system in an indirect way. Another possibility is that hormones have an in­
fluence on the magnitude of the response as caused by stimulating drugs. As 
far as the application of hormones, especially steroid hormones, is concerned, 
there is evidence that after dosage of such compounds a stimulation of the 
glucuronic acid system takes place, manifesting as increased excretion of 
L-ascorbic acid (Section 2.2). These observations were based on the application 
of doses of hormones which must be considered as very high, as compared to 
the quantity of hormones normally involved in the biological regulation pro­
cesses. Moreover, the responses of the glucuronic acid system upon hormone 
treatment were weak. 
A direct approach to the involvement of endogenously released hormones in 
92 
the stimulation phenomenon is the study of the influence of drugs on the 
glucuronic acid system in animals deprived of certain endocrine glands. Applic-
ation of chloretone and barbital to adrenalectomized animals still results in 
a clear increase in the L-ascorbic acid excretion (Burns et al., 1957). On the 
other hand it is possible to stimulate the excretion of corticoid hormones in 
animals by placing them in certain stress situations without the involvement of 
drugs. It has been shown that in such a stress situation the activity of certain 
enzymes e.g. tyrosine aminotransferase in the liver tissue is enhanced (Kenney 
and Flora, 1961). It is known that after application of hydrocortisone the ac-
tivity of this enzyme is also enhanced. The question arises whether in a stress 
situation in which the adrenals are involved an enhanced excretion of L-ascorbic 
acid takes place and whether the activity of hepatic enzymes involved in glucur-
onic acid metabolism e.g. UDPG dehydrogenase and D-glucuronolactone de-
hydrogenase is enhanced. It is known that under the influence of certain steroid 
hormones and of certain stress situations to which animals are subjected the 
activity of the drug-metabolizing enzyme systems can be enhanced (Schenkman 
et al., 1967; Furner and Stitzel, 1968). The question arises whether under stress 
condition to which the animals in our experiment were subjected an increase 
in the drug-metabolizing capacity takes place too. 
Experiments were performed with rats. The animals were treated with the 
stress-inducing agent celite (a soluble diatomaceous earth, which cannot be 
considered as a drug in the usual sense). Studied were the L-ascorbic acid and 
D-glucaric acid excretion, the activity of the liver enzymes UDPG dehydrogen-
ase and D-glucuronolactone dehydrogenase and the drug-demethylation 
activity of liver tissue. In order to check whether a stress situation has been 
reached in the same experiment the tyrosine aminotransferase activity was 
measured. As said before an enhanced tyrosine aminotransferase activity 
follows the stress situation under study. The results are summarized in Table 19. 
It is observed that during a celite-induced stress no enhanced excretion of L-
ascorbic acid or D-glucaric acid takes place in the rats. The activity of hepatic 
UDPG dehydrogenase and D-glucuronolactone dehydrogenase is not en-
hanced, nor is the drug-demethylation activity of the liver microsomes. The 
fact that the activity of the tyrosine aminotransferase is enhanced indicates that 
a stress situation was really reached. The experimental results (Table 19) and 
the results obtained by Burns et 31.(1957) on adrenalectomized rats allow the 
conclusion that stimulation of the adrenals which cause the production and 
release of corticoid hormones does not result in an enhanced activity in the 
glucuronic acid system, nor in an enhanced activity of the drug-demethyl-
ation system of the liver. Through experiments, described in Table 15, it was 
shown that barbital does not influence the activity of hepatic tyrosine amino-
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TABLE 19 Effect of celite treatment* on enzyme activities of rat liver homogenates and 
on urinary excretion of L-ascorbic acid and D-glucaric acid in rats. 
Enzyme activity per mg protein control treated Ρ value 
UDPG dehydrogenase 
units 16.5 ±2.4 (6) 18.0 ± 4 . 3 (6) >o.io 
D-glucuronolactone dehydrogenase 
io2 цтоІез/Ьг 2.3 ± 0.3 (6) 2.6 ± 0.5 (6) > 0.25 
Demethylation 
io3 Mmoles/hr 10.3 ± 2.1 (6) 9.8 ± 2.0 (6) >o.25 
Tyrosine aminotransferase 
units 7.8 ± 1 . 5 (6) 31.5 ±9-7 (6) <o.Oi 
Urinary excretion** 
μηιοΐ68/24 hr 
L-ascorbic acid 12.8 ± 8 . 4 (6) 10.7 ±4.2 (6) >o.25 
D-glucaric acid 0.42 ±0.11(6) 0.51 ± 0.14(6) >o.25 
* Female rats, weighing 180-200 g, were given celite 60 mg/kg i.p. 24 hr before killing; 
control animals were given saline i.p. 
** Collection of urine was started immediately after injection. 
Means with S.D. are shown. Numbers in parenthesis indicate number on which each 
mean is based. Ρ values were obtained by applying the two-sided Wilcoxon two-sample 
test. 
transferase. It may be concluded that the enhanced activity of the glucuronic 
acid system and that of the drug-demethylation system as observed after treat­
ment of animals with barbital, cannot be ascribed to a stress situation induced 
in these animals by barbital. Probably the same holds true for other drugs. 
The possible significance of the hypophysis for the stimulation of the gluc­
uronic acid system by drug treatment has also been analyzed. Burns et al. (1957) 
report that in hypophysectomized rats treated with chloretone or barbital no 
enhanced excretion of L-ascorbic acid in the urine takes place. Hollmann and 
Touster (1962) observed a slightly increased excretion of L-ascorbic acid in 
hypophysectomized rats treated with chloretone, barbital and 3-methylcholan-
threne. Klinger et 31.(1965) found a clear, though subnormal enhancement in 
the excretion of L-ascorbic acid in the urine in hypophysectomized rats after 
treatment with barbital. In our study the L-ascorbic acid excretion as well as 
the D-glucaric acid excretion in hypophysectomized rats under the influence of 
barbital was studied. The results, summarized in Table 20, show that there is an 
enhanced excretion of both products after drug treatment, which means that the 
hypophysis is not essentially involved in the stimulation of the glucuronic acid 
system by drugs. 
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TABLE 20 Effect of barbital treatment* on L-ascorbic acid and D-glucaric acid excretion in alloxan-diabetic, hypophysectomized and 
parathyroidectomized rats. 
Pretreatment** 
Alloxan diabetic 
Hypophysectomized 
Parathyroidectomized 
control 
7.2 ± 4-2 (7) 
i.o ± 0.6(7) 
0.9 ± 0.6 (6) 
L-ascorbic acid 
barbital 
24.6 ± 9-5 (5) 
4.8 ± 2.2 (7) 
3 4 ± 1-9(6) 
Urinary excretion*** 
Mmoles/24 hr 
Ρ value 
<0.0I 
<0.0I 
<O.OI 
control 
0.27 ± 0.16(7) 
0.11 ± 0.05(6) 
0.23 ± 0.12 (6) 
D-glucaric acid 
barbital 
MS ± 0.54(5) 
1.63 ± 0.52 (6) 
1.02 ± 0.40 (6) 
Ρ value 
<0.0I 
<0.0I 
<0.0I 
* Male rats, weighing 180-200 g, were used. Two groups of rats deprived of the same hormonal centre were given injections of 
sodium barbital 150 mg/kg i.p. and saline i.p. respectively. 
** Alloxan (40 mg/kg) was given i.v. After 48 hr it was checked that glucosuria occurred and if so, the rats were given barbital 
or saline. 
Hypophysectomy and parathyroidectomy were performed under light ether anaesthesia. About 3 hr after anaesthesia the rats were 
given barbital or saline. Moreover, the parathyroidectomized rats were given 3 ml 3% calcium lactate about 10 hr after anaesthesia. 
*** Collection of urine was started immediately after injection of sodium barbital. 
The figures and Ρ values are calculated as indicated in Table 19. 
TABLE 21 Sex difference in L-ascorbic acid response of rats to drug treatment.* 
Treatment 
Nikethamide, 
150 mg/kg orally 
DDT, 
30 mg/kg orally 
Chloretone, 
150 mg/kg orally 
male 
1.9 ± 0.8 (6) 
1.4 ± 0.8 (7) 
2.3 ± 0.7 (5) 
Urinary excretion of L-ascorbic acid** 
before treatment 
female 
1.3 ± 0.6 (8) 
1.4 ± 0.6(8) 
1.4 ± 0.9 (7) 
μιηο1β5/24 hr/ioo 
Ρ value 
>0.I0 
>0.25 
0.04 
g rat 
male 
Ι3·9 ± 5-9 
4.9 ± 2.1 
33-7 ± 5-9 
after treatment 
female 
8.1 ± 2.8 
2.2 ± 0.6 
20.4 ± 3-6 
Increase***: 
31-4 ± 5-8 191 ± 3-6 
Ρ value 
0.03 
0.03 
<0.0I 
<0.0I 
* Young adult male and female rats of the same age, weighing 280-320 g and 190-210 g respectively, were used. 
Nikethamide was given in two doses: at zero time and at 8 hr. DDT was given in a single dose. Chloretone was given in two doses: 
at zero time and at 24 hr. 
** Collection of urine was started immediately after first dose; only after chloretone treatment urine was collected after last dose. 
*** Since in this case the untreated male and female rats show a significant difference, the increase in L-ascorbic acid excretion 
(value after treatment minus value before treatment) was tested. 
Means with S.D. are shown; numbers in parenthesis indicate number of animals on which each mean is based. Ρ values were ob­
tained by applying the two-sided Wilcoxon two-sample test. 
The significance of the gonades was also studied. Klinger et 31.(1965) ob­
served that in male rats which were adrenalectomized and castrated an en­
hanced excretion of L-ascorbic acid takes place after barbital treatment. In our 
study the response of the L-ascorbic acid excretion in male rats to nikethamide, 
DDT, chloretone and barbital was compared with that in female rats (Table 21 ; 
Fig. 19; see also Aarts, 1968). The same was done for the D-glucaric acid ex­
cretion during barbital treatment (Fig. 19). The response to drug treatment was 
stronger in male rats. Pretreatment of castrated males with estradiol and of 
castrated females with testosterone propionate followed by treatment with 
barbital gave the following results: the response of the L-ascorbic acid and 
i-glucaric acid (л;*) 
ι moles/lOOg rat 
- 1.4 
- 12 
-10 
•0.8 
-0.6 
-0.4 
-0.2 
0 1 2 3 days 
n o . 19 Effect of barbital on the urinary excretion of L-ascorbic acid and D-glucaric 
acid in male and female rats. 
Rats were treated orally with sodium barbital as shown in figure. Each symbol cor­
responds with 24-hr urine collected after drug administration. Each value represents 
mean ± S.D. for 8 rats. Asterisk denotes a significant difference between males and 
females (P value < 0.05 ; two-sided Wilcoxon two-sample test). 
Note Both the increase in L-ascorbic acid excretion and the increase in D-glucaric 
acid excretion after treatment with sodium barbital are significantly greater in males 
than in females. 
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D-glucaric acid excretion is stronger in castrated testosterone-treated females 
than in castrated estradiol-treated males (Fig. 20). The conclusion may be that, 
although sex and sex hormones have an influence on the degree of stimulation 
sodium barbi ta l 
mg / kg per day 
L-ascorbic acid (<».·> 
¿i moles /100 g r a t 
D-glucaric acid (Δ;Α1 
μ moles /100 g r a t 
29 30 31 32 S3 days 
begin of hormone treatment 
males : estradiol 
females : testosterone propionate 
FIG. 20 Effect of barbital on the urinary excretion of L-ascorbic acid and D-glucaric 
acid in castrated male and female rats before and after treatment with sex hormones. 
Hormone treatment was started as indicated by arrow and continued during the whole 
experiment. To the castrated males estradiol and to the castrated females testosterone 
propionate was given intramuscularly every other day in doses of 2 \ig in ο. 1 ml sesame 
oil. 
Further conditions are similar to those described in Fig. 19. Each symbol corresponds 
with 24-hr urine collected after drug administration. Each value represents mean 
± S.D. for 8 rats. Asterisk denotes a significant difference. 
Note After castration no significant sex difference in the barbital-caused increase in 
L-ascorbic acid excretion is observed (see first section of the curves and compare 
with Fig. 19). In the hormone-treated animals the values after administration of 
150 mg/kg sodium barbital again differ significantly, but now the testosterone-treated 
females show the higher L-ascorbic acid and the higher D-glucaric acid excretion 
(see second section of the curves and compare with Fig. 19). 
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of the glucuronic acid system as caused by drug treatment, this stimulation 
is not strictly dependent on the hormones. This holds true especially since in 
male rats which were castrated and adrenalectomized a response was still to be 
observed after treatment with barbital (Klinger et al., 1965). 
The significance of the thyroid and parathyroid glands and the pancreas for 
the enhanced L-ascorbic acid and D-glucaric acid excretion after barbital in 
rats was studied too. In Table 19 it is shown that after thyroid- and para-
thyroidectomy there is still a clear response to be observed. Klinger et al. (1966) 
also report an enhanced excretion of L-ascorbic acid in thyroidectomized rats 
treated with barbital. In rats treated with alloxan, in order to eliminate the 
ß-cells in the pancreas, the stimulation of the glucuronic acid system after drug 
treatment takes place (Table 20). 
The final conclusion may be that the stimulation of the glucuronic acid system 
in the liver brought about by drugs is not mediated by the products of the 
various endocrine glands studied. 
7. ƒ.2 Comparison of the drug-induced stimulation of the glucuronic acid system 
with the drug-induced stimulation of the pentose phosphate pathway 
Kunz et al. (1966a, b) studied the influence of drugs on the liver growth in 
mice and the biochemical effects which accompany this growth. One of the 
studied effects was the stimulation of the pentose phosphate pathway. Since 
certain aspects of this stimulation may be analogous to the stimulation of the 
glucuronic acid system, this study may be discussed here in some detail. 
In the study in question, barbiturates, chlorcyclizine, nikethamide, DDT, 
halothane and carcinogenic hydrocarbons were used. It is known that in the 
rat these substances stimulate drug metabolism as well as the biosynthesis of 
L-ascorbic acid (Table 1; Section 5.3.1). During treatment of mice with the 
drugs mentioned the metabolism of D-glucose via the pentose phosphate path-
way increases. The redox state of the cytoplasmic NADP system in the liver 
cell is found to be increased. During treatment not only the liver weight but also 
the phospholipid, the protein, the RNA and the DNA amount per gram wet 
liver increases. 
The carcinogenic hydrocarbons are exceptional in the sense that these com-
pounds only cause an increase in the amount of proteins and RNA, whereas 
liver growth is absent and no change of the redox state of the NADP system, 
no stimulation of the pentose phosphate pathway and no change in the phos-
pholipid and DNA amount occur (Kunz et al., 1966b). It is known that the 
carcinogenic hydrocarbons stimulate the glucuronic acid system, as follows 
from the increased L-ascorbic acid biosynthesis occurring after treatment of 
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rats with these compounds (Table ι). The last mentioned data make it question­
able whether stimulation of the pentose phosphate pathway and stimulation of 
the glucuronic acid system are directly interconnected. 
In mice treated with phénobarbital the sequence of the biochemical changes 
mentioned above was studied (Kunz et al., 1966b). It was found that the changes 
in phospholipid, protein and RNA content only occur after a latency time of 
about 48 hours; the changes in incorporation of labeled precursors into free 
nucleotides, RNA, DNA, proteins and lipids occur after a latency time of about 
24 hours. Stimulation of the pentose phosphate pathway is evident already after 
a latency time of about 12 hours. It is interesting that within a few hours after 
administration of the drug the level of NADPH2 of the liver cell falls, while the 
NADP level remains either unchanged or slightly rises. Consequently, the redox 
state NADP/NADPH2 increased markedly. Metabolism of carbohydrates via 
the pentose phosphate pathway is linked to the formation of NADPH2. A hypo-
thesis for the drug-induced stimulation of the pentose phosphate pathway may 
be formulated as follows. The drug causes a shortage of NADPH2. The cell 
may compensate for this shortage by an enhanced activity of the pentose phosph-
ate pathway. Kunz et al. (1966b) treated mice with phénobarbital, a stimulator of 
the glucuronic acid system as well as of the pentose phosphate pathway. They 
conclude that in the liver not only an increase in the redox state of the cyto-
plasmic NADP system but also in that of the NAD system occurs, since during 
phénobarbital treatment the concentration ratio of a-glycerolphosphate/dihyd-
roxyacetone phosphate, of lactate/pyruvate and of malate/oxalacetate is decreas-
ed. The enzymes involved, i.e. glyceraldehyde phosphate dehydrogenase, lactate 
dehydrogenase and malate dehydrogenase, catalyze the conversion of the sub-
strate and NAD to oxidized substrate and NADH2 as well as the reverse of it. 
The glucuronic acid system is linked to NADH2 formation. During the for-
mation of UDPGA hydrogen is transferred to NAD. NADH2 is also formed 
during the biosynthesis of D-glucaric acid and of D-xylulose via D-glucuronic 
acid. Analogous to the hypothesis concerning a possible relationship between 
the shortage of NADPH2 caused by drugs and the attendant stimulation of the 
pentose phosphate pathway, the following may be proposed as regards the 
stimulation of the glucuronic acid system by drugs. The drugs primarily induce 
an increase of the redox state of the cytoplasmic NAD system, viz. a shortage 
of NADH2. As a reaction upon this shortage an enhanced metabolism of 
D-hexose via the glucuronic acid system occurs. 
In connection with this hypothesis it would be interesting to study the follow-
ing points : 
1. To which degree is the UDPGA formation influenced by the redox state of 
the NAD system? 
1 0 0 
2. Is a change in the redox state of the cytoplasmic NAD system of the liver 
cells during treatment of animals with drugs stimulating the glucuronic acid 
system a rule and does this change occur as early after drug administration as 
the stimulation of the glucuronic acid system? 
J.2 Summary 
The mechanism by which drugs stimulate the glucuronic acid system is not 
known. The phenomenon is not effected via hormonal centres as the adrenals, 
hypophysis, pancreas, gonades, glandulae thyreoideae or parathyreoideae. 
Nevertheless some hormones may influence the degree of the stimulation 
(Section 7.1.1). The kidneys do not play an essential role in the mechanism 
(Section 2.3). Many data point to the glucuronic acid system in the liver as the 
main object for the stimulation by drugs (Sections 2.3.1,4.1 and 4.2.2). The pheno-
menon appears not to be directly connected with the enhanced capacity for 
glucuronidation which may follow drug treatment (Section 5.4). Many drugs 
stimulate both the glucuronic acid system and the pentose phosphate pathway. 
There are no indications, however, that these phenomena are directly inter-
related (Section 7.1.2). In contrast to drug-induced enhanced drug metabolism 
the drug-induced stimulation of the glucuronic acid system appears not to be 
dependent on de novo protein synthesis (Section 6.1.2). An activation in vitro 
of enzymes of the glucuronic acid system by drug treatment has not been ob-
served. Nor were signs of such an enzyme activation found in liver preparations 
obtained from animals a few hours after drug treatment (Sections 2.3.2, 5.4 and 
6.1.1). It remains possible that in vivo the stimulating drugs act by enzyme 
activation or by a facilitation of either the substrate transport or the interaction 
between enzyme and substrate, but that as a result of the destruction of the cell 
these effects cannot be observed in vitro. 
In future studies on the mechanism of the stimulation phenomenon the 
following aspects will deserve special attention: 
1. The experimental data suggest that the stimulating drugs exert their in-
fluence on one of the enzymatic steps, probably the rate-limiting step, involved 
in the conversion of UDPG to D-glucuronic acid (Section 2.3.1). It should be 
studied whether the rate-limiting step in the sequence of enzymes leading from 
UDPG to D-glucuronic acid is located before or after the UDPGA formation. 
2. Taking into account the possibility that the stimulation may be effectuated 
by a facilitation of the UDPGA formation, the following should be considered. 
During treatment with barbital the redox state of the NAD system in the cyto-
plasm is shifted towards the oxidized site (Kunz et al., 1966b; Section 7.1.2). 
It should be investigated whether this phenomenon can be generally observed 
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after treatment with drugs stimulating the glucuronic acid system. The for-
mation of UDPGA along various pathways of the glucuronic acid system are 
associated with a production of NADH2. The enhanced metabolism of D-
hexose phosphates via the glucuronic acid system might be tied up to the drug-
induced change in the NAD redox state of the cytoplasm of the liver cells. 
3. Taking into account the possibility that the stimulation of the glucuronic 
acid system is effected by a facilitation of the formation of D-glucuronic 
acid from UDPGA (Section 5.4) the following can be said. The biochemical 
data on the formation of D-glucuronic acid from UDPGA in vivo are far from 
complete. Conclusive experimental data should be obtained in order to answer 
the questions whether D-glucuronic acid is formed from UDPGA via UDP 
glucuronyltransferase and ß-glucuronidase or via pyrophosphatase-phosphatase 
(Section 1.1.1). Subsequently, direction is given to the study on the influence of 
drugs on the enzyme systems involved in the formation of D-glucuronic acid 
from UDPGA. 
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S U M M A R Y 
A review is given of the literature on the metabolism of D-glucuronic acid 
(Chapter i) and on the influence of drugs on that metabolism (Chapter 2). It 
is followed by a report of the materials and methods used (Chapter 3) in the 
investigations presented in this thesis. The results of these investigations can 
be summarized as follows: 
Chapter 4 
1. During barbital treatment an enhanced D-glucaric acid excretion as well as 
an enhanced drug metabolism (demethylation of aminophenazone) takes place 
in guinea pigs. Within 24 hours after a single application of the drug the 
D-glucaric acid excretion is enhanced and levels off to the original value in 
the 5 days following drug administration. 
2. The body pool of D-glucaric acid in guinea pigs is of the same order as 
the amount of D-glucaric acid excreted in the 24-hr urine. Treatment with 
barbital leads to a 24-hr excretion of D-glucaric acid which largely exceeds 
the body pool, indicating that the enhanced D-glucaric acid excretion is the 
result of an enhanced production. 
3. During the treatment of rats with barbital the levels of D-glucaric acid in 
liver and urine are enhanced. It has been made acceptable that these enhanced 
levels are the result of an effect taking place in the liver. 
4. Treatment of guinea pigs with barbital does not result in an enhanced ac-
tivity of hepatic D-glucuronolactone dehydrogenase, the enzyme involved in 
the final step of the D-glucaric acid formation. Barbital treatment has neither 
an influence on the D-glucaric acid excretion in guinea pigs loaded with 
D-glucuronolactone nor on the D-mannaric acid excretion in guinea pigs 
loaded with D-mannuronolactone. The results are in agreement with the hypo-
thesis that the enhanced D-glucaric acid excretion is the result of a drug-
induced stimulation of the glucuronic acid pathway. 
5. An enhanced excretion of D-glucaric acid occurs in patients under thio-
pental anaesthesia and in patients under treatment with phenobarbital-pheny-
toin, phenylbutazone or aminophenazone. 
6. The bisphenylhydrazide of D-glucaric acid has been isolated from urine of 
a patient under treatment with phénobarbital and phenytoin and identified 
ЮЗ 
chemically. The quantity isolated largely exceeds the quantity that may be 
expected on the basis of a normal D-glucaric acid excretion. 
Chapter 5 
7. It has been observed that 2 hours after barbital administration (i.p.) to the 
rat the L-ascorbic acid level in the liver is not enhanced, while 3 houis after 
administration it is enhanced. It has also been observed that in a 3-hr urine 
portion collected immediately after administration of the drug the level of 
L-ascorbic acid and D-glucaric acid is enhanced. The urinary excretions of 
L-ascorbic acid and D-glucaric acid in dogs are found to be increased within 
the first 2 hours after application (i.v.) of barbital and thiopental. 
8. The effect of cumulative doses of barbital on the urinary excretions of 
L-ascorbic acid, D-glucaric acid and D-glucuronic acid has been studied in 
the rat. The response of L-ascorbic acid resembles that of D-glucaric acid. The 
excretion of D-glucuronic acid is enhanced during barbital treatment. The 
response of D-glucuronic acid is difficult to interpret because of the high pre-
treatment level of this acid in the urine. The increase in the excretion of L-as-
corbic acid has been observed even up to the 30th day after the last dose. 
9. In individual untreated rats the amount of L-ascorbic acid excreted from 
day to day in the urine is rather constant. The amounts of L-ascorbic acid 
excreted by different rats of the same strain and sex, however, are found to vary 
considerably. 
10. A single dose of barbital administered to rats results in an enhanced 
excretion of L-ascorbic acid and D-glucaric acid. A single dose or two doses 
of aminophenazone, nikethamide, borneol, phenylbutazone, thiopental, DDT, 
salicylic acid or tolbutamide results in an enhanced L-ascorbic acid excretion, 
but not in an enhanced D-glucaric acid excretion in the 24-hr period after 
drug application. A D-glucaric acid response becomes evident after treating 
rats during 3 to 4 days with aminophenazone, nikethamide, borneol or amino-
phenazone. An enhanced D-glucaric acid excretion is not observed in the 24-hr 
period after administration of high doses of aminophenazone or thiopental 
to guinea pigs. 
11. Treatment of rats with D-glucuronolactone results in an enhanced D-gluca-
ric acid excretion which is relatively strong as compared with a simultaneously 
occurring enhanced excretion of L-ascorbic acid. The results obtained with 
drugs and D-glucuronolactone in rats and guinea pigs may indicate that the 
D-glucaric acid pathway is not an intrinsic part of the glucuronic acid system. 
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12. Barbital, DDT or nikethamide, drugs stimulating the glucuronic acid sys-
tem, do not enhance the glucuronidation in the 8-hr period following salicyl-
amide administration to rats. The drug-induced stimulation of the glucuronic 
acid system as is obvious from the increased L-ascorbic acid excretion, and 
the enhanced glucuronidation as caused by drugs, appear not to be directly 
related. 
Chapter 6 
13. The UDP glucuronyltransferase activity, as measured within the first few 
days of drug treatment with the aid of body-foreign compounds, is not involved 
in the drug-induced stimulation of the glucuronic acid system. 
14. An enhanced activity of hepatic UDPG dehydrogenase is observed during 
chronic treatment of rats with chloretone. After a short treatment (1-3 days) 
with barbital or chloretone no enhanced activity of this enzyme is observed. 
It is concluded that the drug-induced stimulation of the glucuronic acid system 
is not the result of an enhanced UDPG dehydrogenase activity. 
15. It is observed that puromycin and actinomycin D do not prevent the 
enhanced excretion of L-ascorbic acid and D-glucaric acid after barbital ad-
ministration. So the barbital-induced stimulation appears not to be related to 
de novo protein synthesis. It is argued that the same holds true as far as the 
stimulation of the glucuronic acid system by other drugs is concerned. 
16. Many drugs cause stimulation of the glucuronic acid system as well as an 
enhanced drug-metabolizing capacity in the liver. The latter phenomenon is 
based on de novo protein synthesis. One of the starting points of this thesis 
was the notion that an enhanced D-glucaric acid excretion as a result of stimul-
ation of the glucuronic acid system might be considered as a criterion for the 
occurrence of both an enhanced capacity to metabolize drugs and a stimulation 
of the glucuronic acid system in the liver. From the results summarized under 
10 and 15 it is concluded that this notion is untenable. 
Chapter 7 
17. Rats were deprived of one of the following hormonal centres: adrenals, 
hypophysis, pancreas, gonades, glandulae thyreoideae and parathyreoideae. 
Treatment of these rats with barbital resulted in an enhanced excretion of 
D-glucaric acid and/or of L-ascorbic acid, indicating that the stimulation phe-
nomenon is not effected via the hormonal centres mentioned. 
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18. An enhanced excretion of D-glucaric acid and L-ascorbic acid has not been 
observed in rats treated with the stress-agent celile (a diatomaceous earth). An 
enhanced activity of hepatic enzymes involved in D-glucuronic acid metabolism 
e.g. UDPG dehydrogenase and D-glucuronolactone dehydrogenase has not 
been observed either. Drug-induced stimulation of the glucuronic acid system 
appears not to be related to the stress situation initiated via the adrenals. 
19. It is shown that during drug treatment male rats give a stronger response 
in the glucuronic acid system than female rats. The difference disappears upon 
castration and could be reversed by treating castrated female rats with testos-
terone and castrated male rats with estradiol. 
20. On the basis of a study ot literature a comparison is made between the 
drug-induced stimulation of the glucuronic acid system and the drug-induced 
stimulation of the pentose phosphate pathway. Both phenomena do not appear 
to be directly related. An outline of further experiments is given. These experi-
ments are now being performed. 
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STELLINGEN 
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Aarts, E. M.: Biochcm. Pharmacol. 14, 359 (1965) 
Dit proefschrift 
II 
Aan de door farmaca veroorzaakte stimulering van het glucuronzuursysteem 
ligt geen verhoogde de novo synthese van enzymen ten grondslag. 
Dit proefschrift 
III 
De door barbital veroorzaakte stimulering van het glucuronzuursysteem bij de 
rat houdt geen verband met de eveneens door barbital veroorzaakte vergroting 
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IV 
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VI 
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VII 
Voor de beantwoording van de vraag of lever reticulosomen betrokken zijn bij 
de vorming van de membranen van het endoplasmatische reticulum, is een 
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wandige endoplasmatische reticulum tijdens de verschillende ontwikkelings­
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VIII 
De experimenten van Scholtan, die er op wijzen dat sulfonamide door bilirubine 
verdrongen wordt van de bindingspiaatsen aan eiwit zijn meer steekhoudend 
dan die van Josephson en Fürst, waarbij geen invloed van bilirubine op de 
binding van Sulfonamiden aan eiwit wordt vastgesteld. 
Scholtan, W.: Arzneim.-Forsch. 11, 707 (1961) 
Josephson, В., en Fürst, P.: Scand. J. Clin. Lab. Invest. 18, 51 (1966) 
IX 
Het feit dat geen rekening is gehouden met de door Schach von Wittenau en 
Blackwood beschreven stereochemie van Oxytetracycline ontneemt aan de 
discussie door Hussar et al. over de invloed van de 5-OH groep op de epimeri-
sering van de tetracyclines elke zin. 
Hussar, D. Α., Niebergall, P. J., Sugita, E. T. en Doluisio, J. T.: J. Pharm. Pharma­
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χ 
Bij de door geautolyseerde plantaardige en dierlijke weefsels veroorzaakte cel­
differentiatie in calluswcefsel van Phaseolus vulgaris kan naast auxine ook 
cytokinine een rol spelen. 
Sheldrake, Α. R. en Northcote, D. H.: Planta 80, 22 (1968) 
Bergmann, L.: Planta62, 221 (1964) 
XI 
Aan de mogelijkheid een meer verantwoorde farmacotherapie in te stellen 
op geleide van bloedspiegels van geneesmiddelen wordt onvoldoende aandacht 
besteed. 
XII 
De opleiding tot apotheker dient dringend aangepast te worden aan de heden­
daagse ontwikkeling op het gebied van de voorziening met en de toepassing 
van geneesmiddelen. 


